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Abstract  
Breast cancer is a complex, heterogeneous disease encompassing many different tumour entities. 
Management decisions are based on variables such as tumour size, histological grade, expression of 
hormone (oestrogen and progesterone) receptors (ER/PR), and expression of human epidermal 
growth factor receptor-2 (HER2). Clinical outcomes are highly variable amongst patients with 
‘triple-negative’ breast cancer (TNBC; ER/PR/HER2-negative), but we currently cannot accurately 
predict prognosis in this group, thus inadequate disease control and over-treatment are challenges in 
the clinic. Furthermore, new therapeutic options are needed for TNBC, as there are currently no 
molecular-targeted therapies available.  
 
Published data suggest that expression of the SRY (sex determining region Y)-box 10 (SOX10) 
transcription factor is associated with TNBC, particularly those exhibiting molecular similarity to 
the basal/myo-epithelium of the normal breast (‘basal-like’ breast cancer; BLBC). SOX10 belongs 
to the SOX family of transcription factors. It is an important regulator of early neural crest 
development and of melanocyte differentiation, in which expression is highest in melanocyte 
progenitors and is silenced in mature melanocytes. SOX10 is expressed in 87-97% of melanomas, 
and is used as a diagnostic marker clinically  
 
The aims of the current study were to:  
1. Investigate SOX10 mRNA levels and mechanisms controlling its expression in breast cancer; 
2. Investigate the prognostic significance of SOX10 in breast cancer;  
3. Evaluate SOX10 protein expression in normal and tumour-adjacent normal breast;  
4. Use gene expression profiling and in vitro and in vivo functional assays to investigate the 
possible functional roles of SOX10 in breast cancer; and 
5. Investigate the prognostic significance of two cancer-testis antigens (MAGE-A and NY-ESO-
1) in TNBC. 
 
Analysis of published breast cancer genomic datasets showed that SOX10 mRNA expression was 
inversely correlated with gene methylation (r2
 
0.567; p<00001), suggesting epigenetic regulation is 
important in breast cancer. A subgroup of BLBCs (~65%) demonstrated high expression and 
significantly lower SOX10 methylation than non-BLBCs (χ2 p<0.0001). SOX10 copy-number gains 
were also more frequent in BLBCs (χ2
 p=0.0002). SOX10 mRNA expression was not associated 
with the clinical outcomes tested, including response to chemotherapy or overall survival, though 
immunohistochemical (IHC) analysis of breast cancer tissue microarrays showed that SOX10 
protein expression was strongly associated with markers of poor outcome (e.g. histological grade, 
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p<0.0001) and predicted poor survival (hazard ratio (HR): 3.66; 95% CI: 1.78-7.51; p<0.0001). 
Critically, SOX10 protein expression also predicted poor survival in basal-like TNBCs (HR 3.20; 
95% CI: 1.28-8.03; p=0.0168; n=52).  
 
Little is known about the roles of SOX10 in either normal or neoplastic breast tissue. To investigate 
the roles of SOX10 in the human mammary epithelium, we analysed its expression in situ in 
reduction mammoplasty specimens (n=18) and tumour-associated normal breast tissue (n=19). 
SOX10 was consistently expressed in the myoepithelium and heterogeneously expressed in luminal 
cells. In luminal epithelia, there was a strong correlation between expression of SOX10 and the 
luminal progenitor marker c-kit, and an inverse association with ER and cytokeratin 8/18. In silico 
analysis of published gene expression data from mammary epithelial compartments showed SOX10 
was most highly expressed in luminal progenitor cells, and the least in mature luminal cells (χ2
 
p<0.0029). In light of its role in differentiation in other tissues (e.g. melanocytes), these data 
suggest that SOX10 may regulate lineage differentiation in the mammary gland.  
 
In order to investigate possible roles of SOX10 in breast cancer, we employed in vitro and in vivo 
breast cancer models. In-house screening experiments demonstrated infrequent expression of 
SOX10 in breast cancer cell lines. Only 2 of 39 basal-like lines (~5%) had detectable levels of 
SOX10 mRNA. Short hairpin RNA (shRNA)-mediated knockdown of SOX10 in basal-like MDA-
MB-435 breast cancer cells did not alter their proliferation rate, migratory behaviour or sphere 
forming capacity in vitro, but did reduce colony formation on plastic (p=0.028), consistent with the 
idea that it regulates progenitor activity. In vivo tumourigenicity experiments showed that SOX10 
knockdown reduced tumour formation in the mouse mammary fat pad. Differential gene expression 
microarray analysis of these cells coupled with gene ontology analysis of SOX10-high and –low 
BLBCs showed a significant association between SOX10 and immune response genes. 
 
In light of its roles in coordinating differentiation in the neural crest and the melanocyte lineage, we 
hypothesise that SOX10 is involved in regulating mammary epithelial lineage differentiation and 
that its expression is inappropriately activated and/or maintained in sporadic basal-like TNBCs, and 
that the involvement of SOX10 contributes to poor outcome. Future studies are required to fully 
understand the functional role of SOX10 in breast cancer.  
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Chapter I: General Introduction 
1.1 Epidemiology and natural history of breast cancer  
Breast cancer is the most common cancer in Australian women and the second leading cause of 
cancer related death [1]. In 2010, the risk of developing breast cancer before the age of 85 years was 
1 in 8 and the average age of diagnosis was 60 years [1]. The incidence of breast cancer in Australia 
is increasing (Figure 1.1A), and it is estimated that there will be 17,210 new cases diagnosed by 
2020 [2]. However, the age-standardised mortality rate has decreased (Figure 1.1B) as a result of 
technological advances in the early diagnosis using mammographic screening and improvement in 
treatment modalities in the form of adjuvant therapy [2, 3]. Despite early detection and advances in 
systemic therapy, metastatic breast cancer is incurable and is responsible for about 90% of cancer-
associated deaths [4]. 
 
1.2 Breast cancer development 
1.2.1 Breast cancer risk factors 
Breast cancer aetiology is multifactorial, with interplay between genetic and environmental factors 
[5]. The strongest breast cancer risk factor is family history of the disease, with several high-risk 
susceptibility genes, and multiple low-risk/risk modifier genes implicated (as reviewed in [6, 7]). 
Women with one or two first-degree relatives (i.e. mother, sister, daughter) with breast cancer are at 
two to three-fold elevated risk. The risk is even greater when: i) more relatives are affected; ii) if the 
breast cancer occurred before menopause; and iii) if it was bilateral. The genetic basis for familial 
predisposition to breast cancer remained unknown until the discovery of breast cancer susceptibility 
gene known as BRCA1 [8]. Hall and colleagues studied 146 breast cancer cases with 23 extended 
families and found strong evidence for linkage of breast cancer susceptibility to D17S74 
anonymous marker located on chromosome 17q21. This linkage was found specifically in 40% of 
families with early onset of breast cancer [9, 10]. The following year (1993), Narod and colleagues 
Figure 1.1: Age-specific (A) incidence and (B) mortality rates for breast cancer in Australian women [1]. 
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extended this research and determined that hereditary breast cancer in 3 of 5 large families was 
linked to the same marker D17S74 [11], which was later formally named as ‘BRCA1’ [12]. In 1994, 
a second breast cancer susceptibility locus, BRCA2, was found by linkage analysis of 15 high-risk 
breast cancer families to be localised to 13q12-13 [13]. Familial breast cancers account for only 
about 5-10% of all breast cancers [14]. 
 
In addition to genetic predisposition, hormonal factors also contribute to risk. For example, early 
age of menarche (<12 years), late pregnancy, late menopause (>55 years), late age at first full-term 
pregnancy (>35 years) and nulliparity are all associated with increased risk [15]. These 
relationships are likely related to prolonged exposure to endogenous oestrogens [16-19]. Consistent 
with this idea, breast-feeding reduces the risk of breast cancer, with an estimated 4.3% risk 
reduction for every year of breast-feeding, in addition to a 7% decrease for each birth [17, 18, 20]. 
Finally, age has a major impact on breast cancer risk, with incidence doubling every 10 years until 
menopause (<50 years), after which the rate of increase plateaus between 70-80 years [17, 18, 21].  
 
1.2.2 Histogenesis of the breast  
The human breast is characterised by a branching network of ducts and lobules that end in clusters 
(terminal ductal lobular units; TDLUs), which comprise two major epithelial cell types: the inner 
secretory luminal cells that surround a central lumen and the outer contractile myoepithelial cells 
that are basally located adjacent to basement membrane (Figure 1.2) [22, 23]. Mammary epithelial 
cells are dynamic, undergoing cyclical morphogenetic changes during puberty, pregnancy and 
lactation. Evidence suggests the existence of an epithelial differentiation hierarchy within human 
breast, with undifferentiated mammary stem cells (MaSC) at the apex, which are capable of self-
renewal and generation of daughter cells that differentiate into committed progenitor cells, luminal 
and myoepithelial lineages (Figure 1.2) [23]. Lim and colleagues functionally characterised the 
human mammary hierarchy in normal breast specimens based on cell surface markers, and isolated 
four subpopulations using fluorescence-activated cell sorting (FACS): luminal progenitor (LP), 
mature luminal (ML), myoepithelial and MaSC-enriched and stromal (S) populations. Analysis of 
the gene expression profiles of these subpopulations revealed similarities to the intrinsic subtypes of 
breast cancer (See section 1.4.1), raising the possibility that different breast cancer subtypes either 
arise from, and/or adopt phenotypic features of particular normal breast cell types [24, 25]. For 
example, basal-like breast tumours showed greatest transcriptomic similarity to luminal progenitor 
cells of the normal breast (Figure 1.2C) [23]. 
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1.2.3 Breast cancer evolution 
Breast cancer arises from the TDLUs of the breast through a series of morphological changes that 
are recognised as pre-invasive lesions. These lesions are characterised by clonal proliferation of 
epithelial cells that remain contained within the basement membrane and hence confined to the 
ductal structure of the breast. The most commonly identified precursor lesions are columnar cell 
lesions (CCL), atypical ductal hyperplasia (ADH), ductal carcinoma in situ (DCIS), and lobular 
carcinoma in situ (LCIS); with ‘ductal’ and ‘lobular’ breast cancers representing the two most 
common subtypes (see section 1.3.2). 
 
The original model of development suggested that breast cancers evolve in a stepwise manner, 
beginning as hyperplastic benign lesions (hyperplasia of usual type) that progress to atypical 
 
Figure1.2: Normal breast architecture and differentiation hierarchy (A) Structure of 
normal breast showing lobules and ducts, (B) Different cell types of normal breast: 
outer contractile myoepithelial (in red) and inner columnar luminal cells (in blue), 
luminal progenitor cells are shown to be located in between luminal cells adjacent to 
myoepithelial (in grey). (C) Model of differentiation hierarchy in normal breast. The 
common progenitor cells are also called as bipotent progenitor cells which are 
capable of differentiating into committed progenitor cells of luminal and myoepithelial 
lineages [25]. Permission to use figure C was obtained from the publisher through 
Copyright Clearance Center’s RightsLink Service.    
Lobule Duct 
A 
C 
B 
C 
 21 
hyperplasia, followed by in situ carcinoma and finally invasive cancer, as cells penetrate the 
basement membrane and invade the local stroma. This process was thought to be separate for ductal 
and lobular types of cancer. Our understanding of this model has evolved over time with more 
sophisticated molecular analysis of pre-invasive lesions (e.g. sequencing, loss-of-heterozygosity 
(LOH) and comparative genomic hybridization (GGH) analyses). We now understand this to be a 
more complex multistep model. A key molecular finding that supported this multistep progression 
of breast cancer was loss of LOH identified at 16q and 17p in both DCIS and invasive, which was 
also seen at a similar frequency in ADH [26]. Lesions like hyperplasia of usual type are no longer 
considered as clonal precursor lesions, whereas columnar cell lesions are the likeliest and earliest 
morphological stage between normal epithelium and atypical hyperplasia [27]. Importantly, these 
pre-invasive lesions can be detected during early screening programs and are considered to be 
indicators of risk for invasive breast cancer [28]. 
  
1.3 Clinical management 
Currently, breast examination, mammography and ultrasound are the standard screening methods 
for breast cancer [29]. Management and treatment of breast cancer requires a multidisciplinary 
approach, including surgery, radiation therapy and systemic therapy. The choice of treatment varies 
depending on the stage, tumour grade, histological type, expression of hormone receptors (HR; 
oestrogen and progesterone) and expression of human epidermal growth factor receptor 2 (HER2). 
These parameters are included in the St Gallen breast cancer guidelines, the National Institute of 
Health consensus and Adjuvant! Online to facilitate clinical decision-making [30, 31].  
 
Surgery and radiation therapy are local therapies for managing primary disease, which is generally 
considered to decrease the risk of local recurrence. Surgery involves either lumpectomy (breast 
conservation surgery) or mastectomy when the tumour is >40mm in size. Radiation therapy is 
offered to patients who have undergone lumpectomy, have primary tumours >5 cm, skin/chest wall 
involvement or multiple lymph nodes involved (>4).  
 
Systemic therapy (chemotherapy, anti-oestrogen/endocrine therapy and anti-HER2 therapy) is 
considered when there is a high risk of recurrence (e.g. when there is lymph node positivity, or 
other indicators of poor prognosis, see below). This is an important component of treatment for 
patients diagnosed with either locally advanced or metastatic breast cancer to increase the 
likelihood of cure and/or survival. This mode of treatment is usually given to patients 
postoperatively or after surgery (adjuvant setting). Some patients are prescribed systemic therapy 
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before surgery (neoadjuvant setting) in order to debulk the primary tumour to facilitate breast 
conservation surgery, and to facilitate cure.  
 
Breast cancer management decisions are based on detailed histopathologic review and classification 
of the primary tumour. This involves assessment of prognostic and predictive factors (such as 
lymph node, tumour grade/stage, histological type, ER/PR and HER2 status) to select treatment 
regimens most appropriate for individual patients (e.g. tumours expressing HRs are most likely to 
respond to endocrine therapy (section 1.3.4). In addition to these, increasingly newer molecular 
techniques are used to guide clinical decision-making (see section 1.4.4). 
 
1.3.1 Histological type 
According to the latest World Health Organization (WHO, fourth edition) classification, there are 
more than 21 different histological types of breast cancer, which are characterised by differences in 
cellular morphology and growth patterns [32]. Most breast cancers (~75%) are classified as invasive 
carcinoma of ‘no-special type’ (IC NST), a large group of invasive breast cancers that do not 
demonstrate distinguishing morphological characteristics. IC NST is a very heterogeneous group 
and the diagnosis is one of exclusion. IC NST group of tumours is not only hugely variable in 
histologic presentation, but also in clinical outcome/prognosis/response to therapy. Thus 
histological typing is not particularly useful for guiding management for tumours in this category. 
The remaining tumour types are morphologically distinct and are categorised as ‘special types’, 
where ≥90% of the tumour exhibits distinguishing cytological and/or architectural differentiation 
[32, 33]. These include invasive lobular, tubular, mucinous and metaplastic carcinoma and 
carcinoma with medullary, neuroendocrine or apocrine features. Invasive lobular carcinomas (ILCs) 
account for about ~15% of all breast cancers while the other special types of breast cancers such as 
tubular, metaplastic, medullary, apocrine or mucinous etc., account for <2% of all invasive breast 
carcinomas [32]. Importantly, some of these breast cancer special types are associated with 
particular clinical behaviour. For example, tubular carcinomas relatively have better prognosis [34-
37] whereas, metaplastic carcinomas show poor prognosis [38, 39]. Representative images of some 
morphological variants of invasive breast cancer are shown in Figure 1.3 [40] .  
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1.3.2 Histological grade 
Histological grade is one of the main prognostic determinants used in routine practice and involves 
morphological assessment. The Nottingham Combined Histological Grading System evaluates three 
morphologic features scored in routine Haematoxylin and Eosin (H&E)-stained slides: the 
percentage of tubule formation, the degree of nuclear pleomorphism and the mitotic count. Each 
criteria is given a score between 1-3; the lowest score for a tumour being 3 and the highest being 9. 
Breast cancers are then classified as grade 1 or well differentiated (when the score is between 3 to 
5), grade 2 or moderately differentiated (when the score is either 6 or 7) and grade 3 or poorly 
differentiated (with a score of 8 or 9, Figure 1.4 a-c) [41]. Histological grade is an essential 
component of breast cancer prognostication because stratification of patients according to this 
system has shown clear differences in disease-free survival (DFS) and overall survival (OS) (Figure 
1.4 d and e) [42]. The relationship between grade and prognosis was well documented in a study of 
1830 breast cancer patients; most of the cases were invasive carcinoma NST. The results showed 
19% were grade I, 34% grade II and 47% grade III. The recurrence-free survival (RFS) and OS 
Figure 1.3: Representative images of some of the morphological types of breast cancer: (a) invasive 
carcinoma NST, (b) classic lobular carcinoma, (c) tubular carcinoma, (d) mucinous Carcinoma, (e) 
invasive micropapillary carcinoma; (f) pleomorphic lobular carcinoma, (g) medullary carcinoma; (h) 
metaplastic carcinoma, (i) adenoid cystic carcinoma. Figure adapted from [40]. Permission to use figure 
was obtained from the publisher through Copyright Clearance Center’s RightsLink Service.    
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were reduced to about 40% in patients with a poorly differentiated tumour (grade III) compared 
with those with well-differentiated tumours (grade I, >80% DFS).   
 
1.3.3 Assessment of predictive tumour biomarkers  
1.3.3.1 Hormone receptors (oestrogen and progesterone) 
The ER and PR are nuclear transcription factors essential for normal mammary gland development 
and function. Ligand binding induces nuclear translocation of receptor complexes, which leads to 
the transcriptional regulation (activation or repression) of the target genes involved in cellular 
growth, differentiation and proliferation [43]. Expression of HRs in the normal breast epithelium is 
cyclic and fluctuates with the menstrual cycle [44].  
 
About 80% of invasive breast cancers express ER [45, 46], which is significant because ER 
expression is a powerful predictive indicator for adjuvant endocrine therapy. For example, five 
years of adjuvant tamoxifen treatment in patients with HR+ tumours led to proportional reductions 
Figure 1.4: Histological grading of breast cancer according to Nottingham Grading System and its 
relationship with survival outcome. Images represent (a) well- (b) moderately-and (c) poorly 
differentiated IDC-NST (d) recurrence-free survival and (e) overall survival of 1830 patients with invasive 
breast carcinoma stratified according to histological grading (P<0.001). Figure from [41] and [42]. 
Permission to use figures was obtained from the publisher through Copyright Clearance Center’s 
RightsLink Service.    
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in the risk of recurrence and mortality of 47% and 26%, respectively [47]. A collaborative meta-
analysis of data from 20 clinical trials involving 21,457 HR+ breast cancer patients showed that 
treatment with tamoxifen halved the rate of recurrence during years 0-4 and reduced it by one-third 
during years 5-9, with an overall reduction of 39% [48]. Expression of the PR is strongly dependent 
on oestrogen, and therefore PR-positivity is interpreted clinically as a marker of functional ER 
signalling [49, 50]. Around 25% of ER+ breast cancers lack PR expression and are less responsive 
to endocrine therapy [49]. More recently published data has shown that PR is more than just a 
downstream marker of ER, it may re-program ER to different chromatin binding sites within breast 
cancer cells resulting in a unique gene expression programme that is associated with better clinical 
outcome [51].  
 
The relationship between HR expression and disease progression has also been assessed in the 
treatment-naïve setting. The NSABP B-06 trial randomised women with early-stage breast cancer to 
mastectomy, lumpectomy alone, or lumpectomy followed by radiation therapy [52]. No adjuvant 
systemic therapy was administered. The 5-year DFS and OS rates were 74% and 92% for ER+ 
cases, and 66% and 82%, for ER-negative cases respectively [52]. Because ER and PR expression 
in invasive breast carcinomas has a proven prognostic and predictive utility, positive staining by 
immunohistochemistry (IHC) is used clinically to provide prognostic information and to identify 
tumours that may respond to endocrine therapy [53, 54]. The current recommended cut-offs for ER 
and PR positivity by the American Society of Clinical Oncology (ASCO) and College of American 
Pathologists (CAP) is nuclear staining in at least 1% of tumour cells [55]. 
 
1.3.3.2 Human epidermal growth factor 2 (HER2) 
The human epidermal growth factor receptor 2 (HER2) is a receptor tyrosine kinase encoded by the 
ERBB2 gene on chromosome 17q12. Over-expression of HER2 resulting from gene amplification 
drives the basic level of activity above a threshold stimulating tumour growth [56]. HER2 over-
expression is observed in 18-20% of breast cancers and is associated with decreased survival [57]. 
The current recommended cut-off for HER2 positivity by the ASCO and CAP is 3+ by IHC (strong, 
complete membrane staining in at least >30% of homogeneous tumour cells) and > 6 gene copies 
by in-situ hybridization (ISH) [58].  
 
Development of the anti-HER2 monoclonal antibody trastuzumab (Herceptin) marked a major 
breakthrough in breast cancer management in the early 90’s [59]. Trastuzumab is the first line of 
treatment against HER2+ breast cancers in their early-stage; and has shown to significantly reduce 
the risk of recurrence after surgery [60]. Trastuzumab inhibits HER2-mediated signalling via the 
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phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways, 
leading to an increase in apoptosis and decrease in cellular proliferation [61, 62]. When trastuzumab 
was used as a single agent, the response rate in 111 patients with HER2 amplification patients with 
3+ IHC staining was 35% and the response rate for patients with 2+ cases was 0%; the response 
rates in patients with or without ERBB2 amplification examined by FISH were 34% and 7%, 
respectively [63]. In another study of breast cancer treated with trastuzumab in combination with 
chemotherapy, the overall response rates ranged from 67-81% in patients with HER2 amplification 
and 41-46% in patients with normal expression of HER2 [64]. Randomised clinical trials have 
demonstrated that adjuvant chemotherapy with and without trastuzumab had an absolute difference 
in DFS of 12% at 3 years; and was associated with a 33% reduction in the risk of death [65]. In 
metastatic breast cancers that over-expressing HER2, the use of trastuzumab in combination with 
chemotherapy is associated with a longer time to disease progression (median, 7.4 vs. 4.6 months), 
higher rate of objective response (50% vs. 32%), longer duration of response (median, 9.1 vs. 6.1 
months), lower rate of death at 1 year (22% vs. 33%), longer survival (median survival, 25.1 vs. 
20.3 months), and 20% reduction in the risk of death compared with chemotherapy alone [66].  
 
Lapatinib, a dual tyrosine kinase inhibitor that blocks both HER2 and Epidermal Growth Factor 
Receptor (EGFR) [67, 68] inhibits the growth of breast cancer cell lines that are HER2+ in culture 
and in tumour xenografts [69, 70]. Lapatinib is used for the treatment of HER2+ metastatic breast 
cancer that progresses after initial treatment with trastuzumab or taxane-derived chemotherapies. 
Combination therapy of lapatinib with capecitabine in patients with HER2+ advanced breast cancer 
has been shown to reduce the risk of disease progression compared with capecitabine alone [71]. 
New agents are constantly being developed to improve the toxicity profiles and to reduce the 
development of resistance to trastuzumab. The use of pertuzumab, another recently developed 
humanised monoclonal antibody, targets specifically and has shown significant decrease of tumour 
growth in HER2+ metastatic breast cancers [72]. The combination of pertuzumab, trastuzumab and 
docetaxel, as compared with placebo, trastuzumab and docetaxel, used as first-line treatment for 
HER2+ metastatic breast cancer, markedly prolonged progression-free survival in the randomised, 
multinational, phase III CLEOPATRA (Clinical Evaluation of Pertuzumab and Trastuzumab) trial 
[73]. Several other clinical trials are currently examining the efficacy of pertuzumab in patients with 
advanced or metastatic HER2+ breast cancer. One such example is the phase II NeoSphere trial 
(NCT00545688) [72]. Recently, an antibody drug conjugate, ado-trastuzumab emtansine (T-DM1) 
that combines the antitumor properties of the humanized anti-HER2 with maytansinoid, DM1 (a 
potent microtubule-disrupting agent) has been approved by FDA for treatment of patients with 
HER2 positive metastatic breast cancer [74]. HER2 expression in breast cancer strongly predicts the 
 27 
response to HER2-targeted therapies and is therefore a good example of both prognostic and a 
predictive biomarker 
 
1.3.3.3 Triple-negative and basal-like breast cancer (TN and BLBC) 
Triple-negative breast cancer (TNBC) is defined by a lack ER, PR and HER2 expression by IHC, 
and account for 15-18% of all breast cancers [75, 76]. Patients with TNBC are generally younger 
(<50 years) and tumours are more frequently high-grade. TNBCs are often more aggressive than 
other breast cancer types [77] and are associated with higher risk of distant recurrence and death, 
particularly in the first three years after diagnosis. There are no targeted treatment guidelines for 
TNBC and clinical management is challenging. Generally speaking, many TNBCs initially respond 
to first-line adjuvant treatment with anthracycline and taxane-based chemotherapy, but there is a 
high risk of relapse [78, 79]. Recently, Poly-(ADP-ribose)-polymerase (PARP) inhibitors have 
shown favourable results in some TNBC patients [80, 81], however assessment of the long-term 
effects of PARP inhibitors is needed. Combination therapies (including ixabepilone and 
capecitabine) and other useful antiangiogenic agents such as tyrosine kinase and EGFR inhibitors 
have shown varying response rates but with little or no survival benefit. Other molecular-targeted 
agents (e.g. inhibitors of EGFR, c-kit, Raf/MEK/MAPK and mTOR) have shown limited clinical 
benefit (reviewed in [82, 83]). 
 
The ‘basal-like’ subset of TNBCs is characterised by expression of markers normally found in the 
basal (myoepithelial) compartment of the breast. Classification requires expression of at least one of 
the basal cytokeratins (e.g. CK5/6, CK14 or CK17) and/or EGFR [84, 85]. Other basal markers are 
often also expressed (e.g. p63, P-cadherin, caveolins 1 and 2, nestin, αB crystallin and CD109) [85-
87]. The basal-like breast cancer (BLBC) breast cancer subtype came to prominence following 
landmark breast cancer molecular subtyping studies conducted by Perou, Sorlie and colleagues 
around 15 years ago, which identified a BLBC cluster as one of five intrinsic molecular subtypes 
[88, 89] (see section 1.6.1). Although BLBC and basal-like TNBC (defined by gene expression 
profiling and IHC respectively) are sometimes used interchangeably, there is up to 30% discordance 
between the types [85, 90]. For instance, not all BLBCs lack expression of ER, PR, and HER2, but 
there is significant overlap (~75% of BLBCs are TN) [90-92].  
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TNBCs tend to metastasise to the lung and brain, and patients have significantly shorter survival 
after the first metastatic event compared with HER2+ and ER+ cancers (median 22 months, vs 30 
and 63.5 months, respectively) [93]. This was supported by a study from our group, where basal-
like tumours were classified based on CK14 expression using IHC in a cohort of grade III IC NST. 
Overall, CK14+ cases had better long-term survival, yet it was evident that there were subgroups of 
patients with either good or poor long-term outcomes (Figure 1.5A). Indeed, all CK14+ patients 
who developed metastatic disease died within 2 years (Figure 1.5B) [94]. Thus outcomes in this 
group are heterogeneous, and it is not yet possible to predict clinical behaviour in routine diagnostic 
practice. Current management strategies are failing to achieve disease control and this subgroup 
requires better prognostic indicators (e.g. tumour biomarkers) as well as new therapeutic targets.  
 
1.4 Molecular classification of breast cancer  
The conventional method of breast cancer histological typing, grading and staging has been the 
foundation of outcome indicators. However, it has become obvious that not all breast cancers with 
the same type, grade or stage have similar underlying biology or clinical outcome [95, 96]. 
Although the expression of biomarkers ER/PR and HER2 offers information about how a tumour 
behaves clinically, the underlying biology of a tumour can only be resolved further by combining 
histopathologic factors with additional tissue-based molecular testing. In line with this idea, 
attempts have been made to classify breast cancers into different subgroups based on their 
molecular features in order to account for heterogeneity within the histopathologic classification. 
Two large breast cancer genomic datasets have substantially broadened our understanding of the 
molecular basis of breast cancer. The Cancer Genome Atlas (TCGA) research network has 
Figure 1.5: Long term survival in basal (dotted black line) versus non-basal tumour (solid black 
line).  Kaplan-Meier survival plot for basal versus non-basal showing (A) disease-free survival 
and (B) survival from metastasis. The red dotted line represents patients with worse outcome 
and the red solid line represents patients with better outcome. Figure adapted from [94]. 
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on the long-term outcome in patients with grade III IDC-NST,
a subgroup with a traditionally poor prognosis. We have spe-
cifically chosen a cohort of cases diagnosed historically as
grade III ductal carcinomas, not including any special subtypes
such as metaplastic breast carcinoma or medullary carcinoma,
because this is the group of tumours in which the majority of
basal cases seem to arise [5].
Terminology and definitions surrounding the concept of basal
tumours are controversial, and a plethora of different markers
and definitions have been employed to identify cases in clinical
studies. Nielsen and colleagues [22] have proposed a defini-
tion based on ER, HER2, CK5/6, and EGFR (epidermal
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characterised large numbers of human tumour samples to identify molecular aberrations at the 
DNA, RNA, protein and epigenetic levels [97]. Similarly, the Molecular Taxonomy of Breast 
Cancer International Consortium (METABRIC) dataset contains clinical traits, expression, copy-
number and single nucleotide polymorphism (SNP) genotype data from breast tumours collected 
from participants in the METABRIC trial [98].  
 
1.4.1 Breast cancer intrinsic subtypes 
cDNA microarray experiments performed by Perou and Sorlie showed that breast tumours could be 
classified into different molecular subtypes [88]. The original classification was further re-defined 
by the same group and others, which further contributed to characterisation of new molecular 
subtypes. Based on the similarities and differences in the gene expression profiles, breast tumours 
were mainly classified into five intrinsic or molecular subtypes (Stanford taxonomy, Figure 1.6A) 
called, luminal A, luminal B, HER2+, basal-like and normal-like (Figure 1.6A) [89]. The luminal A 
subtype is the most frequent (24%-39%), followed by basal-like (17%-37%), luminal B (10%-
18%), HER2 (4-10%) and normal-like (0-5%) [89, 99, 100]. Subsequent studies using larger 
cohorts have shown greater reproducibility (with >75% samples clustering within the same group) 
and also contributed to identifying new molecular subtypes [101-103]. Although the reproducibility 
of this classification was high, there were some discrepancies in more recent studies. By using three 
different classifiers, Weigelt et al., demonstrated that, only the basal-like subgroup was consistently 
classified as basal-like regardless of the method used. Classification of the remaining molecular 
subtypes (Luminal A, luminal B, HER2 and normal breast) varied considerably depending on the 
classifier used [104]. Also studies have shown that the normal-like subtype was not a robust 
category and represented an artefact of gene signatures related to stromal cells and adipose tissue 
(in the low cellularity tumour samples) [105, 106]. The proportion of unclassified tumours varies 
significantly across different platforms [89, 99, 100] suggesting some discrepancies. 
 
This molecular classification of breast cancer is based on the combined and consistent expression of 
specific gene clusters. Luminal A and B tumours express the ER, PR and genes associated with ER 
pathway activation, such as FOXA1, GATA3 and CCND1 [89, 102]. Unlike luminal A, luminal B 
tumours have higher expression of proliferation-related genes (e.g. CCNB1 and MK167), lower 
expression of hormone receptors (ESR1/PGR) and variable expression of ERBB2 [89, 107]. The 
HER2 subtype is characterised by over-expression of ERBB2 and other genes in the 17q12-21 
amplicon (e.g. GRB7). BLBCs are characterised by expression of basal cytokeratins (CKs 5,6,14), 
KIT, and FOXC1, frequent TP53 mutations and high proliferative activity [108]. BLBC overlaps 
with the group of basal-like TNBCs, which has been known to pathologists for many years, and this 
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overlap validates the molecular taxonomy to some extent. Importantly, classification based on 
intrinsic subtypes has shown predictive value due to the distinct clinical behaviour and overall 
survival of the different subtypes (Figure 1.6 B/C) [89, 109].  For example, luminal A tumours are 
associated with better survival, whereas BLBC and HER2 subgroups show the worst metastasis-
free- and OS rates [110]. The intrinsic subtypes have been validated using more samples and newer, 
denser microarrays [89, 102, 111, 112], and have also been correlated with survival [113, 114] and 
treatment response [106, 115], which gives clinical context to the classification system. 
 
1.4.2 Emerging molecular subtypes of breast cancer  
With an increasing number of publicly available breast cancer datasets and emerging molecular 
profiling technologies, molecular classification of breast cancer is continually being refined. New 
subtypes have emerged through analysis of larger cohorts than the original Stanford study, 
including meta-analyses that account for technical disparities between array platforms. For 
example, ‘claudin-low’ and ‘molecular apocrine’ subtypes of breast cancer have been identified as 
distinct entities within the heterogeneous TN group. The Claudin-low subtype is characterised by 
low expression of cell adhesion genes (E-cadherin, Claudin 3, 4, 7 and Occludin) and high 
Figure 1.6: Molecular classification of breast cancer using gene expression profiling. 
Hierarchical clustering of 115 breast tumour samples classified according to the  (A) intrinsic 
or molecular subtypes of breast cancer [98]. Kaplan–Meier analyses generated from (B) 
Cohort of van’t Veer et al, (n=97) and (C) Norway cohort (n=72) of breast cancer patients 
stratified according to the intrinsic subtypes [89]. Permission to use figure was obtained from 
the author and the publisher. 
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expression of epithelial-mesenchymal transition (EMT) and stem cell (CD44+CD24-) related 
signatures and accounts for 7-14% of all invasive breast cancers [103]. Molecular apocrine tumours 
are enriched with androgen receptor (AR) expression (which regulates ER-responsive genes), 
calcium and ErbB signalling, lipid and fatty acid synthesis [101, 116] and accounts for about 10-
15% of all invasive breast cancers [101, 105, 112].  
 
Several studies have attempted to tease out the heterogeneity of BLBCs to better understand the 
biology of different subgroups and identify biomarkers within this group. Lehmann and colleagues 
identified seven TNBC subgroups based on gene ontologies and differential gene expression 
profiles. These include basal-like 1 (BL1), basal-like 2 (BL2), immunomodulatory, mesenchymal, 
mesenchymal stem-like, luminal androgen receptor, and an unstable cluster. BL1 and BL2 were 
enriched with cell cycle and DNA damage response gene signatures and were highly proliferative. 
The mesenchymal (M) and mesenchymal stem-like (MSL) groups were enriched for epithelial-
mesenchymal transition (EMT) genes, whereas the immune-modulatory (IM) subtype was 
characterised by immune cell signalling features. The luminal androgen receptor (LAR) subtype 
was ER negative, but enriched in hormone-related pathways and found to express high levels of AR 
(androgen receptor) [117]. Survival analysis showed BL1 had better prognosis than BL2, LAR had 
the best OS rate and M had the worst [118]. The clinical relevance of these TNBC entities was 
investigated by determining pathological complete response (pCR) rates after neoadjuvant therapy. 
BL1 had the highest pCR (52%), whereas BL2 and LAR had the lowest (0% and 10%, respectively) 
[118]. This re-emphasises TNBC is a heterogeneous disease with unique molecular and clinical 
characteristics with different prognosis. 
 
1.4.3 Integrated molecular classification of breast cancer  
Curtis et al. recently presented an integrated analysis by combining gene expression and DNA 
copy-number alterations in ~2000 breast tumours (Figure 1.7) [98]. This integrated approach 
identified that >39% of genes were affected by copy-number alterations. By correlating cis-acting 
copy-number alterations and gene expression, this integrative approach identified 10 breast cancer 
subgroups with differences in clinical outcome (IntClust 1–10) [98]. This variation observed in 
clinical outcome across breast cancer subtypes reinforces molecular heterogeneity, as more tumours 
are being included in an unsupervised analysis, more clinically relevant and biologically informed 
subgroupings can be made. 
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1.4.4 Multi-gene prognostic and predictive signatures  
Many research and clinical groups have pursued the use of gene signature-based classifiers for 
prognostication and to facilitate treatment selection [119]. One example is Mamma-Print®  
(Agendia, Netherlands), a commercially available 70-gene test that provides prognostic information 
for patients with stage 1 or 2, node-negative invasive breast cancer of tumour size <5.0 cm. It 
provides an estimate of the risk of metastasis in early-stage breast cancer, and stratifies patients into 
two distinct groups (low vs high risk of distant recurrence) independently from ER status and any 
prior treatment [99]. The 76-gene prognostic signature (VDX2; Veridex LLC, USA) predicts 
relapse in ER+ and ER- breast cancer [120]. The Breast Cancer Index (BCI; bioTheranostics) is 
based on the HOXB13:IL17BR gene ratio, and predicts recurrence in Tamoxifen-treated patients 
[121]. The Genomic Grade Index (GGI, 97-gene signature), based on expression of proliferation- 
and cell cycle-associated genes, can accurately classify grade-1 and -3 tumours, and critically, 
provides further stratification of grade-2 tumours into grade-1- and grade-3-like cases with 
corresponding clinical behaviour [122]. Oncotype DX® (Genomic Health, USA) [109] is a qRT-
PCR assay of 21 genes associated with the ER pathway, proliferation, HER2 and invasion, and 
determines a risk of recurrence (ROR) score ranging from 0 to 100, which is an independent 
prognostic factor in Tamoxifen-treated patients with node-negative, ER+ breast cancer [109]. 
Finally, the PAM50 signature (a 50-gene qRT-PCR assay) enables classification of breast tumours 
into intrinsic molecular subtypes [123-126]. It is commercially available from Nanostring as the 
ProsignaTM assay. A ROR score is generated using an algorithm, which includes the tumour gene 
signature, tumour size, number of involved lymph nodes and its proliferative index. Similar to 
!
 
Figure 1.7: Kaplan–Meier 
analysis of disease-specific 
survival (truncated at 15 
years) for the integrative 
subgroups of breast cancer. 
For each cluster, the 
number of samples at risk is 
indicated as well as the 
total number of deaths (in 
parentheses) [98]. 
Permission to use figures 
was obtained from the 
publisher through Copyright 
Clearance Center’s 
RightsLink Service.    
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Oncotype DX® and the BCI, the ROR score stratifies patients into low, intermediate and high-risk 
groups indicating the probability of disease recurrence within 10 years. The PAM50 intrinsic 
subtype classification currently holds superior to a six-marker immunohistochemical panel (ER, PR, 
HER2, Ki-67, CK5/6, EGFR; see section below) for both prognosis and the prediction of benefit 
from adjuvant tamoxifen [127].  
1.4.5 Molecular subtyping based on surrogate IHC markers 
Studies have shown IHC surrogate markers such as ER, PR, HER2, Ki67 and basal markers (CKs 
5/6,14 and EGFR) can mimic molecular classification of breast cancer [85, 128-130] into different 
subtypes (Figure 1.8):  
 
i) Luminal A (HR+/HER2-, Ki67 low);  
ii) Luminal B (HR+/HER2-/+, Ki67 high);  
iii) HER2 positive (HR-/HER2+);  
iv) Triple Negative (TN; i.e. ER/PR/HER2-); and  
v) TN basal-like (i.e. TN with any positivity for CK5/6, CK14 or EGFR).  
 
Cheang and colleagues showed that a combination of HER2 status and expression of the 
proliferation marker Ki67 (with a cut-off of 13.25% tumour cell positivity) could distinguish 
luminal A and B subtypes [84]. In this study, the luminal B (defined by gene expression analysis) 
and luminal HER2+ (defined by IHC) breast cancers were associated with worse RFS and DFS 
relative to luminal A tumours. These results suggested that Ki67 labelling index may be a clinically 
valuable biomarker [84].  
 
The non-luminal group can be further divided into HER2+ and TN tumours based on HER2 
expression status. Basal-like cancers can be identified by a lack of ER, PR and HER2 coupled with 
the expression of basal/myoeptihelial markers (e.g. EGFR, CKs 5/6 and 14) [85]. Breast cancer 
classification based on IHC surrogate markers has also showed a significant difference in Overall 
survival (OS) rates similar to gene expression studies. Luminal A subgroup had the best OS 
compared with Luminal B and basal-like groups, and that the HER2 group had the worst OS [129, 
130]. The six-biomarker profile seems to be the most useful panel for resembling the molecular 
subtype of breast cancers as determined by gene expression profiling. 
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Breast cancer classification based on gene expression profiling is only selectively used in the clinic 
because of the high cost and complexities associated with the assay and data analysis. Translation of 
molecular signatures into the clinic has been limited due to this reason. High resolution molecular 
profiling has been enormously helpful in understanding the biology of breast cancer, though it is 
likely that prognostication will rely on surrogate IHC markers for some time because of the 
technical and logistical challenges associated with gene signature analysis in a diagnostic setting.  
 
1.5 Possible therapeutic targets in TNBC/BLBC 
There is now fairly extensive evidence that inappropriate regulation of developmental genes can 
contribute to carcinogenesis. For example, silencing of tumour suppressor genes (BRCA1, CDH1, 
HOXA5, CASP8 etc) by hypermethylation shows epigenetic deregulation in breast cancer [131-
133]. Similarly, developmental functions have been identified for many genes initially identified for 
their roles in cancer (e.g. Wnt, Notch, Pax and Hox genes [134-136]), further highlighting the 
relationships between these physiologic processes.  
 
SOX (Sry-related HMG box) gene expression has been investigated comprehensively in human 
cancer because of its critical role in development and cell fate specification [137, 138]. 
Overexpression and amplification of SOX2, 4 and 9 have been reported in various types of cancers 
including breast cancer [137]. Recent studies have shown high expression of transcription factor 
SOX10 in a subset of TN and BLBCs [139, 140]. Supporting this, a pilot study from our research 
group has shown high SOX10 expression in a subset of TNBCs in a small cohort invasive breast 
cancers [141]. Little is known about role of SOX10 in breast cancer. However, in melanomas, 
Figure 1.8: Classification of breast cancer subtype according to IHC marker panel. 
 
tended to be greater (for hazard ratios greater than unity) than the
all-cause mortality hazard ratios, ut the confidenc intervals were
somewhat wider.
The Kaplan-Meier cumulative survival for the three luminal
subtypes adjusted for study, grade, tumour size, and node status is
shown in Figure 3A. This result shows that the cumulative survival
for the luminal 1 subtypes declines almost linearly over time, which
is compatible with a constant mortality rate. In contrast, the
mortality rate in women with the luminal 2 tumours tends to flatten
out over time as the high mortality in the first few years after
di gnosis decli es. It also clearly shows the poorer prognosis for the
luminal 1 tumours that are basal marker positive. The survival
curves associated with nonluminal HER2-positive, CBP, and 5NP
tumours all show a similar pattern to that of the luminal 2 tumours
(Figure 3B). There were significant differences in prognosis between
all pairs of subtypes apart from the nonluminal HER2-positive
tumours compared with the CBP tumours (Table S4). Of particular
note is t e difference between the CBP and 5NP tumours
(p=0.0008). The luminal, HER2-positive tumours and the
nonluminal, HER2-positive tumours are two distinct subgroups,
with the nonluminal tumours having a poorer prognosis
(p,0.0001), and the CBP tumours having a poorer prognosis than
the luminal, basal-positive tumours (p,0.0001). These differences
did not depend on whether or not the patient had been treated with
either adjuvant hormone therapy or adjuvant c emotherapy (Figure
S5). In contrast, the basal markers seem to have no prognostic
significance within the HER2 positive subtypes of disease (p=0.85).
The luminal, HER2-positive tumours and the nonluminal,
HER2-positive tumours represent two distinct subgroups, as do
the ER-positive/negative tumours that are basal positive. In both
cases the ER-negative tumours have a poorer prognosis in the first
few years after diagnosis, but after 5 to 10 y it is the ER-positive
tumours that have the poorer outcome (Figure S6). In contrast, the
basal markers seem to have no prognostic significance within the
HER2-positive subtypes of disease (unpublished data).
Data on the association between the major subtypes and
prognosis have prev ously been published for three of the studies
included in this analysis—BCCA, JGH, and VGH—and it is
possible that the effect estimates that we report here are subject to
publication bias. We therefore repeated all the analyses after
excluding the data for these three studies but there was little
difference in the results (see Figure S7).
Discussion
We evaluated the prognostic significance of five previously
described major subtypes of breast cancer that were classified
using five IHC markers. To our knowledge, this study represents
one of the largest datasets analysed for prognosis research n breast
cancer using IHC markers. Our data confirm the observations of
others that the pattern of survival in ER-positive tumours is
qualitatively different to that in ER-negative tumours. In ER-
positive tumours, the mortality rate is approximately constant over
time since diagnosis, whereas the mortality rate associated with
ER-negative disease is initially high and then progressively declines
over time. However, the pattern of mortality rates associated with
the HER2-positive subgroup of ER-positive tumours (luminal 2) is
similar to those of the nonluminal subtypes (Figure 3A).
Berry et al. suggest [14] that the pattern of mortality after
diagnosis associated with ER-positive tumours is mainly an effect
of treatment with adjuvant hormone therapy and that the pattern
of mortality in women not treated with adjuvant hormone therapy
is similar to that in women with ER-negative d sease. The pattern
of mortality in women with luminal 1 tumours and treated with
adjuvant hormone therapy was similar to those who did not
receive hormone therapy (Figure S3). This result implies that the
time-dependent effects we observed are not simply the result of
adjuvant hormone therapy in a subset of the women with ER-
positive tumours. Few of the participants with HER2-positive
tumours in this study would have been treated with trastuzumab
and so the prognosis in women with these tumours would not
Figure 1. Classification of breast cancer subtypes according to IHC marker profile.
doi:10.1371/journal.pmed.1000279.g001
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studies have shown SOX10 plays a role in tumour progression and metastasis using cell line and 
mouse models ([142-144] discussed in Chapter 4). Exploring the role of SOX10 protein in breast 
cancer cohort and inhibiting their oncogenic properties may be an approach for treatment. Similarly, 
Cancer Testis (CT) antigens are another good example given their expression is aberrantly 
activated in various malignancies [145]. Because of their tumour-selective expression, CT antigens 
have been recently exploited for therapeutic benefit (section 1.5.2).  
 
1.5.1 SOX10 
SOX family of genes function by activating or repressing transcription in a tissue-specific manner, 
and play an important role in cell fate specification and lineage differentiation during development 
[146, 147]. Key developmental processes regulated by SOX proteins include sex determination, 
neurogenesis, neural crest development, skeletogenesis and hematopoiesis [148, 149]. SOX genes 
were identified based on the presence of a homologous DNA-binding domain called the HMG-box 
(high mobility group) [150, 151]. So far, around 20 SOX proteins have been identified in mice and 
in humans, and are classified on the basis of HMG box domain similarities (SoxA to SoxE) [152, 
153].   
 
SOX10 belongs to the SoxE group (SOX8, 9 & 10) of genes [154] and is an important regulator at 
multiple steps of early neural crest development [155]. SOX10 is expressed during the specification 
of migrating neural crest cells and its expression persists in neurons and melanocytes [155]. During 
melanocyte differentiation, SOX10 acts synergistically with MITF (Micropthalmia-associated 
transcription factor) and controls the expression of Dct/TRP2 (dopachrome tautomerase), an 
enzyme essential for melanin synthesis [156]. In the peripheral nervous system (PNS), SOX10 
regulates the expression of the Schwann cell-specific myelin genes P0 (protein zero), MBP (myelin 
basic protein), and PLP (proteolipid protein) [157, 158]. It also regulates expression of connexin-32 
and connexin-47 in the PNS and is involved in the process of gliogenesis [155]. In the autonomic 
nervous system, SOX10 regulates the expression of MASH1 and PHOX2B, two key transcription 
factors necessary for sympathetic nerve fate. In the enteric nervous system (ENS), SOX10 interacts 
with PAX3 and is involved in activation of c-Ret receptor tyrosine kinase pathway [155, 159]. It 
also synchronises normal ENS development in association with endothelin-3 by directly regulating 
its receptor, EDNRB (Figure 1.9) [155]. During brain development, SOX10 not only controls glial 
specification and regulates the transcription of the HER3 (ERBB3), a receptor tyrosine kinase that is 
involved in activation of the PI3K and MAPK signalling pathways [160, 161].  
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The SOX10 gene is located on chromosome 22q13.1 and spans ~15kb in length [162]. The 
predicted protein has 466 amino acids, contains 5 exons, and has a mass of ~50 kDa [162, 163]. 
Five SOX10 splice variants have been reported so far (Ensembl, #ENSG00000100146). Two 
longest isoforms have identical coding sequences that specify full-length, functional protein, but 
differ by ~100nt within the 3’ untranslated region. The other three variants are very small (124-
1095nt), lack the N-terminal portion of full-length SOX10, and currently their function(s) are 
unknown. Full-length SOX10 has two functional domains: a high mobility group-DNA binding 
domain (HMG) and transactivation domain (TAD) [164]. It is an active nuclear-cytoplasmic shuttle 
protein, though is mostly detected in the nucleus and contains two nuclear localisation signals 
(NLS). It also has a functional Rev-type nuclear export signal (NES) within its DNA binding 
domain [164]. Mutational inactivation of NES affects shuttling of SOX10 from the nucleus to the 
cytoplasm and this decreases transactivation of endogenous target genes [165]. SOX10 can bind to 
its target DNA either as a monomer or as a dimer [166]. The dimeric binding cannot be obtained 
with the isolated HMG domain and requires the presence of specific 40 amino acid residues 
Figure 1.9: Role of SOX10 in neural crest (NC) cell development. SOX10 is first expressed during neural 
crest (NC) specification in premigratory, early delaminating and migrating NC cells. SOX10 is involved in 
the development of melanocytes. During gliogenesis, SOX10 is involved in the formation of peripheral 
nervous system (PNS) cells such schwann cells and glia. In autonomic nervous system (ANS), SOX10 
controls other transcriptional factors (Mash1 and Phox2b) that are responsible for sympathetic nerve fate 
and is involved in the development of enteric nervous system (ENS). Arrows indicate positive regulation 
by SOX10. Mitf: Micropthalmia-associated transcription factor; Dct: dopachrome tautomerase; P0: 
protein zero gene; Mbp: myelin basic protein; Plp: proteolipid protein; Gdnf: glial cell derived 
neurotrophic factor; Ednrb: endothelin receptor-β. Illustration by Diantha La Vine. MUTAGENETIX (TM), B. 
Beutler and colleagues, Center for the Genetics of Host Defense, UT Southwestern, Dallas, TX. 
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immediately preceding the highly conserved HMG domain of SOX10 [166]. These residues 
cooperate with the HMG domain in a specific manner within the first two α-helices of the HMG 
domain and change the overall conformation of DNA-bound dimer [167]. Several SOX10 target 
genes have been identified, including Mitf, P0, Cx32, Oct6/Scip, and Erbb3 that are involved in 
formation of Schwann cells melanocyte differentiation [161, 166, 168-170]. In addition, recent 
ChIP-Seq data has identified novel target genes of SOX10 activity, including EGR2, Sh3tc2, Lgi4 
and Cldn19, which are required for formation of peripheral myelin [171]. 
 
SOX10 expression has been reported in several malignancies including glial derived tumours [172], 
melanoma [144], digestive carcinoma [173] and breast carcinoma [139, 140]. In human gliomas, 
high SOX10 expression inversely correlates with tumour grade [174]. SOX10 is expressed in 87-
97% of melanomas and so it has been proposed that IHC-based detection could be used in a clinical 
diagnostic setting [175-177]. Conversely, SOX10 is heavily methylated and not expressed in 
digestive cancers [173, 178, 179]. In breast cancer, SOX10 is expressed in only a subset of TNBC 
and BLBCs [139-141] and its clinical implications is currently unknown.  
 
1.5.2 Cancer-testis (CT) antigens 
Cancer-testis (CT) antigens are a group of protein antigens that are predominantly expressed only in 
the germ cells of adult testis. These antigens are usually down regulated in somatic adult tissues but 
are aberrantly activated in various malignancies [145]. About 153 CT genes have been identified to 
date and are recorded in the CT database (www.cta.lncc.br/) [180, 181]. CT antigens encoded on 
chromosome X are referred to as CT-X antigens and are distinguished from those that are located 
on other chromosomes referred as non-CT-X antigens [145, 180, 181]. Although roles for CT 
antigens in transcription, translation, chromosomal recombination and signalling have been 
proposed, their physiological functions remain poorly understood [145, 180-182]. CT-X antigen 
expression varies significantly between tumour types, being more frequent in breast, melanomas, 
bladder, lung, ovarian, hepatocellular carcinomas (‘CT-rich’) and uncommon in renal, colon and 
gastric malignancies (‘CT-poor’) [182]. CT-X expression is common in high-grade, advanced stage 
tumours, and is associated with poorer outcome [183-187]. Given their tumour-selective expression, 
CT-X antigens are conceptually attractive therapeutic targets, particularly as targets for cancer 
vaccines [187]. A range of tumour antigen genes such as MAGE [188], BAGE [189], GAGE1 [190], 
SCP1 [191] and, NY-ESO-1 [192] have been identified. In cancer patients, MAGE-A [193] and NY-
ESO-1 were the first human CT-antigens to promote spontaneous cytotoxic T cell responses [194, 
195] – they are amongst the most developed in terms of clinical translation.  Recent studies have 
shown an association between expression of the CT-X antigens MAGE-A and NY-ESO-1, and 
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TN/basal-like phenotypes in breast cancer [196-200] (as well as brain metastases in a study from 
our group [197]). Since there are currently no molecular-targeted therapy options for TNBC, and 
these cancers often carry a worse prognosis, it has been proposed that CT-X immunotherapy could 
provide therapeutic benefit for some TNBC patients [201]. Clinical trials of vaccines targeting 
MAGE-A and NY-ESO-1 are underway in melanoma, and cancers of the lung and ovary [145, 202-
207]. 
 
1.6 Project hypothesis and aims  
TNBC is a genetically, histologically and clinically diverse disease. A subset of patients in this 
group has a very poor outcome, and currently the therapeutic options available are very limited. 
Recent studies have shown high expression of transcription factor SOX10 and CT-X antigens 
(MAGE-A and NY-ESO-1) in a subset of TN and BLBCs [139, 140]. Supporting this, a pilot study 
from our lab has shown high SOX10 expression in a subset of TNBCs in a small cohort invasive 
breast cancers [141]. Although published data show that SOX10, MAGE-A and NY-ESO-1 
expression is associated with TNBC, their clinical implication is currently unknown. We 
hypothesise that SOX10 and CT-X antigens will have prognostic value in this disease, and could be 
viable therapeutic targets.  
 
A study with the following aims was developed to address this hypothesis and generally improve 
our understanding of TNBC biology: 
1. Investigate the expression and prognostic significance of SOX10 in breast cancer.  
2. Investigate functions of SOX10 in the normal breast and experimental models of breast cancer.  
3. Investigate the prognostic value of MAGE-A and NY-ESO-1 CT-X antigens in TNBC. 
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Chapter II: Materials and Methods 
2.1 Clinical samples and ethics  
This study included five clinical sample cohorts: 
i. The Queensland Follow-Up (QFU) cohort: formalin-fixed, paraffin embedded (FFPE) breast 
tumour samples from 449 patients who underwent surgical breast cancer resection at the Royal 
Brisbane Women’s Hospital (RBWH, Herston, Queensland) between 1987 and 1994. Familial 
breast cancer was not consistently identified and recorded at this time in Queensland, and thus 
we estimate the cohort comprises ~90% sporadic and ~10% of cases associated with inherited 
susceptibility [208, 209].  
ii. A cohort of 105 FFPE metaplastic carcinomas (whole sections) was obtained from Pathology 
Queensland.  
iii. FFPE TMA sections containing BRCA1 (n=139), BRCA2 (n=114) and BRCAX (n=353) cases, 
obtained from kConFab (Kathleen Cuningham Foundation Consortium for research into 
Familial Breast cancer). Mutation status was confirmed by denaturing high performance liquid 
chromatography (dHPLC) and sequencing [210]. The criteria for classifying all BRCA1 and 
BRCA2 variants by diagnostic or research laboratories are posted on kConFab’s website 
(http://www.kconfab.org/progress/mutations.asp).  
iv. A cohort of 18 FFPE reduction mammoplasty samples, obtained through collaboration with Dr 
William Cockburn, his team at the Wesley Tissue Bank (Wesley Hospital, Auchenflower, 
Queensland). Age, parity and menopausal status of these patients were unknown. Thirty-
precent cases showed fibrocystic change and 10% presented with columnar cell lesions.  
v. A cohort of 32 FFPE tumour-associated normal samples was obtained from patients who were 
part of the QFU cohort.  
 
The use of clinical samples in this study was carried out in accordance with our governing human 
research ethics committees at the RBWH (2005/022; last amendment 14/5/14) and the University of 
Queensland (2005000785, last amendment 28/05/15, expires 31/12/16). 
 
2.2 Histology review and clinical follow-up  
2.2.1 QFU and metaplastic cohort 
Four micron thick sections were cut from each tumour block and stained with haematoxylin and 
eosin (H&E) using an automatic staining machine (Tissue Tek DRS, Sakura). H&E slides for all 
donor tumour blocks were reviewed and tumour areas were annotated by a surgical pathologist. 
Clinical data from patient such as date of birth, age, date of diagnosis, death data, date of last 
follow-up and cause of death, histological grade, tumour size, presence or absence of axillary lymph 
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node, number of positive and negative nodes etc were obtained from the pathology reports (Dept. of 
Pathology, Royal Brisbane Women’s Hospital (RBWH), Herston, Queensland), Queensland Cancer 
Registry (QCR), Auslab and Paris reports. Internal review of clinical features such as histological 
type, grade, invasive type, lymphovascular invasion, lymphatic infiltration, tumour border etc. was 
performed by Prof. Sunil Lakhani as described in the formal pathology report (Appendix 2.1). A 
detailed database containing biomarker status (used clinically and conceptually), histopathologic 
and clinical variables were built using information collected from different sources.  
 
2.2.2 kConFab cohort  
Date of birth, age, date of diagnosis, death data, date of last follow-up and cause of death for 
BRCA1, 2 and X cases was obtained from original pathology reports (Cancer Council, Victoria). 
Hormone receptor, HER2 and basal marker (CK5/6, 14 and EGFR) status for all cases were 
obtained from kConFab and their collaborators. A database containing date of birth, date of 
diagnosis, death date and biomarker status were built using information collected from kConFab 
and their collaborators.  
 
2.3 Construction of tissue microarrays  
For the QFU cohort, tissue microarrays (TMAs) were constructed according to pre-designed maps 
(Appendix 2.2) using a tissue arrayer (model MTA-I, Beecher Instruments Inc., Sun Prairie, WI, 
USA). An H&E-stained section was selected from each case, and tumour-rich regions were 
identified by histopathological review, preferentially on the periphery of the tumour where the 
tissue tends to be best preserved and to avoid necrosis, selecting areas most representative of overall 
tumour histopathology. Two 0.6 mm biopsy cores per sample were arrayed into recipient paraffin 
blocks at 1 mm grid spacing. All arrays were built in duplicate. Unmatched, histologically normal 
tissue from breast, liver, testis, and pancreas were used as controls and for map orientation. After 
construction, blocks were heated to 55 °C for 10 min, then cooled to room temperature to solidify 
the donor tissue cores within the recipient block. Arrays were sectioned at 4 µm onto slides 
(SUPERFROST PLUS) for downstream analyses.  
 
2.4 Immunohistochemistry (IHC) 
2.4.1 Sectioning, deparaffinisation and antigen retrieval 
Tissue sections were incubated at 37 °C overnight to facilitate full adhesion to glass slides, and 
were subsequently deparaffinised to expose the tissues for immunostaining: xylene (three x 3 min), 
100% alcohol (two x 2 min), 90 % alcohol for 2 min, 70 % alcohol for 2 min and MilliQ water (two 
x 2 min). Heat induced epitope retrieval (HIER), also called as antigen retrieval was selected based 
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on optimisation tests for individual antibodies (Table 2). Antigen retrieval causes reversal or 
unfolding of proteins within the tissue exposing the epitope, enabling antigen binding. Tissue slides 
were put into a slide rack in a container with either of the following antigen retrieval buffers: 
- Sodium citrate: 1 in 10 dilution of 10X stock solution of 0.01 M sodium citrate (pH 6.0).  
- EDTA: 1 in 10 dilution of 10X stock solution of 0.001M EDTA (pH 8.8). 
- Chymotrypsin (1% in 10mM HCl) 
Antigen retrieval was performed in a decloaker at 125 °C for 5 min (sodium citrate) or 105 °C for 
15 min (EDTA), and then 90 °C for 10 sec. After this, the slides were left to cool for 20 min at 
room temperature (RT) and washed with TBS buffer.  
 
Washes: All washes (3 x 2 min, each) were performed using 1X TBS (Tris Buffered Saline: NaCl, 
Tris, HCL; 1.0N; ph 7.4). One litre of 10X TBS was prepared mixing 24 g Tris base (50mM), 88 g 
NaCl (150mM) and 900 ml of distilled water. To prepare a 1X solution, 10X TBS was diluted in 
distilled water. 
 
2.4.2 Immunostaining and chromogenic detection 
Staining was performed according to the manufacturer’s instructions using MACH 1 Universal 
HRP-Polymer detection kit (Biocare Medical, Cat # M1U539 G, L10). The slides were incubated 
with 30% hydrogen peroxide solution for 10 min in order to block the endogenous peroxidase 
activity, followed by TBS wash. The non-specific background staining was blocked using a reagent 
called “background sniper” for 15 min at room temperature. This was followed by incubation with 
the primary antibody for 60 min. After removal of the primary antibody with TBS washes (3 x 2 
min), incubation with the appropriate secondary antibodies (HRP-Polymer) was performed for 30 to 
45 min at room temperature.  
 
MACH 1 Universal HRP-Polymer Detection kit (Biocare Medical, Cat # M1U539 G, L10). It was 
performed as per the manufacture’s instructions using reagents supplied in the kit, except for the 
primary antibody and the TBS washes. However, peroxidase blockage was performed using the 
reagent “Background Sniper” for 15 min at RT. This was followed by incubation with the primary 
antibody diluted in TBS buffer. 1-200 µL of diluted antibody was added to each slide depending on 
tissue section sizes. The dilutions and incubation times were pre-optimised using appropriate 
control tissues (Table 2.1). After incubation with the primary antibody, tissue sections were washed 
with TBS (three x 2 min) and the secondary antibody (HRP-Polymer) and incubated for 30 min at 
room temperature. The poly-HRP is used to remove unconjugated streptavidin molecules that 
reduce signal intensity by competing for binding sites with horseradish peroxidase (HRP)-
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conjugates molecules. This allows the detection of low levels of the target molecule by decreasing 
the background staining. Finally the slides were washed (TBS: three x 2 min) followed by 
chromogenic staining. 
 
DAB chromogenic staining was prepared using VECTASTAIN ABC or MACH 1 Universal HRP-
Polymer Detection kit. Depending on the size of the tissue section, 100-200 µL of this working 
solution was added to each section and incubated for 10 min. Tissue slides were then rinsed with 
deionised water and counterstained using an automatic staining machine (Tissue Tek DRS, Sakura), 
based on a very light counterstaining program as follows: sections were incubated with 
haematoxylin for 30 s followed by washes in tap water (two x 3 min) and then 90% alcohol for 1 
min, 100% alcohol (two x 2 min) and Xylene (two x 2 min). The slides were then coverslipped 
using an automatic glass coverslipper (LJUNG TECH by INSTRUMEC, GCS 600) with a standard 
water-based mounting media. 
 
Table 2.1: Antibodies, staining methods and positivity thresholds used for immunohistochemistry 
in this study.  
Antigen 
Ab 
clone 
Catalogue no. Sp. Supplier Dilution Ag Ret. 
Cellular 
Localisation of 
staining scored? 
Positivity threshold or 
parameters scored 
ER 6F11 NCL-L-ER-6F11 M Novocastra 1/100 C Nuc > 1% 
PR 1A6 NCL-L-PGR-312 M Novocastra 1/200 C Nuc > 1% 
HER2 CB11 K5204 R Dako 1/200 C Memb 3+ by IHC and >6 by CISH 
CK5/6 D5/16B4 MAB-1620 M Chemicon 1/400 C Memb, cyto Any positivity 
CK14 LL002 NCL-LL002 M Novocastra 1/40  C Memb, cyto Any positivity 
EGFR 31G7 280005 M Invitrogen 1/100 E Memb Any positivity 
Ki-67 MIB-1 M7240 M Dako 1/200 C Nuc > 20% 
AR AR441 M3562 M Dako 1/50 C Nuc >1 % 
c-kit - A4502 R Dako 1/800 E Memb Any positivity 
SOX10 sc-17342 N-20 G Santa Cruz 1/100 C Nuc % and intensity (1-3+) 
p53 DO7 M7001 M Dako 1/200 C Nuc % and intensity (1-3+) 
Vimentin V9 M0725 M Dako 1/400 C Nuc Any positivity 
MAGE-A 6C1 sc-20034 M Santa Cruz 1/500 C Nuc, cyto % and intensity (1-3+) 
NY-ESO-1 E978 sc-53869 M Santa Cruz 1/30 E Nuc, cyto % and intensity (1-3+) 
Abbreviations: Ab- antibody; Sp- species, M-mouse, R-rabbit, G-goat; .Ag Ret- antigen retrieval, C-citrate, E-EDTA; Memb, plasma 
membrane, Nuc, nucleus, Cyto- cytoplasm.  
  
2.5 IHC biomarker scoring 
Stained slides were scanned using the Aperio ScanScope T2 digital scanning system at 20x 
magnification. Images were subjected to array image segmentation using the TMA module of 
Spectrum software (Aperio). Cores were extracted as high-resolution JPEG images with file names 
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used as metadata to link them to corresponding positions in the array. Image files were then 
imported to iPhoto (iPhoto11, v. 9.2.1), and scored by two observers independently.  
 
2.6 Chromogenic in situ hybridisation (CISH) 
HER2 typing on QFU cohort was obtained from Pathology Queensland, RBWH laboratory and 
scored by Prof. Sunil Lakhani, according to clinical diagnostic criteria (CISH score ≥ 6).  
 
2.7 Kaplan Meier survival analysis and chi square tests for association 
Statistical analysis was performed using PRISM Software (version 6.0c). The association of SOX10 
expression and different clinicopathologic parameters was evaluated using chi square and Fisher’s 
exact tests. Survival associations were identified by Kaplan-Meier analysis using log-rank test to 
assess significance. Breast cancer specific survival (BCSS) was defined as the time from primary 
breast cancer diagnosis to death due to breast cancer. For cases with locally recurrent disease 
(second/multiple primary breast cancers) the first event was used. Death due to other causes was 
censored. P-values of < 0.05 were considered significant. Multivariate analysis was performed by 
Dr Jodi Saunus using MelCalc software (v12.7). 
 
2.8 Immunofluorescence (IF) on FFPE sections 
Immunofluorescence was performed for SOX10 and CK8/18 using FFPE sections of normal breast. 
Four µm tissue sections were cut from paraffin blocks using a microtome (Lieca RM2135). The 
slides were placed at 37 °C overnight followed by deparaffinisation as described above. Citrate 
buffer was used for antigen retrieval and the sections were processed as for IHC (section 2.4.2). 
Anti-SOX10 (goat polyclonal) and CK8/18 (mouse monoclonal) primary antibodies (Santa Cruz 
Biotechnology, Cat # sc-68853 and Novocastra, Cat # NCL-L- 5D3) diluted to 1:50 and 1:100 in 
TBS, respectively, were incubated on tissue sections for 1 h at room temperature. Slides were then 
washed in TBS buffer (three x 2 min) followed by incubation with secondary antibodies: rabbit 
anti-goat IgG (Alexa Fluor 594, Invitrogen, Cat #A11008; 1:500 in TBS) and goat anti-mouse IgG1 
(Alexa Fluor 594, Invitrogen, Cat #A21125; 1:400 in TBS) for 30 min in the dark. The slides were 
then stained with SUDAN Black dye for 20 min in dark (Sigma, Cat # S-2380) to block auto-
fluorescence, washed with TBS-Tween (0.1%) for 30 min and washed again with TBS for 10 min at 
room temperature. After washing, slides were mounted using Vectashield (Vecta Laboratories, 
H1000) with DAPI (Sigma, Cat # D9542), coverslipped and sealed using nail polish, and stored in 
the dark at 4 °C. Slides were imaged with a Carl Zeiss MicroImaging system and analysed using 
Axio Vision LE version 4.8.2 (PerkinElmer, Glen Waverley, VIC, Australia).  
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2.9 Cell culture  
Breast cancer cell lines used for screening experiments were cultured according to the 
recommendations from American Type Culture Collection (ATCC) and authenticated by STR 
profiling (GenePrint 10 System, Promega Cat # B9510); Queensland Institute of Medical Research 
(QIMR) Berghofer cell line authentication service. The list of cell lines used in this study and their 
intrinsic subtypes are presented in the table 2.2.  
 
Table	  2.2:	  List	  of	  cells	  lines	  used	  in	  this	  study	  classified	  according	  to	  their	  intrinsic	  subtypes.	  	  
#	   Cell	  line	   Intrinsic	  subtype	   #	   Cell	  line	   Intrinsic	  subtype	  
1	   Bre80	  Tert	   B-­‐UC	   21	   184B5	   CL-­‐UC	  
2	   MDA-­‐MB-­‐468	   Basal	  A	   22	   T47D	   Luminal	  
3	   PMC	  42ET	   Basal	  A	   23	   MCF7	   Luminal	  
4	   HCC70	   Basal	  A	   24	   ZR751	   Luminal	  
5	   HCC1937	   Basal	  A	   25	   MDA-­‐175-­‐VII	   Luminal	  
6	   SVCT	   Basal	  A	   26	   KPL-­‐1	   Luminal	  
7	   HCC1954	   Basal	  A	   27	   UACC812	   Luminal	  
8	   HCC1143	   Basal	  A	   28	   MDA-­‐MB-­‐330	   Luminal	  
9	   BT-­‐20	   Basal	  A	   29	   SKBR3	   Luminal	  (HER2+)	  
10	   8701BC	   BB	   30	   BT474	   Luminal	  (HER2+)	  
11	   SUM159	   Basal	  B/Claudin	  low	   31	   MDA-­‐MB-­‐453	   Luminal	  (HER2+)	  
12	   MDA-­‐MB-­‐231	   Basal	  B/Claudin	  low	   32	   NIH	  3T3	   Non	  breast	  
13	   MDA-­‐MB-­‐436	   Basal	  B/Claudin	  low	   33	   HaCaT	   Non	  breast	  
14	   Hs578T	   Basal	  B/Claudin	  low	   34	   293	  T	   Non	  breast	  
15	   HBL100	   Basal	  B/Claudin	  low	   35	   HeLa	   Non	  breast	  
16	   BT549	   Basal	  B/Claudin	  low	   36	   A549	   Non	  breast	  
17	   184A1	   Basal	  B/Claudin	  low	   37	   D22	   Melanoma	  
18	   MCF10A	   Basal	  B/Claudin	  low	   38	   D05	   Melanoma	  
19	   RHB1	   Basal	  B/Claudin	  low	   39	   D41	   Melanoma	  
20	   MDA-­‐MB-­‐435	   Basal	  B/Claudin	  low	   	  	   	  	   	  	  
  
2.10 Generation of MDA-MB-435 cells with stable, shRNA-mediated knock-down of SOX10 
2.10.1 Transformation of pLKO.1 into competent bacterial host cells 
The pLKO.1 is a transfer vector backbone suitable for cloning and expressing shRNA sequence. 
pLKO.1 can be introduced into cells via direct transfection, or can be converted into lentiviral 
particles for successive infection of a target cell line. pLKO.1 vector has a puromycin resistance 
marker encoded within that allows convenient stable selection. For transformation, LB media was 
prepared by adding 10g Trypton, 10g NaCl and 5g of yeast to 1000 mL distilled water. LB agar was 
prepared by adding 15 g agar to 1000 mL LB media. LB agar (1.5%) plates were prepared by 
pouring preheated LB broth containing Ampicillin onto culture plates. Round bottom BD falcon 
polypropylene tube (14 mL) was pre-chilled on ice. Fifty µL XL1-Blue competent E. Coli cells 
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were aliquotted into the falcon tube, to which 50 ng pLKO.1 plasmid DNA was added, mixed 
gently and incubated on ice for 20 min. The tubes were subjected to heat-pulse in a water bath at 42 
°C for 45 s and transferred on ice for 2 min. Approximately 200 µL of transformation mixture was 
plated onto LB agar plates and incubated at 37 °C, overnight.  
2.10.2 Plasmid preparation 
A homogeneous starter culture of 5mL LB medium was prepared by inoculating a single colony 
from a freshly streaked plate. The mixture was incubate at 37 °C for approximately 8 h while 
shaking at 250–300 rpm. Fifty mL culture was prepared from the starter culture and incubated at 37 
°C overnight. Cells were harvested from an overnight culture by centrifuging the culture media at 
5000 x g for 10 min. Plasmid isolation was performed using the GenElute HP Plasmid Midiprep Kit 
(Cat #NA0200, Sigma) according to the manufacturers instructions. The concentration of DNA was 
estimated by measuring absorbance (optical density) at 260 nm (A260) using NanoDrop 1000 
spectrophotometer. The read outs are based on linear relationship between absorbance and 
concentration of an absorbing species (Beer-Lambert’s Law) using the formula, Concentration 
(µg/ml) = (A260 reading-A320 reading) x dilution factor x 50µg/ml. The ratio between 260 and 280 
nm was used to assess purity of DNA. An average ratio of 1.8-2.0 was considered good quality 
DNA.  
2.10.3 shRNA retroviral transduction  
A set of pre-validated pLKO.1 (puromycin-resistance) constructs encoding three different SOX10-
targeted shRNAs, and a non-target shRNA control pLKO.1-puro construct (NTNC; encodes a 
hairpin that does not target any known human gene) were purchased from Sigma as glycerol stocks 
of host E. Coli suspensions (TRCN0000018984, TRCN0000018987, TRCN0000018988 and 
SHC002, respectively). Plasmid DNA was isolated from overnight bacterial cultures as described 
above (section 2.10.2).  
 
Lentiviral particles encoding each of the shRNAs were produced by triple transient transfection of 
HEK-293T (human embryonic kidney) packaging cells with one of the four transfer plasmids 
(pLKO.1-puro; 2 µg), together with two companion plasmids encoding lentiviral packaging and 
replication elements (2 µg pHR’8.2ΔR and 0.25 µg pCMV-VSV-G, which encode viral packaging 
and envelope elements; donated by Dr Wei Shi, QIMR Berghofer) in OptiMEM media (Cat 
#31985070, Invitrogen). Packaging cells were transfected at ~60% confluence in 100 mm dishes 
according to the manufacturer’s instructions. Following completion of transfection the next 
morning, media was replaced with 5 mL target cell (MDA-MB-435) media that evening for 
overnight viral production. Viral supernatants were collected on the following two days, and filtered 
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(0.45 µm 25 mm filters, Acrodisc Syringe Filters, Cat #4614, Pall Corporation) before target cell 
transduction to ensure no cross-contamination with packaging cells. MDA-MB-435 target cells 
were seeded at 3.1×104/cm2 in 6-well plates, then after 24-48 h (at ~50% confluence), cells were 
infected with filtered viral supernatants, supplemented with 1 mg/mL polybrene (Cat #H9268, 
Sigma) for 24 h. Stably transduced cells were then selected with 1 µg/mL puromycin (Cat #P9620, 
Sigma) for two weeks to eliminate uninfected cells. SOX10 protein levels were then investigated by 
Western analysis. 
 
2.11 Western analysis 
2.11.1 Sample preparation and quantification 
Cells were briefly washed in PBS and the pellet was resuspended in 150 µl RIPA buffer: 50 mM 
Tris-HCl, pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% deoxycholic acid, and fresh protease inhibitors 
(1 mM PMSF (phenyl-methylsulfonylfluoride) with protease inhibitor cocktail (Thermo Scientific, 
Cat #78440; 10 µg/ml leupeptin, 10 µg/ml aprotinin, and 1 µM pepstatin)). After incubation at 4 °C 
for 30 min, the lysates were subjected to sonication for 10 s (10 times) and centrifuged at 13000 g 
for 30 min at 4 °C. Protein concentration was determined using Bradford Protein Assay (Biorad) 
using Bovine Serum Albumin concentration standards (BSA; Sigma: 0, 50, 100, 200 and 500 
µg/mL). Equal volumes of protein lysates (diluted in PBS to within the quantitative range of the 
assay) were analysed in 96-well plates in triplicate. The protein assay reagent was diluted 1:5 and 
then mixed with the standards and the samples and incubated for 10 min at RT, before optical 
density measurement (595 nm). Protein concentration was determined by fitting the absorbance data 
to the standard curve obtained from the BSA samples (Microsoft Excel).  
2.11.2 Western transfer and immunoblotting  
Protein lysates (30 mg) were denatured in sample buffer (cat #161-0747, BIO-RAD) with reducing 
agent (2-mercaptoethanol, cat #21985-023, Thermo Scientific) for 5 min at 95 °C, and subjected to 
Sodium Dodecyl Sulphate-Polyacrylamide gel electrophoresis (SDS-PAGE) on gradient gels (4-
15%; cat # NP0322BOX, Life Technologies). The separated proteins were transferred to PVDF 
membrane (Cat #IPVH00010, Merck-Millipore) for 60 min at 4 °C. The membrane was air-dried 
and then non-specific binding sites were blocked using 5% milk in TBS-T (20 mM TrisHCl, 137 
mM NaCl and 0.05% Tween 20, pH 7.4) for 60 min. After blocking, membranes were incubated 
with primary antibodies (SOX10, Santa-Cruz Cat # sc-17342, 1:500 dilution; β-actin, Cell 
Signalling, cat # 8H10D10, 1:5000 dilution) in TBS with 1% milk overnight at 4 °C. The blots were 
then incubated with an appropriate secondary antibody (HRP-conjugated anti-goat or anti-mouse) at 
1:5000 in TBS-T for 60 min at room temperature. Bound antibodies were detected by 
chemiluminescence (ECL, Cat #34087, Thermo Scientific), and signals developed with a Konica 
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Minolta SRX-101A tabletop processor.  
 
2.12 In vitro tumourigenicity assays  
2.12.1 Proliferation assay 
Cells were seeded at 5×104 cells/well density in a 6-well plate. The IncuCyte real-time imaging 
system (Essen Bioscience) was used to record proliferation under normal conditions every 6 h over 
a period of 5 d. Measurement of cell growth is based on area or confluence. Three technical 
replicates were assayed for each sample and two biological replicates were performed on different 
days.  
2.12.2 Scratch wound assay  
Cells were seeded in triplicate (3×104/well) in 96-well Essen ImageLock plates and cultured in 
regular conditions overnight. Monolayers were then scratched using a 96-pin WoundMaker 
(IncuCyte, Essen Bioscience) to create precise and reproducible wounds in all wells simultaneously. 
IncuCyte image analysis software was set to scan the experiment every 2 h for 72 h. Three technical 
replicates were assayed for each sample and two biological replicates were performed on different 
days.  
2.12.3 Colony formation assay  
Cells were seeded at low density (500 cells/well) in a 6-well plate in triplicate and maintained in 
complete media (DMEM supplemented with 10% foetal bovine serum and 1% 
penicillin/streptomycin) for 14 d at 37 °C in a standard CO2 incubator. The colonies were fixed in 
methanol for 15 min and stained with crystal violet (0.01% v/w) for 20 min. Colonies (size 
threshold of >50 cells) were counted by microscopy. Three technical replicates were assayed for 
each sample and four biological replicates were performed on different days.  
 
2.12.4 Tumoursphere formation assay 
Cells were seeded at very low densities (500 cells/well) in a 6-well plate in triplicate and maintained 
in NSA media [DMEM F12 containing recombinant human epidermal growth factor (EGF; Sigma; 
20 ng/mL), recombinant human basic fibroblast growth factor (bFGF; R&D Systems; 10 ng/mL), 
heparin (Sigma; 4mg/mL), human or mouse proliferation supplement (NeuroCultH; Stem Cell 
Technologies; 10%), bovine serum albumin (BSA; Sigma; 0.15%), and penicillin G-streptomycin 
solution (Gibco; 1%)] for 7 d at 37 °C in a standard CO2 incubator. Tumourspheres (discriminated 
from cell clumps using a size threshold of >50 cells) were counted manually (microscopic 
examination with the 10 x objective). Three technical replicates were assayed for each sample and 
two biological replicates were performed on different days.  
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2.13 In vivo xenograft experiments 
2.13.1 Animal Housing and ethics 
Four-week-old female NOD/SCID mice were purchased from Animal Recourse Centre (ARC). 
Mice were housed at the QIMR Berghofer Animal Facility in the optiMICE® caging system 
(Centennial, Colorado) on a 12 h light/dark cycle at 25 °C. Animals were handled under sterilised 
airflow conditions. Animal work was approved by the QIMR Berghofer Animal Ethics Committee 
and performed by Mariska Miranda and Fares Al-Ejeh in accordance with their guidelines. 
  
2.13.2 Mammary fat pad xenografts 
NOD/SCID mice were allowed to acclimatise to their surroundings for 7 days then used at 5 weeks 
of age for xenograft experiments. Mice were given anaesthesia before injecting the cells. For 
injections, 5x106 MDA-MB-435 cells were resuspended in PBS with 50% matrigel (BD, 
Biosciences, Bedford, USA) to a final volume of 50 uL and injected into the right 4th mammary fat 
pad. Tumour growth was measured twice weekly for a period of six weeks by experienced 
experimentalists (MM/FA-E) using manual calliper measurement. To calculate tumour volume the 
following formula was used: tumour volume = (B/2)*S2 where B = largest tumour measurement 
and S = the smallest, based on two-dimensional calliper measurements. Statistical analysis for in 
vitro and in vivo functional assays was performed using PRISM Software (version 6.0c) p value ≤ 
0.05 considered statistically significant. Mice were euthanased by cervical dislocation when the 
tumours reached 600mm3 in size. Tumours were fixed in paraformaldehyde (PFA) for 24 h, washed 
with 70% ethanol and stored in ethanol at 4 °C. Five mice per group were used and the experiment 
was performed only once due to time constrain. This experiment will is currently being repeated at 
QIMR Berghofer Animal Facility.  
 
2.14 In-silico analysis of published datasets 
2.14.1 Analysis of SOX10 expression, methylation and copy-number in published datasets  
Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) gene expression 
and copy-number data were obtained from the European Genome-Phenome Archive (n=1992; 
accession number EGAS00000000083). This included 209 cases classified as basal-like, 218 as 
claudin-low, 224 as HER2, 700 as Luminal A, 475 as Luminal B and 148 as normal-like (according 
to the PAM50 classifier [98]). A second, independent SOX10 dataset, comprising RNA-sequencing 
(Illumina), copy-number (Affymetrix SNP 6.0 array) and methylation (Illumina 450k) was 
extracted from The Cancer Genome Atlas (TCGA) provisional (as they are more updated compared 
to published) breast cancer dataset (1104 tumours) using the cBio Cancer Genomics Portal [97]. 
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Methylation value included was the average of probes across the gene and not just main promoter 
data. PAM50 classification results of all samples were obtained from the TCGA group, distributed 
as follows: Basal-like (n=187), Her2 (n=80), Luminal A (n=549) Luminal B (n=213), and Normal-
like (n=38).  
 
In order to understand the impact of SOX10 methylation on its expression, we performed spearman 
correlation analysis of log2-transformed SOX10 expression data and methylation data (n=737) in 
basal-like versus other breast cancers. A non-parametric test was used because the datasets were 
found to be non-normally distributed using the D-Agostino/Pearson omnibus and Shapiro-Wilk 
normality tests (GraphPad Prism, v6.0f). SOX10 is highly and consistently expressed in melanoma, 
and was hypomethylated compared to breast cancer. We applied a 90th percentile methylation 
threshold that captured the majority of the low-expression melanoma cases (11/13), and found this 
also segregated BLBC from non-BLBC. This threshold value (0.68) captured ~75% of melanoma 
cases with bottom 5th percentile expression. Melanoma data derived from TCGA (n=~450) was 
used for comparison as good model because SOX10 is over-expressed in ~95% cases. Similarly, in 
order to understand whether SOX10 expression is regulated in part by copy-number, spearman 
correlation analysis of log2 transformed RNA-seq mRNA expression and log ratio (cbs) smoothed 
copy-number data for SOX10 was performed. We used spearmen correlation analysis as cbs 
smoothed copy-number data was not normally distributed. “R” statistical software was used for all 
statistical tests [211].  
2.14.2 Normal breast epithelial compartment analysis 
To investigate SOX10 mRNA expression in the normal breast, we made use of publicly available 
gene expression array profiling data derived from fluorescence-activated cell sorting (FACS)-based 
enrichment of particular epithelial compartments: mature luminal cells, luminal progenitor cells, 
myoepithelial/mammary stem cells (MaSC) and a stromal compartment [24]. Gene expression array 
data were extracted from the Gene Expression Omnibus (GEO: GSE16997), quartile-normalised 
and assessed for quality by Mr Samir Lal using arrayQualityMetrics tool where individual array 
quality was determined by MA plot, spatial effects, density plots and heatmaps (as described in 
[212]). Probes were mapped using the illuminaHumanv3.db annotation package. For cases where 
multiple probes mapped to a single gene, probes with the highest expression across all samples were 
used. Analysis of variance (ANOVA) tests were conducted using R statistical software [211] to 
investigate expression SOX10 and a panel of genes associated with mammary epithelial 
differentiation (CK14, CK5, KIT, ELF5 and CK18) between the compartments. p<0.05 was 
considered significant.  
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2.14.3 Gene set enrichment analysis (GSEA) 
Gene signature list from Lim et al.[24] (section 2.15.2) was divided into positive and negative fold-
change subsets. mRNA expression data for luminal progenitor genes (RNA-seq) from the TCGA 
cohort was extracted from cBioportal. Data were transformed using voom tool (which transforms 
RNA-seq data to micro array format) prior to GSEA analysis [213]. For mRNA expression data, the 
relative expression of an individual gene in a reference population (both normal and tumour) is 
computed. The reference population is all samples that are diploid for the gene (by default for 
mRNA), or normal samples (when specified). The returned value from cBioportal indicates the 
number of standard deviations away from the mean of expression in the reference population (z-
score). This measure is useful to determine whether a gene is up- or down-regulated relative to the 
normal samples or all other tumour samples. SOX10 RNAseq z-scores were extracted from the 
cBioportal (TCGA provisional dataset; n=1104 cases). The cohort was separated into ‘SOX10-low’ 
and ‘SOX10-high’ groups using z-score cut-off of 2 as it separated the two groups. A total of 1000 
permutations based on the SOX10-high vs -low phenotype were used to calculate a false discovery 
rate using multiple hypothesis testing. GSEA results were shown using a normalised enrichment 
score (NES), which is the value assigned to each gene-set after normalisation across all analysed 
gene sets. The NES was determined as: actual enrichment score (ES)/mean (ES against all 
permutations in the dataset). p<0.05 was considered significant.  
 
2.15 SOX10 expression analyses  
2.15.1 RNA extraction and quantification 
Isolation of total RNA from cell pellets was performed using TRIzol (Invitrogen) according to the 
manufacturer’s protocol. Briefly, cells were collected after trypsinisation and centrifuged at 1000 
rpm for 10 min. 0.2 mL chloroform/1 mL TRIzol was added to the cell pellets for homogenisation. 
The samples were vigorously shaken for 15 s, incubated at RT for 3 min and then centrifuged at 
12,000×g for 15 min at 4 °C. The mixture was separated into three phases: upper aqueous, 
interphase and a lower phenol-chloroform phase. The aqueous phase (containing RNA) was 
removed and transferred to a new tube. For RNA precipitation, 0.5 mL of 100% isopropanol was 
added to the tube; the samples were incubated at room temperature (RT) for 10 min and then 
centrifuged at 12,000×g for 10 min at 4 °C. RNA pellets were washed with 1 mL of 75% ethanol 
and centrifuged at 7500×g for 5 min at 4 °C, then air-dried for 30 min at RT and dissolved in 20 µL 
nuclease-free water. RNA samples were qualified and quantified by qubit/bioanalyser. RNA 
integrity numbers were found to be between 9.4 and 10. 
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2.15.2 Quantitative reverse transcription polymerase chain reaction (qRT-PCR)  
SuperScript III Reverse Transcriptase (Invitrogen) was used for reverse transcription of 1µg RNA 
from each sample, according to the manufacturer’s instructions. Briefly, 1 µL (50 mM) oligo (dT), 
1 µL (10 mM) dNTP mix and 1 µg of RNA was added to nuclease-free water to make up the total 
volume 13 µL. The mix was heated to 65°C for 5 min and then incubated on ice for 1 min. 4 µL 5X 
First- Strand Buffer, 1 µL 0.1 M DTT, 1 µL SuperScript III RT and 1 µL RNaseOUT Recombinant 
RNase Inhibitor was added to each tube and the mixtures were incubated at 25 °C for 5 min 
followed by 50°C for 1 h. The reaction was inactivated by heating at 70 °C for 15 min.  
 
Primers were designed using pBLAST (http://www.ncbi.nlm.nih.gov/tools/primerblast/index). 
(SOX10- CTTCATGGTGTGGGCTCAGG and TCACTTTCGTTCAGCAGCCT) qRT-PCR was 
performed on a StepOnePlus instrument (Applied Biosystems). The PCR assay was performed in a 
final volume of 20 µL containing 1x SYBR® Green SuperMix (Invitrogen, Cat #11733-038) , 2 µL 
of cDNA samples and 10 pmol each of forward and reverse primers. PCR cycles (40 total) 
consisted of 15 s denaturation at 95 °C and a combined annealing/extension step for 30 s at 60 °C. 
Melt curve analysis was applied to validate that primers produced single PCR products. 
Hypoxanthine phosphoribosyltransferase1 (HPRT1) was amplified as a loading control, and the fold 
change in expression of each target mRNA relative to HPRT1 was calculated using the comparative 
ΔΔCt
 
method [214].  
2.15.3 Differential gene expression analysis of SOX10-depleted MDA-MB-435 cells 
Whole genome gene expression array analysis of non-target shRNA (NTC)- and shSOX10-infected 
MDA-MB-435 cells (n=3 independently infected, pooled clones each) was performed on the 
Illumina HT-12 v4 platform and analysed using the beadarray package [215] Arrays were run at the 
Ramaciotti Centre for Genomics (University of New South Wales) and the differential gene 
expression analyses were performed in collaboration with Mr Samir Lal. BASH [216] program was 
used to correct for any defects (spatial artefacts) on the array. Briefly, the bead-level data were 
checked for quality (including log transformation) and only probes with annotations were selected 
for further analysis. arrayQualityMetrics [212] was used for array comparisons to identify potential 
outliers across all arrays in the dataset by visual inspection of the arrays through sample correlation 
heatmaps and boxplots. Normalised gene expression data was then used for multidimensional 
scaling (MDS) which highlighted differences in expression profiles between samples (NTC and 
shSOX10) and differential expression analysis was conducted using the ‘limma’ package [217]. 
Differential gene expression analysis was performed on multiple genes (>10,000), which increases 
our chances of false positivity therefore, p-values were adjusted (as p<0.01 was not significant) 
using the Benjamini-Hotchberg method as it controls for false discovery rate.  
 53 
Chapter III 
SOX10 as a prognostic marker in triple-
negative and basal-like breast cancer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 54 
Chapter III: SOX10 as a prognostic marker in triple-negative and basal-like breast cancer 
3.1 Background 
Triple negative breast cancers (TNBCs) are a diverse and a heterogeneous group of tumours that are 
characterised by lack of hormone receptors (oestrogen and progesterone) and amplification of 
HER2 growth factor [218]. TNBC are typically high grade, aggressive tumours, seen in young 
women and most harbour a basal-like phenotype [77, 219]. Gene expression studies have recently 
identified six distinct TNBC subtypes, each of which displays a unique biology [117]. The 
prognosis for patients diagnosed with TNBC is variable. A subset has very poor outcome, with 
higher risk of relapse including development of lung and brain metastases [220, 221]. Current 
clinicopathologic markers, including grade, tumour size and lymph node status, do not fully explain 
this clinical behaviour, as TNBC subtype is already enriched for high-grade tumours and are lymph 
node negative. This separation of TNBCs in overall breast cancer-related survival is particularly 
marked for the ‘basal-like’ subset of TNBCs (TN-BLBC) [94], where the survival rates in not 
change considerably after five years post-diagnosis [222].  
 
Management of TNBC/BLBCs is limited and challenging as they have an overall poor outcome 
compared to other subgroups and they lack therapeutic targets in addition to standard therapy 
(unlike ER+ and HER2+ breast cancers). Despite the heterogeneity (exemplified by molecular 
profiling (section 1.6) and non-linear survival curves (Figure 1.5), they’re all managed the same 
way, using surgery, radio- and chemotherapy (although some refinement is possible by considering 
the grade and stage). There is a major requirement to better understand the molecular basis of 
TNBC development – it is anticipated that this will help identify novel drug targets and facilitate the 
development diagnostic tests and new prognostic indicators for this very heterogeneous disease. 
Current management strategies are failing to achieve disease control, and therefore this subgroup 
needs better early prognostic indicators (e.g. tumour biomarkers) and novel therapeutic targets. 
Recent meta-analysis study identified TTK, a gene associated with chromosomal instability (CIN) 
that was deregulated in TNBC [222]. Molecular inhibition of TTK supports the idea of targeting 
chromosomal segregation in tumours with a high CIN phenotype as a therapeutic strategy. This 
study demonstrated that IHC assessment of TTK provided better characterization and understanding 
for the involvement of CIN to tumour aggressiveness and prognosis [222]. Biomarkers that can be 
assessed by IHC using procedures and infrastructure that are already established in molecular 
diagnostic labs and that are associated with a high degree of accuracy and precision are needed as 
that could facilitate better diagnostic tests.  
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SOX proteins are a family of transcriptional factors 
that have an Sry-related HMG DNA-binding 
domain [223]. During development, SOX genes 
function as transcriptional activators and are often 
associated with regulation of fate specification and 
cellular differentiation. SOX10 has been studied 
extensively in melanomas and in glial-derived 
tumours. In human gliomas, high SOX10 
expression inversely correlates with tumour grade, 
and is higher in low grade than in high-grade 
gliomas [174]. IHC staining of SOX10 is now 
being used in pathology to support the preliminary 
diagnosis of melanoma [175-177]. Initial interest in 
SOX10 as a biomarker of interest in breast cancer 
came from gene expression data from our lab, showing high expression of SOX10 mRNA in TNBC 
compared to non-TNBCs, albeit the data were obtained from a very small cohort [141]. Validation 
of this finding in an independent cohort of invasive breast cancer (n=37) showed a bimodal SOX10 
mRNA distribution within TNBC (n=21) with ~60% tumours (13/21) exhibited significantly higher 
levels of SOX10 compared with luminal (n=9) and HER2+ tumours (n=7) (Figure 3.1). Recently 
published studies have reported SOX10 protein expression in a small cohort of invasive breast 
carcinomas and that its expression was enriched in TNBC and BLBCs [139, 140].  
 
3.2 Hypothesis and aims 
Although our preliminary and published data suggest that SOX10 expression correlates with triple-
negative and basal-like phenotypes, the relationships with clinical outcomes are unknown, and the 
role of SOX10 in breast cancer has not been fully characterised. Given the aforementioned 
expression pattern in breast cancer, we hypothesised that:  
1. SOX10 may be important in the biology of a subset of TNBC; and 
2. That its expression might stratify outcome in TN-BLBC, which is known to comprises 
subgroups with good and bad outcome subgroups.  
To test these hypotheses, we designed a study with the following aims: 
i) To investigate SOX10 mRNA expression, and any relationships with molecular subtypes and 
survival, using published datasets (METABRIC and TCGA)  
ii) To investigate the genomic mechanisms regulating SOX10 mRNA expression in breast cancer 
using published whole-genome expression, methylation and copy-number data 
Figure 3.1: SOX10 mRNA expression 
levels in Triple negative (TN) vs 
Luminal/HER2 amplified samples (non-TN 
breast cancer). Relative quantification (RQ) 
data normalised to the endogenous control 
(RLP13A) and to reference samples 
(normal breast). Logarithmic scale is 
displayed, **: p<0.001 (Mann Whitney U 
test). 
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iii) To generate a breast cancer tissue resource comprising up to 500 cases, with accompanying 
clinical follow-up data and TMAs for high-throughput biomarker analyses 
iv) To investigate the relationships between SOX10 protein expression, breast cancer clinic-
pathological variables and overall survival in a large cohort of invasive breast cancers. 
 
3.3 Results 
3.3.1 SOX10 expression and regulation in published genomic datasets 
3.3.1.1 Pan-Cancer analysis of SOX10 mRNA expression  
The Pan-Cancer project initiative by The Cancer Genome Atlas (TCGA) research network has 
profiled a large number of tumour samples of different cancer types [224]. When SOX10 expression 
was investigated across different cancer types, we noticed that SOX10 levels were high in 
melanoma and glioblastoma/glioma (LGG, GBMLGG, GBM), followed by neuroendocrine 
tumours and breast cancer (BRCA) in the most variable of cancers (Figure 3.2). The expression 
pattern in breast cancer in particular seems to be heterogeneous and is represented by wide error 
bars (Figure 3.2).  
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Figure 3.2: Box plot represents SOX10 gene expression in different cancer types. 
Expression is highest in melanoma (SKCM and UVM), followed by glial derived tumours 
(PCPG, GBM,GBMLGG, LGG). In breast cancer, SOX10 expression shows a wider spread 
compared with other types of cancer. (Abbreviations: ACC, Adrenocortical carcinoma; KICH, 
Kidney Chromophobe; DLBC, Lymphoid Neoplasm Diffuse Large B-cell Lymphoma; KIRP, Kidney renal 
papillary cell carcinoma; SARC, Sarcoma; THCA, Thyroid carcinoma; CHOL, Cholangiocarcinoma; 
THYM, Thymoma; KIPAN, Pan-kidney (KICH+KIRC+KIRP); LUAD, Lung adenocarcinoma; UCS, 
Uterine Carcinosarcoma; KIRC, Kidney renal clear cell carcinoma; LIHC, Liver hepatocellular 
carcinoma; UCEC, Uterine Corpus Endometrial Carcinoma; CESC, Cervical squamous cell carcinoma 
and endocervical adenocarcinoma; LUSC, Lung squamous cell carcinoma; MESO, Mesothelioma; OV, 
Ovarian serous cystadenocarcinoma; BLCA, Bladder Urothelial Carcinoma; HNSC, Head and Neck 
squamous cell carcinoma; COAD, Colon adenocarcinoma; COAD/READ, Colon and rectal 
adenocarcinoma combined; READ, Rectum adenocarcinoma; TGCT, Testicular Germ Cell Tumours; 
LAML, Acute Myeloid Leukemia; PRAD, Prostate adenocarcinoma; PAAD, Pancreatic 
adenocarcinoma; BRCA, Breast invasive carcinoma; PCPG, Pheochromocytoma and Paraganglioma; 
GBM, Glioblastoma multiforme; GBMLGG, Glioblastoma multiforme and Brain Lower Grade Glioma 
combined; LGG, Brain Lower Grade Glioma; SKCM, Skin Cutaneous Melanoma; UVM, Uveal 
Melanoma).  
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3.3.1.2 SOX10 mRNA expression in breast cancer molecular subtypes 
To assess SOX10 mRNA levels across different breast cancer subtypes, breast cancer datasets from 
the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) and The Cancer 
Genome Atlas (TCGA) were investigated [97, 98]. These datasets comprise clinical information, 
global gene expression, copy-number variation and methylation profiles of breast tumours collected 
as part of various clinical trials, and the data are readily available online.  
 
Using molecular subtype classifications applied by the respective study groups, analysis of the 
subtype distribution of SOX10 mRNA expression showed that it is enriched in basal-like tumours in 
both datasets (Figure 3.3), although it is bimodally distributed. A large proportion of claudin-low 
molecular subtype have a basal-like phenotype, and are characterised by increased expression of 
genes associated with the EMT phenotype, and also are enriched for stem cell-like gene expression 
signatures. Therefore, in this study, we have also investigated SOX10 expression in claudin-low 
subtype. We noticed high SOX10 expression and bimodal distribution patterns in the claudin-low 
subtype, which was not surprising given that a larger proportion of these tumours have basal-like 
phenotype. SOX10 expression was also high in some Luminal A and normal-like breast cancers.  
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Figure 3.3: SOX10 mRNA expression across six molecular subtypes of breast cancer classified 
according to the PAM50 classifier in (A) TCGA (n=1104) and (B) METABRIC (n=1992) dataset. 
Boxplot shows enrichment for SOX10 expression in basal-like subtype in both TCGA and 
METABRIC dataset (top panel). Frequency distribution plot (bottom panel) shows bimodal 
distribution pattern for SOX10 in basal-like (both METABRIC and TCGA) and claudin-low subtype 
of breast cancer (METABRIC only). TCGA had only eight cases defined as claudin-low and so 
was excluded for analysis. Boxplots shows the minimum, first quartile, median, third quartile and 
maximum for each subtype. Significance was assessed using Kruskal-Wallis test (p<0.0001).  
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SOX10 expression in integrative clusters (IntClust) of breast cancer (classified by a combination of 
gene expression and copy-number variations) showed high levels of expression in the IntClust-10 
subgroup and was bimodal in distribution (Figure 3.4). Given that the IntClust-10 group is thought 
to be a basal-like subgroup [98], this emphasises the enrichment of SOX10 is enriched in the basal-
like subtype regardless of classification system used. 
 
 
3.3.1.3 SOX10 copy-number (CN) variations in breast cancer 
Since SOX10 expression was enriched in the basal-like subtype of breast cancer, we wanted to 
investigate the mechanisms that were driving its high expression. We know that SOX10 is regulated 
by epigenetic mechanisms during neural crest development and melanocyte differentiation 
therefore; we investigated whether genomic alterations such as copy-number changes and 
methylation are involved in regulating SOX10 expression in breast cancer. We used matching data 
from melanoma (n=~450, from TCGA) as a reference, since SOX10 is highly expressed in 
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Figure 3.4: SOX10 mRNA expression in integrative molecular classification of 
breast cancer as defined by copy-number and gene expression profiles. Box plot 
shows enrichment for SOX10 expression within integrative cluster 10. The 
frequency distribution plot (bottom panel) shows bimodal distribution pattern for 
SOX10 in cluster 10 subgroup. Boxplot shows the minimum, first quartile, median, 
third quartile and maximum for each IntClust cohort. Significance was assessed 
using Kruskal-Wallis test (p<0.0001). 
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melanoma (87-97% of cases). SOX10 copy-number gains/amplifications were more frequent in 
basal-like cancers compared to non-BLBC (χ2 p=0.0002, Figure 3.5A). There are CN aberrations 
affecting SOX10 and these do effect expression, but overall there are only few cases with 
amplification, and across the whole cohort this generates only a weak association with expression 
(r=0.438 vs r=0.068) (Figure 3.5B). The pattern of correlation was visually similar when compared 
to melanoma cases (Figure 3.5C). Figure 3.5 B and C represents a simple linear correlation analysis 
that shows a linear relationship between CN and expression.  
 
3.3.1.4 SOX10 genomic methylation in breast cancer  
Methylation data across all probes with the strongest negative association between methylation 
signal and gene expression were included in this correlation analysis. The results showed that a 
subgroup of basal-like breast cancers (~65%) demonstrated a high expression compared with non-
BLBC (χ2 p<0.0001, Figure 3.6A). SOX10 is highly and consistently expressed in melanoma, and 
was hypomethylated compared to breast cancer. We applied a 90th percentile methylation threshold 
that captured the majority of the low-expression melanoma cases (11/13), and found this also 
segregated BLBC (r=-0.766, p<0.0001) from non-BLBC (r=-0.822, p<0.0001, Figure 3.6B). This 
strong correlation between SOX10 expression and methylation status in breast cancer suggests that 
this gene is tightly regulated by methylation in breast cancer and that hypomethylation characterizes 
BLBCs with high expression. The pattern of methylation-gene expression correlation in BLBC (red 
dots) was similar when compared with that for melanoma cases (black dots, Figure 3.6C).  
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Figure 3.5: Copy-number variation at the SOX10 locus and its association with gene expression 
(A) Bar plot depicting the percentage of samples with copy-number changes in breast cancer 
and melanoma. Scatter plot showing the correlation between SOX10 gene expression and copy-
number changes in (B) breast cancer and (C) melanoma. Melanoma cases (TCGA, n=~450) 
were used as a reference for comparison and to define thresholds. X-axis in B and C reflects raw 
CN data (log2 SNP array data). Significance was assessed using Chi-square and Spearman’s 
correlation test. 
 
 60 
 
 
 
3.3.1.5 Relationships between SOX10 mRNA expression and breast cancer survival 
There was no significant relationship between SOX10 mRNA expression and breast cancer survival 
at five years in METABRIC and TCGA datasets. However, survival after 5 years showed a trend 
towards poor prognosis in SOX10 positive cases (Figure 3.7 A and B). Since METABRIC and 
TCGA datasets represents total mRNA levels, it is important to investigate whether there is a 
correlation between SOX10 mRNA and protein levels and whether SOX10 protein expression 
correlates with poor survival.  
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Figure 3.6: Methylation status at the SOX10 locus and its association with gene expression (A) Bar plot 
depicting the percentage of samples with high/low methylation levels in breast cancer and melanoma. 
Scatter plot shows correlation between SOX10 gene expression and methylation changes in (B) breast 
cancer and (C) melanoma. Melanoma cases (TCGA, n=~450) were used as a reference for 
comparison and to define thresholds. High and low methylation levels were defined based on cut-off 
value of 0.68 as this cut-off separated high/low methylation levels in melanoma samples. The same cut-
off was then superimposed on breast cancer samples, which separated BLBCs from non-basals. Dotted 
line indicates the 90th percentiles of SOX10 methylation. Significance was assessed using Chi-square 
and Spearman’s correlation test. 
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Figure 3.7: Kaplan-Meier survival analysis comparing SOX10 positive and negative cases in 
basal-like subtype of breast cancer in (A) METABRIC and (B) TCGA datasets.  
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3.3.2 Construction of the QFU breast cancer resource 
Preliminary data from the group, and also data from publicly available breast cancer genomic 
datasets suggested that SOX10 hypomethylation (and copy-number gains in some cases) contributes 
to the relatively high expression of SOX10 mRNA in BLBC. To investigate whether this 
corresponds to SOX10 protein expression, we assembled a large cohort of invasive breast cancer 
samples with long-term clinical follow-up data, and constructed tissue microarrays (TMAs) 
comprising duplicate samples of each tumour for high-throughput IHC analysis.  
 
Of the 500 cases identified and retrieved for the study, 449 satisfied the inclusion criteria: survival 
and clinical information accessible via the Queensland Cancer Registry, and diagnostic blocks 
conducive to sampling of areas with sufficient tumour cellularity (minimum 20%). We performed a 
comprehensive clinicopathological review of the cohort, involving: (i) collection of survival data, 
patient age, lymph node status and tumour size information from clinical pathology reports; (ii) 
independent histological assessment of H&E-stained whole sections (Prof Lakhani); and (iii) 
expression of prognostic biomarkers by IHC, in order to classify cases as HER2+, ER+ (high vs low 
proliferation), TN and basal-like. The median age of patients in the cohort was 60 years. The 
median follow-up and follow-up of patients still alive were 13.2 and 25 years, respectively. The 
histopathological features of the cohort are summarised in Table 2 (Appendix 3.1). 
 
3.3.2.1 Validation of the QFU cohort: investigation of known prognostic indicators 
We validated the QFU resource by performing univariate survival analysis of the prognostic 
indicators used currently in diagnostic practice: grade, lymph node status, ER/PR and HER2 status. 
The trends observed were as expected, with high grade, lymph node-positivity, HR negativity and 
HER2 positivity (by ISH) all associated with poor outcome (Figure 3.8).  Stratification of breast 
cancer cases into different prognostic subgroups based on expression of immunohistochemistry 
markers ER, PR, HER2, Ki67, EGFR and CK 5/6 and 14 is represented in the form of a flow chart 
(see Appendix 3.2). Kalpan-Meier survival analysis of QFU cohort showed that the cohort 
separated into different breast cancer subtypes as expected (see Appendix 3.3). Ki67 threshold was 
determined by analyzing different expression cutoff values such as 10% (low) and 20% (high, 
percentage represents tumour cell positivity). Twenty per cent cutoff value showed a difference in 
breast cancer survival outcome compared to 10% (Appendix 3.4), and thus was used for 
stratification of breast tumours in this study. Comparison of the clinicopathological variables within 
different breast cancer subtypes is presented in Appendix 3.5. This analysis demonstrated that the 
QFU resource were robust and reliable for analysis of new candidate biomarkers. The baseline data 
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generated were also then available for future correlation and subgroup-specific analyses (e.g. 
analysis of SOX10 prognostic significance specifically in TN-BLBC; see section 3.3.2.4 below).  
 
 
 
3.3.2.2 SOX10 expression in sporadic breast cancer 
The intensity of nuclear expression was recorded as either negative (n=363), weakly positive (n=7) 
or strongly positive (n=30, Figure 3.9). The percentage of tumour nuclei positivity was 80-100%. 
Similarly, SOX10 staining in the cytoplasm was recorded as either negative (n=191), weakly 
positive (n=199), moderately positive (n=37) or strongly positive (n=10) as shown in Figure 3.10. 
Approximately 73% (27/37) of SOX10 nuclear positive cases showed weak cytoplasmic staining, 
about 13% (5/37) showed moderate to strong cytoplasmic staining and the remaining 14% showed 
no staining in the cytoplasm. 
Years
Pe
rc
en
t s
ur
vi
va
l
0 5 10 15 20 25
0
20
40
60
80
100
Grade I (n=60)
Grade II (n=210)
Grade III (n=157)
p<0.0001
Years
Pe
rc
en
t s
ur
vi
va
l
0 5 10 15 20 25
0
20
40
60
80
100
HR negative (n=90)
HR positive (n=329)
p<0.0001
0 5 10 15 20 25
0
20
40
60
80
100
Pe
rc
en
t s
ur
vi
va
l
Years
LN negative (n=134)
LN positive (n=113)
p<0.0001
0 5 10 15 20 25
0
20
40
60
80
100
Years
Pe
rc
en
t s
ur
vi
va
l
HER2 negative (n=381)
HER2 positive (n=43)
p<0.0001
Figure 3.8: Validation of QFU cohort according to expected outcomes for different prognostic 
variables. Kalpan-Meier survival analysis according to (A) Grade and (B) Lymph node status 
(C) ER Status and (D) HER2 status. Significance was assessed using Gehan-Breslow-
Wilcoxon test. 
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SOX10 nuclear and cytoplasmic expression across different subtypes of breast cancer is shown in 
Figure 3.11. The results showed 50% (27/54) of TN-BLBC, 25% (4/16) TN non-basal, 10% (5/49) 
Luminal B and <1% (2/266) Luminal A cancers were positive for SOX10 nuclear staining. Chi-
square analysis showed a positive association between SOX10 nuclear expression and TN-BLBC 
(Figure 3.11A, p<0.0001). However, between 60-70% of all cases in each subtype showed SOX10 
cytoplasmic staining was not associated with any of the breast cancer subtypes (Figure 3.11B).  
 
 
 
50um 
B A C 
Figure 3.9: Representative images of SOX10 nuclear staining on breast tumour 
cases at 10X magnification showing (A) completely negative (B) weakly positive and 
(C) strong positive. 
 
50um 
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Figure 3.10: Representative images of SOX10 cytoplasmic staining 
on breast tumour cases at 10X magnification showing (A) completely 
negative (B) weakly positive (C) moderately positive and (D) strong 
positive. 
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3.3.2.3 Relationships between SOX10 expression and clinicopathologic variables  
Chi-square analysis showed a strong positive association between SOX10 nuclear expression and 
histopathologic parameters (e.g. grade and mitotic score, p<0.0001) within the whole cohort. This 
was not surprising because SOX10 expression marks a subset of BLBCs, which are high-grade 
tumours to begin with. Among the different biomarkers tested, SOX10 expression showed a 
positive correlation with Ki67, p53, Vimentin and c-kit and an inverse correlation with the androgen 
receptor (AR), p<0.0001 for each) (Appendix 3.6). However, there was no association with age, 
tumour size, lymph node status and lymphovascular invasion.  
 
Comparison of the clinicopathological variables based on SOX10 status within TN and TN-BLBC 
is presented in Table 3 (Appendix 3.7). Mitotic score showed a positive correlation with SOX10 in 
the TN group (p=0.0467). Among the different biomarkers examined, SOX10 expression correlated 
positively with c-kit and vimentin within the TN group (p=0.0068 and 0.007 respectively). 
Androgen receptor showed an inverse correlation with SOX10 expression within the TN and TN-
BLBC groups (p=0.0010 and p=0.0177 respectively).  
 
3.3.2.4 Relationship between SOX10 expression and breast cancer-related survival 
Kaplan-Meier analysis of the QFU cohort (n=426 with informative staining) showed SOX10 
cytoplasmic positivity was not associated with survival (Figure 3.12C). By contrast, nuclear 
positivity was associated with a 40% decrease in the disease specific survival at five years (Figure 
 
Figure 3.11: Frequency of SOX10 expression in the (A) nucleus and (B) 
cytoplasm across different subtypes of breast cancer. Significance was 
assessed using Chi-square test (p<0.0001).  
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3.11A, p<0.0001; hazard ratio (HR): 3.66 +95% confidence interval (CI): 1.78-7.51. Given that 
most of the nuclear staining was in a subset of TN/BLBCs, we analysed survival specifically in this 
subgroup and found a similar result (Figure 3.12B; p=0.0188; HR: 3.20 +95% CI: 1.28-8.03). 
SOX10 nuclear expression did not stratify outcome in the other subgroups; however it was 
observed infrequently and the case numbers were not sufficient for robust statistical analysis.  
 
In a univariate model, SOX10 nuclear expression in TN/BLBC showed strong prognostic 
significance at 5 years post-diagnosis with a difference in the survival rate was similar to that of 
grade (GI vs GIII) and lymph node status (log-rank test), which suggests that the SOX10 nuclear 
expression may have independent prognostic value. Our TN/BLBC cohort was of insufficient size 
to investigate this in a multivariate model. Whether SOX10 nuclear expression should be 
considered as a useful marker in the diagnostic setting needs to be confirmed in studies with a larger 
cohort, and is therefore a priority for future work along with validating the data in an independent 
cohort. 
 
 
3.3.3 SOX10 expression in breast cancer special types enriched for basal-like phenotypes 
 
Immunohistochemistry based study has shown ~91% (59/65) of metaplastic breast carcinomas have 
basal-like immunophenotype as defined by Nielsen et al [85] regardless of type of metaplastic 
element [225]. These tumours express several other markers usually found in BLBCs such as 
vimentin [226, 227], caveolin 1 [228] and EGFR [229, 230]. More recently, microarray based gene 
expression analysis of 20 metaplastic breast cancers revealed that 95% of all cases have basal-like 
molecular subtype [231].  
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Figure 3.12: Kaplan-Meier survival analysis of SOX10-negative and–positive subgroups within (A) the 
whole cohort (QFU) (B) TN-BLBC and (C) survival analysis comparing SOX10 positive staining in the 
nucleus and cytoplasm. p values are represenated at 5 and 25 years respectively. Significance was 
assessed using Gehan-Breslow-Wilcoxon test. 
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Similarly, immunohistochemistry profiles and morphological characteristics of sporadic basal-like 
breast cancers shows striking similarities to that of tumours arising in BRCA1 mutations carriers 
[94, 232, 233]. Using overlapping but not identical definitions, it has been demonstrated that a large 
proportion of BRCA1 mutations carriers have a basal-like phenotype [89, 232, 234]. Lakhani et al., 
has shown that ~70% of BRCA1 tumours express basal cytokeratins (CK5/6 and/or CK14) are 
negative for ER [234]. BRCA1 tumours have shown to segregate with sporadic basal-like breast 
cancers consistently in hierarchical clustering analysis using gene expression profiling data [89]. 
There is also evidence that metaplastic carcinomas harbour BRCA1 dysfunction where BRCA1 gene 
promoter is being methylated in about 60% of these cases [235].  Therefore, keeping these 
observations in mind, a natural extension of our work was to see whether SOX10 expression has 
prognostic significance in metaplastic and familial breast cancers as a large proportion of these 
tumours have basal-like phenotype. 
 
3.3.3.1 Metaplastic breast cancer 
Metaplastic carcinomas comprise a group of typically high-grade tumours, which have both 
epithelial and mesenchymal elements and often have basal-like phenotype. They account for 4-5% 
of all breast cancers, and are often associated with aggressive clinical behaviour and poor outcome. 
SOX10 expression has been previously investigated in a small cohort of metaplastic carcinomas, 
with 6/13 (46%) of which showed high SOX10 expression. We therefore investigated SOX10 
expression in a larger, independent cohort of metaplastic carcinomas (n=105); whole sections rather 
than TMA were used (to ensure that we considered intrinsic morphologic heterogeneity). Overall, 
48% of cases (51/104) showed SOX10 nuclear positivity. Unlike sporadic breast cancers, SOX10 
expression in was not only restricted to TNBCs, it was seen in ~50% cases regardless of which 
subtype (Figure 3.13A). SOX10 staining intensities ranged from weak (3/51), to moderate (30/51) 
and strong (18/51) (Figure 3.13B-D). The percentage of tumour cell positivity was 20-100% in each 
group. Most positive cases were classified as mixed metaplastic type (42/51) the other subtypes also 
included squamous cell spindle cell and chondroid cell carcinoma (9/51). SOX10 expression within 
the whole cohort showed a trend towards better outcome in Kaplan-Meier survival analysis. This 
was not a strong correlation, as the data did not reach statistical significance (p=0.06). However, 
within only mixed metaplastic subtype, SOX10 expression showed a significant correlation towards 
better outcome (p=0.04, Figure 3.12F).  
 
 
 67 
 
 
3.3.3.2 Familial breast cancers  
The relationships between tumour SOX10 expression, the basal-like phenotype and survival are 
unknown in familial breast cancers. Since tumours arising in germline BRCA1 mutation carriers are 
enriched with basal-like phenotypes, we examined whether SOX10 also has prognostic significance 
in a large cohort of familial breast cancers with BRCA1 germline mutations (n=139). About 71% 
BRCA1 cases were basal-like based on expression of basal markers (CK5/6 and/or CK14 and/or 
EGFR) and about 35% were TN basal-like. Our results showed within BRCA1 cohort, 46% 
(64/139) were SOX10 positive. We also assessed the relationships between SOX10 expression and 
breast cancer-specific survival in BRCA2 (n=114) and BRCAX cases (n=353) for comparison. 
Within these groups 46% BRCA2 and 69% BRCAX cases were basal-like; about 11% BRCA2 and 
9% BRCAX cases were TN basal-like. SOX10 expression in BRCA2 and BRCAX groups were 
10.5% (12/114) and 9% (33/353) respectively.  
 
SOX10 expression in familial cancers was not associated with triple negative phenotype and was 
similar to metaplastic cancers with no difference in the frequency of expression between TNBC 
(~50%) and other subtypes (~60%, Figure 3.14A). Interestingly, SOX10 expression correlated with 
better outcome in BRCA1 cases (Figure 3.14B) in contrast to sporadic cancers. There was no 
difference in breast cancer-specific survival in BRCA2 cases (Figure 3.14C), though the small size 
of the SOX10 positive subgroup prevented robust statistical analysis. In BRCAX cases, which are 
not enriched for any particular subtype, SOX10 expression correlated with poor outcome at five 
years post-diagnosis. Interestingly, four out of six cases responsible for the early decline in 
mortality were basal-like TNBCs. This effect was lost when observed across 25 years (Figure 
3.14D).  
 
Figure 3.13: SOX10 nuclear expression in metaplastic carcinomas. (A) frequency of SOX10 expression in 
TN group versus others. Light microscopy images showing (B) negative (C) weak positive (D) moderately 
positive and (E) strong positive; (F) Kaplan-Meier survival analysis comparing SOX10 positive and 
negative staining. Significance was assessed using Chi-square and Gehan-Breslow-Wilcoxon test. 
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As SOX10 expression correlated with better outcome in BRCA1 cases, we wanted to investigate 
whether this difference existed in the TNBC subset. Similarly, we wanted to know whether SOX10 
expression in BRCA2 and BRCAX cases showed any difference in survival within TN and basal-like 
TN subsets of these cohorts. The results showed no significant difference in survival at 5 years in 
both BRCA1 and BRCAX groups (Figure 3.15) within TN and basal-like TN subsets. We could not 
investigate this in BRCA2 cases, as the sample size was small.  
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Figure 3.14: SOX10 nuclear expression in familial brest cancer. (A) frequency of SOX10 expression 
in TN group versus others. Kaplan-Meier survival analysis comparing SOX10 positive and negative 
staining in (B) BRCA1+, (C) BRCA2+ (D) BRCAX cases. p values are represenated at 5 and 25 
years respectively. Significance was assessed using Chi-square and Gehan-Breslow-Wilcoxon test. 
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Figure 3.15: Kaplan-Meier survival analysis comparing SOX10 positive and negative 
cases within triple negative (TN) and TN basal-like subgroups in familial breast cancer (A-
B) BRCA1+ (top panel) and (C-D) BRCAX cases (bottom panel). Significance was 
assessed using Gehan-Breslow-Wilcoxon test. 
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3.4 Discussion  
Breast cancer is a complex heterogeneous disease that encompasses different tumour entities with 
different biological features and clinical outcomes. New therapeutic options are particularly needed 
for patients with breast tumours that are TN, as there are currently no targeted therapies available, 
and these tumours can be associated with aggressive clinical behaviour. Identifying new biomarkers 
may hold the key to a better biological understanding of the development of these tumours, and may 
also improve the clinical management through more accurate prognostication and/or as companion 
diagnostics for new targeted therapies.  
 
In this study, analysis of published breast cancer genomic datasets showed that high SOX10 mRNA 
expression was enriched in basal-like breast cancer subtype and was inversely correlated with 
methylation leading to increased expression, suggesting epigenetic regulation is important in breast 
cancer. There is clear evidence that DNA methylation profiles for BLBCs are different to other 
types of breast cancer [236, 237]. BLBC have lower methylation levels compared to Luminal or 
HER2 [238, 239]. SOX10 may be one of the differentially methylated genes in breast cancer, which 
would explain its high expression levels in BLBC compared to other subtypes.   
 
We also found that the nuclear expression of SOX10 is strongly associated with poor outcome in 
TN/BLBC. This observation needs to be validated in an independent cohort in order to strengthen 
our hypothesis for SOX10 as a potential breast cancer biomarker. This is in process through 
collaboration with the Nottingham group (Prof. Ian Ellis). The use of SOX10 monoclonal antibody 
(Santa Cruz, Clone N20) as a diagnostic marker for melanoma has been reported in different studies 
[175, 176]. Our data therefore may raise an interesting possibility regarding potential utility of 
SOX10 assessment to guide management decisions in TN/BLBC. Only a subset of TNBCs have 
poor survival outcome and yet at this point all TNBCs are treated with standard adjuvant therapies. 
There is a subset within TNBC with better come post 5 years of diagnosis that are currently not 
identified or separated in routine diagnostic practice who may not require standard therapy. In this 
chapter, we have shown TNBCs can be characterised as “good” and “bad” outcome groups based 
on SOX10 expression using IHC and this stratification may help in better management of these 
patients in future. SOX10 positive patients can therefore be classified as high-risk group (as they 
have the worst survival outcome within 5 years of diagnosis) and this group may benefit from 
intense surveillance and risk reducing interventions in future. Having said this, identifying new 
TNBC biomarkers is not just enough given that there is no therapy that targets SOX10. This study 
is leading to further understanding of functional role of SOX10/downstream signalling pathways 
regulated by SOX10, which would help identify targets for new therapeutic regimens in future.  
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The reason for different relationships observed between SOX10 and survival in the different TN 
cohorts in this study may be for the following reasons. Metaplastic carcinomas are enriched with 
mesenchymal and stem cell-like characteristics, and are often inherently aggressive in terms of 
clinical behaviour. This is distinct from sporadic, triple-negative IC NST, which comprise both 
aggressive and treatment-responsive cases with very good outcomes. TN tumours arising in BRCA1 
mutation carriers are characterised by DNA repair deficiency and genome instability, and overall 
have a poor outcome, but lower mortality rate in the first 5 years after diagnosis compared with 
sporadic TN cases [240], which tend to metastasise rapidly if they progress. Thus although they 
have in common a TN, basal-like phenotype, there are still clear differences in the biology 
underlying their development. Recent published study showed that sporadic and BRCA1 BLBC 
have independent miRNA expression profiles supporting the underlying difference [241]. There is a 
possibility that these differing biological backgrounds might affect SOX10 function, which may 
explain the different relationships with clinical correlates observed in the different cohorts. 
Alternatively, SOX10 expression may be an inconsequential correlate in metaplastic and BRCA1 
mutation carriers. Therefore, further functional experiments are required to fully role of SOX10 in 
breast cancer (see chapter IV). 
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Chapter IV 
Evaluating the functional role of SOX10 in 
breast cancer and normal breast 
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Chapter IV: Evaluating the functional role of SOX10 in breast cancer and normal breast 
4.1 Background 
Preliminary and published data show that SOX10 is strongly associated with aggressive clinical 
behaviour in sporadic breast cancers when expressed and localised in the nucleus, suggesting this 
could be a causal association, since SOX10 is a transcription factor. This tends to occur in a subset 
of triple-negative, basal-like tumours. However, little is known about SOX10 function in the breast, 
in either normal or neoplastic contexts. 
 
SOX10 expression is initiated in the pre-migratory neural crest cells during development [242]. Its 
expression controls multipotency, survival, proliferation and differentiation of neural crest cells into 
melanocytes, as well as specialised cells of peripheral and autonomous nervous system (as 
described in Chapter 3) [155, 243, 244]. During melanocyte differentiation, SOX10 expression is 
restricted to the bipotent melanoblast glia progenitor cells and is completely absent in the 
differentiated melanocyte suggesting an inverse association with differentiation (Figure 4.1) [156]. 
SOX10 in adult mature tissues is restricted to a few cell types, expressed mainly in mature glial 
lineages from the peripheral and central nervous system and melanocytes (reviewed in [155]). Less 
common cell types include the basal cells of salivary glands and a subset of smooth muscle cells of 
the pancreas and prostate [175, 245]. The expression SOX10 in the normal breast was originally 
reported to be restricted to the basal compartment [175]. A recent study reported SOX10 expression 
in both luminal and basal compartment [140]. There is evidence from the literature that SOX10 is 
essential for the survival of notch4-immortalised mouse mammary epithelial cells [246], which is 
consistent with its role in regulating differentiation, although this was in melanocyte development. 
 
 
 
 
 
Figure 4.1: Differentiation of neural crest cell (NCC) into melanocyte [156]. Permission to use figure was 
obtained from the publisher through Copyright Clearance Center.    
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SOX10 knockdown in Xenopus model showed loss of NC precursors, decreased expression of Slug 
and Foxd3, enlargement of non-NC domains, increased apoptosis and decreased proliferation. In 
vivo and In vitro, SOX10 knockdown blocks the formation of melanocytes and ganglia [247]. 
SOX10 homozygosity in mice is associated with defects of the entire PNS and motor neurons [166]. 
SOX10 haploinsuffiency causes aganglionosis of the colon and pigmentation defects whereas, 
homozygous deletion of SOX10 in mice leads to embryonic lethality [248]. In humans, 
heterozygous mutations in SOX10 gene are associated with Waardenburg-Hirschprung disease 
(colonic aganglionosis, hearing defects, pigmentation abnormalities and myelinopathies [249]).  
 
Little is known about functional role of SOX10 in cancer development, studies on functional 
aspects of SOX10 have been largely in melanomas. Low frequencies of intragenic mutations in the 
SOX10 gene have indicated that maintenance of SOX10 wild type function is essential for 
melanoma formation [142, 250]. Role of SOX10 in melanomagenesis has been demonstrated using 
different mouse models [142, 144]. Cronin and co-workers have shown that loss of SOX10 causes 
cell cycle arrest at G1 phase and demonstrated that SOX10 expression is fundamental for 
melanomagenesis in vivo, low SOX10 expression reduced tumour formation in melanoma mouse 
model [142, 144]. Another study showed SOX10 controls migration of B16F10 melanoma cells 
through multiple regulatory target genes. This study showed that a cascade of gene expression 
initiated by SOX10 and subsequently facilitated in part by MITF (microphthalmia-associated 
transcript factor) represented an important regulatory axis of migration and metastasis in a subset of 
melanoma cases [251]. Additionally, Graf and co-workers investigated role of SOX10 in different 
human melanoma cell lines and showed SOX10 inhibition revealed a critical role in melanoma cell 
invasion and survival [143]. 
 
4.2 Hypotheses and aims 
Melanocytes, glia and mammary epithelia all derive from a common ectodermal origin, thus it is 
possible that they might retain some common developmental features. Indeed, high expression of 
SOX10 is a feature of neoplastic transformation in cancers of all three tissues (possibly due to 
epigenetic dysregulation; Figure 3.2), and inappropriate reactivation of developmental/embryonic 
pathways is known to be a mechanism used in cancer to achieve critical growth advantages [252]. 
Given that SOX10 expression is inversely associated with differentiation in the melanocyte lineage, 
we hypothesise that it is associated with an undifferentiated phenotype in the normal breast. Since 
high SOX10 expression in basal-like breast cancer (BLBC) is associated with poor outcome, we 
propose that it is causally associated with aggressive/tumourigenic cell behaviour.  
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To address these hypotheses, we aim to: 
i) Investigate SOX10 protein expression in normal breast tissue in situ. 
ii) Investigate SOX10 mRNA expression in published gene expression data from fluorescence-
activated cell sorting (FACS)-derived normal breast cell compartments. 
iii) Investigate SOX10 expression in a panel of breast and melanoma cell lines. 
iv) Investigate the effect of short hairpin (sh) RNA-mediated SOX10 knockdown on proliferation, 
migration, invasion and colony formation by breast cancer cells in vitro. 
v) Investigate the effect of SOX10 shRNA on tumour growth and metastasis in vivo. 
 
4.3 Results  
4.3.1 SOX10 expression in the normal breast 
4.3.1.1 In situ analysis of SOX10 expression in the normal breast  
A report from Nonaka et al., suggested that SOX10 expression is restricted to the myoepithelium 
[175]. However, a more recent study reported its expression in myoepithelial and some luminal 
cells [140]. To clarify this discrepancy, we investigated SOX10 expression by IHC analysis of 11 
reduction mammoplasty specimens using commercially available antibody from Santa Cruz.  
 
The results showed SOX10 
nuclear expression in normal 
breast was heterogeneous in 
both ducts and lobules. Six of 11 
cases (55%) showed both 
myoepithelial and luminal cell 
staining in the lobules of normal 
breast sections. Four cases 
(36%) showed combinations of 
staining within the same section 
i.e, some lobules stained only 
myoepithelial cells (Figure 4.2 
A) and the others stained both 
myoepithelial and luminal cell 
(Figure 4.2 B). Only 1 case (9%) showed SOX10 staining in only myoepithelial cells.  
 
 
Figure 4.2: Representative images of SOX10 staining in normal 
breast sections (10X magnification) in (A) basal compartment 
(myoepithelial cell) and (B) luminal and basal compartment 
(myoepithelial/luminal cell) within the same case. 
50um
A B
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Next, we investigated if there was any difference in expression between ducts and lobular units. The 
percentage of luminal cells positive for SOX10 was calculated in ducts and lobules of 20 normal 
breast cases. Within the ducts, 70% cases were homogeneously positive and 20% expressed SOX10 
heterogeneously (~40-90% luminal-positive). Ten per cent of cases (Q695 and Q725) were 
excluded due to a lack of ductal structures (Figure 4.3A). Within lobules, luminal expression of 
SOX10 was mixed. Of the cases containing lobular units (80%), ~30% were homogeneously 
positive, and ~50% cases showed mixed staining; with either 100% (positive), or 0% (negative) or 
10-80 % (heterogeneous). Twenty per cent of cases (Q556, Q689, Q725 and Q778) were excluded 
due to a lack of ductal structures (Figure 4.3 B). When looked at the difference in the percentage of 
SOX10 positive luminal cells, lobules showed higher percentage compared to the ducts (Figure 4.3 
C, p=0.0168).  
 
4.3.1.2 SOX10 expression in mammary epithelial compartments  
Tissue and cell type-specific expression of genes can often provide clues about their functions, as 
can an understanding which other genes are co-expressed. In 2009, Lim, Visvader and colleagues 
published a landmark paper describing a method for generating single cell suspensions from 
reduction mammoplasty tissues that were enriched for functionally distinct compartments of the 
normal breast [23, 24]. The method used fluorescence-activated cell sorting (FACS) to segregate 
A 
B Figure 4.3: SOX10 staining pattern and percentage positivity within the luminal 
compartment of reduction mammoplasty 
cases. Percentage of SOX10 luminal 
positivity is shown in (A) ducts, (B) 
lobular units and (C) ducts vs lobular 
units. The boxplot shows the minimum, 
first quartile, median, third quartile and 
maximum for each group. Q695 and 
Q725 were excluded due to lack of 
ductal structures. Q556, Q698, Q725 
and Q778 were excluded due to lack of 
lobular structures.  Significance was 
assessed using unpaired t test 
(p=0.0168).  
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cells expressing different combinations of CD49f and EpCAM, characteristic of the myoepithelium 
and bipotent progenitor cells (CD49f+/EpCAM-), mature luminal (CD49f-/EpCAM+), luminal 
progenitor (CD49f+/EpCAM+) and stromal (CD49f-/EpCAM-) cells. Importantly, the authors also 
performed gene expression profiling analysis on the four compartments from three separate 
patients, and these data are now publically available.  
 
SOX10 was moderately expressed in the Myo/MaSc compartment, consistent with our IHC data 
(Figure 4.2 A). Within the luminal compartment, where protein expression was heterogeneous by 
IHC, SOX10 mRNA levels were significantly higher in luminal progenitor compared with mature 
luminal cells (Figure 4.4A), with expression levels similar to known luminal progenitor markers 
KIT [24] and ELF5 [253] (Figure 4.4). Together these data suggest that SOX10 could be involved in 
regulating epithelial differentiation in the breast.  
 
  
Since SOX10 is associated with neural crest stem cell activity in development and in certain 
derivatives in the adult (e.g. melanocyte differentiation), we hypothesised that it may also be 
associated with stem/progenitor cell activity in the breast. The observation that SOX10 is highly 
expressed in luminal epithelia is consistent with this hypothesis, as the frequency of progenitor cells 
 
Figure 4.4: mRNA expression of selected genes in human mammary 
epithelial subpopulations derived from reduction mammoplasties. Box plots 
shows expression of (A) SOX10, (B) KIT and (C) ELF5, and (D) CK8/18. 
Boxplots shows the minimum, first quartile, median, third quartile and 
maximum for each subtype. Significance was assessed using ANOVA test. 
P value corresponds to the difference among the group means. LP: luminal 
progenitor, MaSc: mammary stem cell, ML: mature luminal and S: stromal. 
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expressed in the luminal compartment (specially in the lobules) is high during different stages of 
development (e.g. at puberty and during pregnancy) [254, 255].  
 
In order to investigate the involvement of SOX10 in luminal differentiation, we analysed the 
relationship between SOX10, c-kit (luminal progenitor marker), ER (marker of mature epithelial 
cells) and Ki67 (marker of cell proliferation) by performing IHC analysis on serial sections of 
normal breast (11 of the most epithelial-rich samples from the cohort used in section 4.3.1.1). 
SOX10 expression in luminal cells showed a direct correlation with c-kit and an inverse correlation 
with ER (Figure 4.5) on a cell-by-cell level in both ducts and lobules. There was no relationship 
with Ki67 expression.  
 
We also analysed SOX10, c-kit, ER and Ki67 staining on serial sections of normal breast associated 
with triple-negative breast tumours (n=19; described in chapter 3). Among these, 11 cases were 
SOX10 positive and the remaining were SOX10 negative. Compared to reduction mammoplasty 
specimens, similar staining patterns of SOX10, c-kit and ER were observed in the tumour-adjacent 
normal tissue (data not shown). However, we did not find any correlation with proliferation marker 
Ki67. These data further suggest that SOX10 maybe involved in regulating mammary epithelial 
differentiation. 
 
We then analysed the relationship between expression of SOX10 and CK8/18, a marker of mature 
luminal cells [256] (Figure 4.6). For this analysis we used immunofluorescence to enable 
 
Figure 4.5: Light microscopy images of normal breast sections showing SOX10, c-kit, ER and Ki67 
staining on serial sections (20X). Arrows indicate SOX10 positive luminal cells have a direct correlation 
with c-kit and an inverse correlation with ER. Images were scanned and analysed using Aperio 
software. 
SOX10 c-kit ER Ki67 
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multiplexing of the antibodies (dual analysis in the same cells; Figure 4.6 A and B), as well as IHC, 
using a high dilution of CK8/18 to make the analysis semi-quantitative (Figure 4.6 C and D). In 
lobules with a myoepithelial-restricted pattern of SOX10 expression (no luminal staining), the 
luminal compartment was CK8/18-positive (Figure 4.6Aii); whereas CK8/18 was weakly expressed 
in lobules with SOX10-positive luminal cells (Figure 4.6Bii).  
 
 
Individual cells in SOX10 heterogeneous lobules also exhibited this inverse relationship (Figure 
4.6Biii, arrows). IHC analysis showed SOX10-negative luminal cells (Figure 4.6 D) express higher 
levels of CK8/18 compared to SOX10-positive luminal cells (Figure 4.6 C) with weak staining of 
CK8/18. Arrows in the figure indicate presence of adjacent duct where SOX10 is negative in the 
luminal cells, while area marked in red indicates a lobule with SOX10-positive luminal cells. Based 
on these data we hypothesised that SOX10 may be involved in regulation of terminal differentiation 
in the luminal epithelial compartment of the normal breast. 
 
!
!! !
!!
 
Figure 4.6: Immunofluorescent staining on FFPE sections (A) SOX10 staining (green) in myepithelial 
cells and CK8/18 staining (red) in mature luminal cells. (B) SOX10 staining in both myepithelial and 
luminal cells. Arrows indicate SOX10 negative CK8/18 postive cells. Circles highlight strong and weak 
CK8/18 in lobular units. Light microscopy images of (C) SOX10 nuclear staining and (D) CK8/18 
cytoplasmic staning. Dotted red lines marks a lobular unit and arrows shows neighbouring duct.  
C D 
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4.3.2 SOX10 expression in breast cancer cell lines.  
In order to select an appropriate cell line model into investigate functional role of SOX10 in breast 
cancer, we looked at SOX10 expression levels across a panel of breast cancer cell lines. In-house 
screening showed only 2/30 cell lines, which were basal-like (HCC1143 and MDA-MB-435) 
showed detectable levels of SOX10 (Figure 4.7A) suggesting SOX10 could be silenced and/or a 
SOX10-positive cell subpopulation could be lost during adherent in vitro selection. Melanoma cell 
lines were used as a control in our in-house screening experiment as we know that SOX10 is 
expressed in most melanomas (up to 97%). Cell culture conditions that promote de-differentiation 
(growth factor deprivation and suspension format) did not induce SOX10 expression in breast 
cancer cell lines (Figure 4.7C). This suggests that in vitro cell culture conditions promoting 
selection of stem/progenitor cells did not induce SOX10 expression in a panel of basal-like breast 
cancer cell lines.  
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Figure 4.7: SOX10 mRNA and protein expression in cell lines (A) SOX10 mRNA levels in a panel of 
breast and non-breast cell lines that have been clustered according to intrinsic molecular subtype. 
Immuno blot shows SOX10 protein expression in (B) MDA-MB-435, HCC1569, HCC1143 and HCC38 
cell lines; (C) SOX10 expression in a range of breast cancer cell lines grown as tumour spheres.  	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Although in-house screening detected SOX10 mRNA in MDA-MB-435 and HCC1143 basal-like 
cell lines, analysis of protein expression by IHC (on cell-line TMA) and Western blot showed only 
MDA-MB-435 was positive for SOX10 (Figure 4.7B). We also tested the basal-like cell lines 
HCC1569 and HCC38 by Western analysis, since a published report showed SOX10 expression in 
these lines [140], but we could only detect SOX10 in HCC1569 (Figure 4.7B). Therefore, we used 
MDA-MB-435 and HCC1569 cell line as models to investigate the functional role of SOX10 in 
breast cancer.  
 
4.3.3 shRNA-mediated knockdown of SOX10 using lentiviral transduction 
We used lentiviral transduction to establish stable shRNA-mediated knockdown of SOX10 in 
HCC1569 and MDA-MB-435 cells. We were able to generate two stable MDA-MB-435 sublines 
with very efficient knockdown (SOX10 protein virtually undetectable by Western blot), and one 
sub-line with partial knockdown (Figure 4.8A; red and black respectively). HCC1569 cells showed 
changes in cell morphology after viral transduction from cobble stone-like (Figure 4.8B) to 
mesenchymal/spindle-like (Figure 4.8C), and ultimately failed to proliferate and survive post-
transduction. Therefore, we were not able to perform western blot, as there was not enough cells 
that survived for protein extraction. These results suggest that SOX10 is essential for cellular 
proliferation, growth and survival in HCC1569 cells. There was no difference observed in cellular 
morphology for MDA-MB-435 post transfection (hence, images not shown).  
 
 
4.3.3.1 Effect of SOX10 knockdown in vitro in MDA-MB-435 cell line 
We next investigated whether loss of SOX10 had any effect on cell proliferation, migration and 
invasion. To assessing proliferation rate, cell growth was measured at regular time intervals based 
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Figure 4.8: SOX10 knockdown in MDA-MB-435 and HCC1569 cell lines using lentiviral transfection 
system (A) Immuno bolt shows SOX10 expression in MDA-MB435 cell line and effective knockdown in 
shRNA transduced lines, NTNC was used as a non-target negative control. Change in cell morphology of 
HCC1569 cells from (B) cobble stone-like to (C) mesenchymal/spindle like. 
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on the area of confluence. To assess cell migration and invasion, the relative wound density (wound 
area expressed relative to the cell density outside the wound area) at was measured at regular time 
intervals. The results showed SOX10 knockdown did not alter the rate of proliferation (Figure 
4.9A) or migratory behaviour (Figure 4.9B) compared to the non-target negative control 
(NTC/NTNC) (Figure 4.9).  
 
 
Given that SOX10 expression is inversely associated with differentiation in the melanocyte lineage 
and possibly in mammary epithelia (as seen in section 4.3.1.2), we investigated whether SOX10 
knockdown affected colony and sphere forming capacities (as they mark an undifferentiated state) 
under normal culture. There was a significant decrease in the number of colonies formed in the 
knockdown line compared to the control line (Figure 4.10A, p=0.028). However, we did not see 
any difference in tumour sphere formation (Figure 4.10B).  
Figure 4.9: Effect of SOX10 knockdown on (A) proliferation and (B) migration between NTNC and 
shSOX10 in MDA-MB-435 cell line. Error bars represents standard error of mean (SEM). Significance was 
assessed using unpaired ‘t’ test. 
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Figure 4.10: Effect of SOX10 knockdown on (A) colony formation and (B) sphere formation 
in MDA-MB-435 cell line. The number of colonies/spheres were normalised to NTNC. CFU: 
colony forming units and SFU: sphere-forming units. Error bars represents standard error 
of mean (SEM). Significance was assessed using unpaired ‘t’ test. 
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4.3.3.2 Effect of SOX10 knockdown in vivo 
Analysis of the relationship between SOX10 expression and outcome in breast cancer showed that 
high expression in basal-like breast tumours is associated with significantly poorer survival (chapter 
3). Although, loss of SOX10 showed no effect on cell proliferation and migration in vitro, we 
wanted to investigate SOX10 loss in a physiological context using an in vivo xenograft model. Cells 
stably expressing the SOX10 shRNA construct or the control were injected into the mammary fat 
pads of BALB/c nu/nu (immunocompromised) mice; five mice were used in each group. The mice 
were monitored for 30 days, and xenografts were regularly measured with vernier calipers. Tumour 
growth was calculated from calliper measurement of tumour’s longest (a) and shortest (b) diameters 
using the formula, tumour volume (mm3) = a/2 x b2.  The results showed that SOX10 knockdown 
significantly impaired primary tumour growth (Figure 4.11, p=0.0013). These data suggest SOX10 
expression has a significant impact on cell proliferation promoting tumour growth in vivo. The 
results showed that SOX10 knockdown significantly impaired primary tumour growth (Figure 4.11, 
p=0.0013). These data suggest SOX10 expression has a significant impact on cell proliferation 
promoting tumour growth in vivo.  
 
 
4.3.4 Differential gene expression analysis of MDA-MB-435 basal-like breast cancer cells 
with and without SOX10 silencing  
In order to investigate possible mechanisms underlying the aggressive phenotype of SOX10 
positive breast cancers, we performed comparative gene expression analysis of MDA-MB-435 cells 
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Figure 4.11: MDA-MB-435 cell line xenografts. (A) Effect of SOX10 knockdown on 
primary tumour growth and (B) Bar graph shows fold change in growth rate. Error bars 
represents standard error of mean (SEM). Significance was assessed using unpaired ‘t’ 
test with Welch’s corrections. 
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with (NTNC) and without SOX10 (shSOX10), using gene expression array profiling. This 
identified a total of ~257 differentially expressed genes (120 induced and 137 suppressed, with at 
least two-fold change in expression and a corrected p value of <0.05). Strikingly, the 15/20 
differentially expressed probes (highlighted in blue) were highly enriched for genes in the MHC-II 
antigen presentation pathway (Table 4.1, 15 probes corresponding to 8 genes).  
 
All these genes were significantly induced in shSOX10 cells (which were not seen in the wild type 
cells). Consistent with this, gene ontology analysis of the full list of differentially expressed genes 
showed that enrichment for the immune response antigen presentation by MHC class II, Cell 
adhesion glycoconjugates, immune response MIF mediated glucocorticoid regulation and immune 
response oncostatin M signalling via MAPK in human cells, immune response antigen presentation 
and inflammation IL4 signalling. Collectively these data implicate SOX10 in suppression of antigen 
presentation in MDA-MB-435 cells, raising the possibility that this may also occur in BLBC. 
Functional validation of this idea was outside the scope of this study, and further studies are 
required to fully understand the link between SOX10 and immunogenicity in BLBC.  
 
PROBES SYMBOL GENENAME logFC AveExpr t P.Value adj.P.Val 
ILMN_2157441 HLA-DRA MHC, class II, DR alpha 6.66 10.33 69.34 1.67E-16 8.05E-12 
ILMN_1792455 TMEM158 transmembrane protein 158 5.56 10.68 60 8.86E-16 2.13E-11 
ILMN_1689655 HLA-DRA MHC, class II, DR alpha 5.02 10.77 50.33 6.70E-15 1.07E-10 
ILMN_1761733 HLA-DMB MHC, class II, DM beta 4.66 8.83 48.4 1.05E-14 1.27E-10 
ILMN_3228688 HLA-DRB1 MHC, class II, DR beta 1 5.62 9.28 45.72 2.03E-14 1.94E-10 
ILMN_3228688 HLA-DRB4 MHC, class II, DR beta 4 5.62 9.28 45.72 2.03E-14 1.94E-10 
ILMN_3228688 HLA-DRB3 MHC, class II, DR beta 3 5.62 9.28 45.72 2.03E-14 1.94E-10 
ILMN_1736567 CD74 MHC, class II invariant chain 4.77 8.66 45.01 2.42E-14 1.94E-10 
ILMN_1772218 HLA-DPA1 MHC, class II, DP alpha 1 5.48 8.78 43.76 3.35E-14 2.30E-10 
ILMN_2379644 CD74  MHC, class II invariant chain 4.2 8.04 42.86 4.26E-14 2.56E-10 
ILMN_2066066 HLA-DRB6 MHC, class II, DR beta 6  5.03 8.81 41.36 6.41E-14 3.39E-10 
ILMN_2066060 HLA-DRB6 MHC, class II, DR beta 6  4.75 8.68 41.02 7.04E-14 3.39E-10 
ILMN_3243714 HLA-DRB1 MHC, class II, DR beta 1 4.17 8.19 40.35 8.51E-14 3.72E-10 
ILMN_3243714 HLA-DRB3 MHC, class II, DR beta 3 4.17 8.19 40.35 8.51E-14 3.72E-10 
ILMN_1703178 SCG2 secretogranin II 4.43 9.34 39.82 9.91E-14 3.97E-10 
ILMN_1725139 CA9 carbonic anhydrase IX 3.69 8.36 39.4 1.12E-13 4.14E-10 
ILMN_1813704 CEMIP cell migration inducing protein 3.57 11.07 36.98 2.31E-13 7.54E-10 
ILMN_1695311 HLA-DMA MHC, class II, DM alpha 3.95 9.98 36.72 2.51E-13 7.54E-10 
ILMN_1762899 EGR1 early growth response 1 -3.49 9.78 -36.79 2.45E-13 7.54E-10 
ILMN_1752592 HLA-DRB4 MHC, class II, DR beta 4 3.77 9.52 36.22 2.94E-13 8.31E-10 
Table 4.1: Differentially expressed probes in shSOX10 and non-target negative (NTNC) sublines of MDA-
MB-435 breast cancer cells in vitro (e.g. mean of n=3 shSOX10 or NTNC samples were compared for each 
probe).  
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4.4 Discussion  
Although, SOX10 expression is reported in several malignancies including melanoma, glioma, 
digestive cancers and breast carcinomas, very little is known about its functional role in cancers. 
SOX10 role has been broadly investigated in melanomas and studies using mice models have 
demonstrated that loss of SOX10 causes cell cycle arrest at G1 phase that SOX10 expression is 
fundamental for melanomagenesis [142, 144]. There is evidence that SOX10 controls invasion, 
migration in melanoma cells lines and is involved in metastasis in melanoma cases [251].  
 
In breast cancer, we noticed a subset of basal-like breast cancer show high SOX10 expression and 
are linked to poor survival outcome. As there is limited data on SOX10 and its function in breast 
cancer and normal breast, we investigated its functional role in malignant and normal cells. 
Analysis of in-house screening experiments demonstrated infrequent expression of SOX10 in breast 
cancer cell lines, suggesting SOX10 is silenced and/or a SOX10-positive cell subpopulation is lost 
during adherent in vitro selection.  Another possible reason for difference in SOX10 expression in 
primary breast cancer cell lines could be due to the fact that the majority of cell line samples are 
derived from metastases. In vitro cell culture conditions promoting selection of stem/progenitor 
cells (suspension format and/or growth factor-deprivation) did not induce SOX10 expression in a 
panel of basal-like cell lines. shRNA-mediated knockdown of SOX10 in basal-like MDA-MB-435 
breast cancer cells did not alter their proliferation rate, migratory behaviour or sphere formation in 
vitro, though did reduce colony formation on plastic (p=0.028). However, in vivo tumourigenicity 
assays showed that SOX10 knockdown in mice reduced tumour formation suggesting high SOX10 
expression promotes tumour growth in mice.  
 
TNBC are highly mutagenic [257] and are characterised by an increased number of tumour 
infiltrating lymphocytes, which can facilitate an immune response [258]. Cells with greater influx 
of tumour infiltrating lymphocytes respond better to neoadjuvant therapy compared to less 
immunogenic tumours [259]. Immunotherapy strategies in treatment of breast cancer has shown 
some hope in recent studies, for example, two new related classes of drugs called anti-PD-1s and 
anti-PD-L1s, also called as ‘immune checkpoint blockers’ have shown some promising results in 
breast cancer. PD-1 inhibitor, pembrolizumab in a phase Ib KEYNOTE-012 trial demonstrated an 
overall response rate of 18.5% in patients with PD-L1–positive TNBC (unpublished, San Antonio 
Breast cancer Symposium 2015). In the current study, we found that differential gene expression 
analysis using MDA-MB-435 cell line showed enrichment for immune related genes post SOX10 
knockdown suggesting a link between SOX10 and immunogenicity. This suggests that targeting 
SOX10 may improve survival outcome in a subset of TNBC/BLBC.   
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In normal breast, SOX10 expression was initially described to be restricted to the myoepithelial 
compartment [175]. However, a more recent study by Ivanov et al., reported SOX10 expression in 
myoepithelial and in some luminal cells [140]. Our analysis in both normal and tumour-associated 
normal breast tissue, agreed with the findings of Smith and colleagues that showed both 
myoepithelial cells and luminal epithelial cells were positive for SOX10 in normal ducts and lobular 
units. Based on IHC and IF results, we noticed SOX10 expression is heterogeneous within normal 
breast structures. Regardless of ducts and lobules, SOX10 expression was not only restricted to 
myoepithelial cells but is also expressed in luminal epithelial cells. In this chapter, in silico and in 
situ analysis confirmed a direct correlation of SOX10 expression with luminal progenitor marker c-
kit. Complementary to our findings, a recent study has reported that SOX10 is specifically 
expressed in mammary cells exhibiting the highest levels of stem/progenitor activity [260]. These 
data, together with our data on clonogenicity and knowledge of SOX10’s role in progenitor function 
in other tissues (e.g. melanocytes), we hypothesise that SOX10 could be involved in progenitor 
function in basal-like breast cancers. Further functional studies are required to fully understand the 
role of SOX10 in breast cancer and normal breast (see chapter 6 for future directions).  
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Chapter V: Analysis of prognostic significance of MAGE-A and NY-ESO-1 cancer testis 
antigens in breast cancer  
5.1 Background  
 
Melanoma-associated antigen A (MAGE-A) was identified in melanoma cells as a testis tumour 
antigen gene [193]. To date, ~60 MAGE genes have been discovered, which all share a central 
conserved region called the MAGE homology domain (MHD), and are subdivided into groups I and 
II based on their protein expression patterns [261]. The MAGE-A subfamily includes MAGE-A1 to 
A15 and all known genes of this family are located on chromosome Xq28. Each gene is ~4.5 kb, 
has three exons and encodes a protein of 309-319 amino acids (with the exception of MAGE-A10, 
which is slightly larger at 369 amino acids) [262].  
 
Cancer testis antigen 1B (CTAG1B), also known as, NY-ESO-1 is another prominent CT antigens 
located on the X-chromosome. It spans about 1.6 kb, has 3 exons and encodes a protein of 180 
amino acids [263]. NY-ESO-1 is expressed in variety of human cancers [263] but in the normal 
tissues it is primarily limited to the testis and ovaries. NY-ESO-1 is thought to be one of the most 
immunogenic CT antigens, and is capable of inducing spontaneous humoral immunity in patients 
whose tumors express this antigen [200, 264, 265]. Because of this property, NY-ESO-1 has been 
an attractive candidate for immunotherapy.  
 
Amongst the studies evaluating MAGE-A and NY-ESO-1 expression in breast cancer, there have 
been contradicting reports on the expression frequency in breast cancer, with MAGE-A-positivity 
ranging from 20-74% and NY-ESO-1 from 2-40% [196-200]. One possible explanation could be 
variation in the size and composition of the tumour cohorts (for example, the cohort used in [197] 
was enriched for ER-negative and basal-like tumours). Other factors that varied among these studies 
were the use of different antibodies and their antigen retrieval techniques (reviewed in [201]).   
 
At the molecular level, MAGE proteins promote the viability of malignant melanoma cell lines by 
suppressing apoptosis [266, 267]. Several MAGE-A proteins (1-3 and 6) inhibit p53 transactivation 
by recruiting histone deactylase 3 (HDAC3) to sites of p53 interaction at the promoters of target 
genes, leading to resistance to chemotherapies that promote apoptosis? (e.g. etoposide) [266]. 
Mechanistically, MAGE-A suppresses the p53 transcriptional program during tumour development 
by interacting with its DNA-binding domain, blocking its association with cognate sites in 
chromatin. Silencing MAGE-A induces p53-responsive genes in a p53-dependent manner and 
stimulates interaction of p53 with the p21, MDM2, and PUMA promoters [268]. 
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CT-X antigen expression in breast cancer was interrogated by meta-analysis of a large massively 
parallel sequencing dataset (nine studies, 1259 breast tumours and 51 breast cancer cell lines) [197]. 
Expression of some MAGE-A genes was associated with ER-negativity (MAGE A3, A6 and A9), 
and others were specifically associated with the basal-like subgroup (A1, A4-6, A12 and NY-ESO-
1-1), and these relationships were validated at the protein level by TMA-based IHC analysis of two 
separate breast cancer cohorts. Other large cohort studies have also confirmed these associations 
[269, 270]. Since there are currently no molecular-targeted therapy options for TNBC, and these 
cancers often carry a worse prognosis, it has been proposed that CT-X immunotherapy could 
provide therapeutic benefit for some TNBC patients [201]. Although published data show that 
MAGE-A expression is associated with TNBC, it is currently unknown whether it stratifies 
outcome in this group. A recent study assessing MAGE-A expression in breast cancer by qRT-PCR 
reported a trend towards poorer survival in MAGE-A 3/6-high, hormone receptor-negative cases, 
however the association was not statistically significant [271].  
 
In ER-positive breast cancer, gene expression profiles of ER+ Tamoxifen resistant (TR) breast 
tumour-derived lines identified and functionally validated MAGE-A2 as a novel TR-associated 
gene [272]. MAGE-A2 localises to the nucleus and forms complexes with p53 and ERα in ER 
positive Tamoxifen-resistant cells, resulting in repression of the p53 pathway but increased ER-
dependent signalling [272]. Expression of MAGE-A2 in 144 ER+ TR breast cancers was assessed 
by IHC. Thirty-five showed high expression of MAGE-A2 and positive staining was significantly 
associated with reduction in overall survival in this cohort [272], suggesting a link between 
expression of MAGE-A proteins and failure of Tamoxifen therapy. 
 
5.2 Hypothesis and aims  
The main focus of this thesis has been investigating novel prognostic biomarkers within hormone 
receptor negative breast cancers. Published data suggest MAGE-A and NY-ESO family proteins 
show an association with high-grade triple negative breast cancers. MAGE-A interacts directly with 
p53 in vitro, resulting in repression of the p53 pathway whereas, very little is known about NY-
ESO. Others members in our lab have examined the relationship between MAGEA and NY-ESO-1 
in breast cancers, and identified an association of MAGE-A with p53 expression. Although, mRNA 
expression of MAGE-A in ER negative and protein expression MAGE-A in ER positive breast 
cancers are linked with poor outcome, it is currently not known whether MAGE-A and NY-ESO-1 
protein expression is related to clinical outcomes within triple negative breast cancer. Therefore, we 
hypothesize that i) MAGE-A and/or NY-ESO-1 expression can stratify human breast cancers into 
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clinically meaningful groups and that ii) MAGE-A family proteins could be potential therapeutic 
target in triple negative breast cancers. To address this, we aim to  
 
i) Investigate MAGE-A and NY-ESO-1 expression in a larger cohort of invasive breast 
cancers (n=449) with long-term follow-up (25 years, QFU cohort) in order to correlate 
with clinical outcome 
 
ii) Associate MAGE-A and NY-ESO-1 expression with biomarkers used either clinically or 
conceptually  
 
iii) Investigate prognostic significance of MAGE-A and NY-ESO-1 in breast cancer cohort 
 
 
5.3 Results 
5.3.1 MAGEA and NY-ESO-1 expression in breast cancer  
Using commercially available antibodies, we optimised IHC staining conditions using a small panel 
of normal tissues, and selected conditions that produced the strongest signal in testis compared to 
other normal tissues (e.g. intestinal, lymphoid and epithelia). The MAGE-A antibody used is 
known/predicted to bind to A1-4, A6, A10 and A21 MAGE-A proteins. When staining pattern was 
investigated in QFU tumour cohort, MAGE-A was characterised by localisation to the nucleus and 
cytoplasm of tumour epithelial cells. Among positive cases, 33% stained exclusively in the 
cytoplasm, 33% were exclusively nuclear and 34% exhibited both nuclear and cytoplasmic staining. 
The intensity of nuclear expression was recorded as either negative (n=364), weakly positive (1+; 
n=2), moderate (2+; n=7) or strongly positive (3+; n=22) (Figure 5.1). The intensity of cytoplasmic 
expression was recorded separately as either negative (n=364), weakly positive (1+; n=7), moderate 
(2+; n=5) or strongly positive (3+; n=3). 
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NY-ESO-1 staining was also characterised by localisation to the nucleus and cytoplasm of tumour 
epithelial cells in the QFU tumour cohort. Only 14/403 cases were positive for NY-ESO-1, of 
which two were exclusively cytoplasmic and 12/14 exhibited both nuclear and cytoplasmic staining. 
The intensity of expression was recorded as either negative (n=391), weakly positive (1+; n=4), or 
strongly positive (2+; n=8) (Figure 5.2). The percentage of tumour nuclei positive was categorised 
as 1 (<33 % tumour cell nuclei stained), 2 (33-66%) or 3 (>66%). Fifty precent cases (6/12) were in 
category 3, 33% (4/12) were in category 2 and 17% (2/12) were in category 1.  
 
 
 
Figure 5.1: Representative images of MAGE-A staining on breast tumour cases in the QFU 
cohort showing (A) negative (B) weak positive (C) moderately positive and (D) strong positive 
staining. 
50um 
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5.3.2 Distribution of MAGE-A and NY-ESO-1 expression across breast cancer subtypes  
Chi-square analysis showed a positive association between MAGE-A and NY-ESO-1 expression 
with the triple-negative phenotype (p<0.0001; Figure 5.3), which is consistent with published data 
for MAGE-A and NY-ESO-1 [201, 270, 273]. MAGE-A positivity was observed in ~34% (18/53) 
TNBCs with basal-like features, 27% (4/15) of non-basal TNBCs, 4% (9/241) of HR+/HER-/+ 
(Ki67low) and 8% (4/48) HR+/HER2- (Ki67high) cases. NY-ESO-1 positivity was restricted to ~21% 
(11/52) of basal-like TNBCs.  
 
 
 
5.3.3 Comparison of MAGE-A expression with breast cancer clinicopathologic variables 
Across all invasive breast cancers, regardless of molecular subtype, Chi square analysis showed a 
strong positive association between MAGE-A nuclear expression and markers of poor prognosis 
(grade, mitotic score, HR status, triple-negative status and Ki67 expression). Among different 
 
Figure 5.2: Representative images of NY-ESO-1 staining on breast tumour cases in the QFU cohort 
showing (A) negative (B) weak positive and (C) strong positive staining. 
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Figure 5.3: Bar plots shows distribution of (A) MAGE-A and (B) NYESO-1 
expression across different breast cancer subtypes in the QFU cohort. Significance 
was assessed using chi-square test. 
TN
 Ba
sal
TN
 no
n b
asa
l
HR
- /HE
R2
+
HR
+ /HE
R2
-/+
 
(Ki
67
low )
HR
+ /HE
R2
- 
(Ki
67
hig
h )
0
50
100
150
200
250
no
. o
f c
as
es
MAGE-A PositiveMAGE-A Negative
χ2 <0.0001
TN
 ba
sal
TN
 no
n b
asa
l
HR
- /HE
R2
+
HR
+ /HE
R2
-/+
 
(Ki
67
low )
HR
+ /HE
R2
- 
(Ki
67
hig
h )
0
50
100
150
200
250
no
. o
f c
as
es
NY-ESO PositiveNY-ESO Negative
χ2 <0.0001A B 
 93 
biomarkers tested, MAGE-A expression showed a positive correlation with basal markers (CK5/6, 
CK14 and EGFR), p53 expression, c-kit, Vimentin, and an inverse correlation with androgen 
receptor (AR), (Figure 5.4 and 5.5, and Appendix 5.1). There was no association with age, tumour 
size, LN or LVI (lymph node status, lympho-vascular invasion). Within TNBCs, there was no 
association between MAGE-A nuclear expression and known clinicopathologic variables, though 
interestingly, there was an association with the luminal progenitor marker, c-kit (Appendix 5.2).  
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Figure 5.4: Association between MAGE-A expression with clinical and histopathological indicators 
in breast cancer. Significance was assessed using chi-square test. 
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5.3.4 Prognostic significance of MAGE-A in breast cancer 
Kaplan-Meier analysis for MAGE-A nuclear-positive cases within the whole cohort (n=426) 
showed a 40% decrease in disease-specific survival at 5 years (Figure 5.6A, p=0.0035). However 
there was no stratification within TNBCs and basal-like TN (Figure 5.6B and C), suggesting that in 
published reports where MAGE-A family genes was suggested to be a prognostic indicator in breast 
cancer based on its mRNA expression [271], it could be simply acting as a surrogate marker for 
poor outcome TNBCs. Also, the number of TN samples may not be sufficient to determine if 
MAGE-A can alter disease outcome. There was no relationship with survival in TNBC when we 
analysed nuclear and cytoplasmic expression separately (data not shown).  
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Figure 5.5: Association between MAGE-A expression with biomarkers such as Ki67, basal 
markers (CK5/6, CK14, EGFR), p53, c-kit, vimentin and androgen receptor (AR). Significance 
was assessed using chi-square test. 
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5.3.5 Characteristics of NY-ESO-1 positive tumours and correlation with survival outcome 
NY-ESO-1 expression in this study was observed in a small group of basal-like TNBCs (14/403 
cases; ~3%). The clinical characteristics of NY-ESO-1 positive tumours are presented in Appendix 
5.3. All positive cases were either grade 2 or 3, 68% were above the age of 50 years, 27% showed 
high Ki67 expression (>20%) and almost all cases were positive for MAGE-A and p53. Analysis of 
the relationship between NY-ESO-1 expression and survival showed a trend towards poorer 
outcome in the whole cohort (QFU) and the TNBC subgroup, which was interesting. However, 
these relationships were not statistically significant as the numbers were too small for any statistical 
power. These findings should however be followed up in a larger breast cancer cohort in future 
(Figure 5.8). 
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Figure 5.6: Kaplan-Meier survival analysis of MAGE-A negative and positive cases within (A) whole 
cohort (B) triple negative and (C) triple negative (TN) basal-like breast cancers. Significance was 
assessed using Gehan-Breslow-Wilcoxon test. 
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Figure 5.7: Kaplan-Meier survival analysis of NYESO-1 negative and positive cases 
within (A) whole cohort and (B) triple negative (TN) basal-like breast cancers. 
Significance was assessed using Gehan-Breslow-Wilcoxon test. 
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5.4 Discussion 
Triple negative breast cancers (TNBC) constitute a heterogeneous group of tumours. The clinical 
outcome of patients with this subgroup of breast cancer are often linked to poor outcome compared 
to those with hormone receptor positive breast cancer that generally have better outcome. There are 
currently no molecular targets available for treatment of TNBC and unfortunately chemotherapy is 
the only standard treatment given to these patients. Anti-cancer vaccines may help in the 
management of these patients if a suitable target antigen/s and patient population can be identified. 
Cancer testis (CT) antigens are a group of protein antigen that are predominantly expressed in 
human germ line cells and become activated frequently in different cancer types. Numerous CT 
antigens have proved to be useful markers and promising therapeutic targets for cancer vaccines.  
 
A study from our group has previously reported that expression of CT-X antigens, MAGE-A and 
NY-ESO-1 was observed in ER- breast cancer cell lines and primary breast cancers using gene 
expression analysis [197]. These results were in concordance with protein expression of MAGE-A 
and NY-ESO-1 in ER- breast cancers, and showed a trend for their co-expression with basal cell 
markers [197]. Although, several published studies have shown expression of MAGE-A and NY-
ESO-1 in breast cancer, results from these studies have shown contradicting results with MAGE-A 
positive rate ranging from 20-74 % and NY-ESO-1 positive rate ranging from 2-40 %. Subsequent 
studies with large cohorts have shown members of MAGE-A family and NYESO-1 expression to 
be correlating with high grade TNBC [269, 270]. Matkovic and colleagues have reported expression 
of MAGE-A and NY-ESO-1 in medullary breast carcinomas and the results from this study 
showed, 33% of cases were positive for MAGE-A and positive cases were associated with poor 
prognosis (p=0.004). Whereas, NY-ESO-1 expression in the same cohort was reported in 22% 
cases and also showed a trend towards poor prognosis (p=0.007) [274]. Currently, there is only one 
study that has reported most rigorous investigation of NY-ESO-1 expression in a larger cohort of 
TNBC (n=168) and showed 16% of triple negative breast cancers (TNBC) were positive for NY-
ESO-1. There was no association with survival outcome between positive and negative cases in this 
study; on the other hand, prognostic significance of MAGE-A protein expression in TNBC has not 
been investigated so far. In this study, we have investigated frequency of MAGE-A and NY-ESO-1 
expression in a large cohort of invasive breast cancers and also investigated prognostic significance 
of MAGE-A and NY-ESO-1 expression specifically in TNBC.  
 
Results from this study showed, MAGE-A nuclear expression strongly correlated with markers of 
poor prognosis such as grade, mitotic score, hormone receptor (HR) status, triple negative status, 
and Ki67 expression within a large cohort of invasive breast cancers. Across all invasive breast 
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cancers, MAGE-A were predominantly expressed in a subset of TN basal-like (48%) and TN non-
basal breast cancers (33%). Although, Kaplan-Meier analysis for MAGE-A nuclear positive cases 
within the whole cohort (n=426) showed a 40% decrease in the disease specific survival at early 
stages within 5 years (p=0.0035), there was no difference in survival when specifically looked at 
TN and TB-basal group in this cohort. NYESO-1 expression on the other hand was observed in 2% 
of all invasive breast cancers and was restricted to a subset of TN-basal like breast cancers (21%). 
Kaplan-Meier analysis of NY-ESO-1 positive expression showed a trend towards poor outcome 
within the whole cohort and TN-basal group but the results were not significant in this cohort. In 
conclusion, these results suggests that it is still unclear whether cancer antigen expression 
particularly MAGE-A and NY-ESO-1 contributes to tumourigenesis, as the sample size in TN 
group may not be sufficient to determine if MAGE-A can alter disease outcome. Further 
investigations are required on larger cohort to fully understand the role of MAGE-A and NY-ESO-1 
in breast cancer.  
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Chapter VI: General discussion and future directions 
Breast cancer is the most common cancer in Australian women and is the second leading cause of 
cancer related death worldwide. The incidence of breast cancer in Australia is increasing however; 
the mortality rate has declined for the last three decades as a result of a collection of measures 
including improvements in screening, local management and the development of targeted therapies 
for hormone receptor positive and HER2 positive disease [275].  
 
Breast cancer is a complex heterogeneous disease encompassing different tumour entities with 
different biological features and clinical outcomes. Management decisions are based on clinic-
pathologic parameters including age, tumour size, histological grade, clinical stage, and expression 
of ER, PR, and HER2. Treatment of breast cancer requires a multidisciplinary approach, including 
surgery, radiation and systemic therapy and may vary depending on the stage, histological type. 
Women with ER and/or PR positive tumours have better overall survival and DFS at 5 years 
compared to women with ER negative tumours. The presence of ER and/or PR is a powerful 
predictive factor for the likelihood of benefit from adjuvant endocrine therapy. Similarly, studies 
have shown that HER2 overexpression predicts response to trastuzumab. Therefore, the presence of 
ER, PR and HER2 has proven to be both prognostic and predictive of therapeutic response in 
invasive breast cancer. In contrast, management of patients with TNBC has been challenging 
because of the lack of therapeutic targets. Cytotoxic chemotherapy (anthracycline and taxane) is 
currently the only standard treatment options for treating this particular group. Although PARP 
inhibitors have shown favourable results in some TNBC patients with germline BRCA mutations 
[80, 81], assessment of its long-term effects is needed. Other therapeutic targets (e.g. inhibitors of 
EGFR, c-kit, Raf/MEK/MAPK and mTOR) have been developed, but their clinical benefits are 
limited (reviewed in [82, 83]). 
 
There is significant overlap between TN and BLBC; studies have shown that around 75% of TN 
cancers have basal-like phenotype. A subset of TNBC/BLBCs patients have a high risk of relapse 
including development of lung and brain metastases and poor outcome within five years after 
diagnosis. Long-term survival rates for the remaining TN/BLBC patients are actually very good 
[77, 94, 222]. Current clinicopathologic markers, including grade, tumour size and lymph node 
status, do not fully explain this dichotomous clinical behaviour. Recent molecular studies have 
highlighted there is significant heterogeneity even within TN/BLBCs and these tumours show 
different pCR rates (after neoadjuvant therapy) and clinical outcomes [97, 98, 117]. Therefore, it 
would be favourable to develop methods to predict the risk of relapse earlier in the course of disease 
 100 
to inform clinical management and to provide an appropriate level of surveillance for metastatic 
disease.  
 
The primary aim of this study was to therefore to identify new prognostic and/or predictive 
biomarkers within TN/BLBCs to help improve the management of this group of patients in the 
future. The main focus was on SOX10, but we also investigated the CT-X antigens MAGE-A and 
NY-ESO-1. Some of the key findings from our immunohistochemical analysis of SOX10 in a 
cohort of 449 sporadic breast cancers with long term follow up are reiterated below: 
i) the vast majority of breast tumours are uniformly negative for SOX10 protein, which appears to 
be related to hypermethylation of the SOX10 gene;  
ii) positive staining of SOX10 protein, depicted as nuclear localisation, was detected in 8% of all 
tumours and correlated with a TN/BLBC phenotype. Importantly the staining is easy to 
interpret, with 80-100% of tumour cells exhibiting strong nuclear positivity. 
iii) SOX10 expression correlated with various clinical and biological features related to poor 
prognosis (including grade, mitotic score, hormone receptor and Ki67 status).  
iv) Kaplan-Meier survival analysis demonstrated SOX10 nuclear positivity is associated with poor 
outcome in all breast cancers and importantly identifies a poor outcome subgroup of 
TN/BLBC.  
 
This exciting data suggests SOX10 might be useful prognostic marker for TN/BL breast cancer. 
There are, however a number factors that need to be considered in order to move this idea forward. 
Firstly, our cohort was of insufficient size to enable a multivariate analysis to determine whether 
SOX10 represents an independent prognostic marker. Secondly, the SOX10 positive TN/BLBC 
group remains heterogeneous, with respect to outcome. Approximately half the patient group died 
within 5 years post diagnosis whereas the other half experienced a good long-term outcome. Again 
our cohort was too small to try and tease out whether this dichotomy could be related to specific 
clinic-pathological or biological factors. Thirdly, these observations need to be validated in an 
independent cohort to strengthen the role of SOX10 as a potential breast cancer biomarker. To 
address these issues we have initiated a collaboration with the Nottingham Breast Cancer group 
(Prof. Ian Ellis, Emad Rakha, Andrew Green), who have developed a very large breast cancer 
cohort with long term clinical follow up on TMAs and have published widely using this resource to 
investigate the expression of a large number of biomarkers in breast cancer [276-278]. Analysis of 
SOX10 using this additional cohort will occur in due course. This may also lead to a better 
understanding of the biology of SOX10 positive tumours given the large volume of biomarker data 
already available for tumours in this cohort. 
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Meta-analysis of gene expression profiling data also confirmed the observation that SOX10 
correlates with the TN/BL phenotype, indicating there is probably good agreement between mRNA 
and protein for this molecule. It will therefore also be interesting to determine whether SOX10 
mRNA correlates with a particular TN/BLBC subgroup, as defined by Lehmann and colleagues 
[117, 118] (see section 1.4.2). In that study, six distinctive subgroups were defined based on gene 
expression profiles (e.g. BL1, BL2, mesenchymal, mesenchymal stem cell, immunomodulatory, 
luminal androgen receptor) and these were shown to have different prognosis and response to 
chemotherapy. Determining whether SOX10 identifies a specific subgroup may help us further 
understand the biological role of SOX10 in breast cancer and whether it can be developed as a 
robust biomarker of treatment response and outcome. 
 
We have undertaken a preliminary analysis to begin to understand the functional role of SOX10 in 
breast cancer. Our in-silico, in vitro and in vivo analysis demonstrated that, 
i) SOX10 is rarely expressed in breast cancer cell lines. Only ~15% had detectable levels of 
SOX10 mRNA levels across a panel of breast cancer cell lines. SOX10 protein expression was 
evident only in the MDA-MB-435 basal-like breast cancer cell line.  
ii) In vitro cell culture conditions promoting selection of stem/progenitor cells did not induce 
SOX10 expression in a panel of SOX10-negative basal-like cell lines.  
iii) shRNA-mediated knockdown of SOX10 in MDA-MB-435 breast cancer cells did not alter their 
proliferation rate, migratory behavior or sphere formation in vitro, though did reduce colony 
formation on plastic.  
iv) In vivo tumourigenicity assays using MDA-MB-435 cells injected into the mouse mammary fat 
showed that SOX10 knockdown reduced primary tumour formation. 
v) Differential gene expression profiling of shRNA mediated SOX10 knockdown vs. normal 
MDA-MB-435 cells showed enrichment for immune related genes.  
 
Although we found some interesting results using in vitro and in vivo functional assays, we were 
limited to using a single cell line model (MDA-MB-435), as SOX10 was not frequently expressed 
in breast cancer cell lines. Therefore, we will have to complement our findings with additional 
experiments in order to further tease out the role of SOX10 in breast cancer and support our 
hypothesis that SOX10 overexpression contributes to an aggressive phenotype. To address this, 
future experiments need to focus on SOX10 over expression in other basal-like breast cancer cell 
lines (e.g. MDA-MB-468 and MDA-MB-231). In vivo analysis suggests SOX10 may be playing an 
important role in tumour growth, and this may be the reason for its aggressive phenotype in basal-
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like breast cancers. However, due to time limitations we were unable to investigate the effect of 
SOX10 knockdown on spontaneous metastasis in this study. This will be completed in due course 
by analysing the expression of markers such as trichrome, Ki67, ApopTag and SOX10 using 
immunohistochemistry on sections from resected tumours and/or organs. This will give insight as to 
whether SOX10 has a role in distant metastasis. Alternately, this may be achieved by transducing 
shSOX10 with luciferase and injecting the transduced control and knockdown lines into the mice. 
The mice would then be monitored for the formation of spontaneous metastasis using 
bioluminescence imaging.  
 
A really interesting finding that needs a significant level of additional work was an association 
between SOX10 and immune-related gene expression. Differential gene expression analysis of 
SOX10 control and knockdown lines showed that loss of SOX10 in MDA-MB-435 cells is 
mediating/regulating an immune-related gene expression program that may have an effect in vivo 
on the immune response. This observation needs to be further validated using experimental models 
that can help determine the effect of SOX10 knockdown on immune system. In hindsight, use of the 
NOD-SCID mice model to investigate tumour progression in this study may not have been an 
appropriate model to study the effects of the immune response because these mice are immuno-
compromised. However, the 4T1 metastatic mouse model may be a more appropriate model to 
study the possible link between SOX10, the immune system and tumour growth/metastasis in 
future. There are many advantages of using this model; firstly, it is a syngeneic xenograft model 
with a luciferase-expressing clone, it is easily transplantable, highly tumourigenic and highly 
metastatic [279]. This makes it easier to study the effect of SOX10 overexpression and knockdown 
on spontaneous metastasis using bioluminescence imaging. Secondly, this model closely resembles 
the human breast cancers (particularly the basal-like cancer) as they have a propensity to 
metastasise to the lungs, liver, brain and bone. This would be interesting as we know that SOX10 
expression marks a subset of aggressive basal-like breast cancers and investigating loss/gain of 
SOX10 in a model like this would further give us some insight into its aggressive tumourigenic 
behavior. 
 
We have also investigated SOX10 in the context of normal breast biology and showed, overall, a 
possible association with luminal progenitor cell populations. The following were key findings: 
 
i) Immunohistochemistry and immunoflouresence analysis of SOX10 in normal epithelia from 
reduction mammoplasty samples and in normal adjacent to tumour demonstrated that SOX10 
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expression was either restricted to the myoepithelial cell compartment or was found in both 
myoepithelial and luminal epithelial cell compartments.  
ii) We found a striking correlation between SOX10 and the luminal progenitor marker c-kit, and 
an inverse association with markers of fully differentiated luminal epithelia, ER and CK 8/18.  
iii) An in-silico analysis showed that SOX10 mRNA expression was highest in a FACS sorted 
luminal progenitor cell population, was moderately expressed in mammary stem cell-enriched 
(MaSC) populations, and was lowest in mature luminal cells.  
 
Based on this association and in light of what is known about SOX10 in melanocytes where it 
controls a differentiation program, we hypothesise therefore that SOX10 may be regulating 
mammary epithelial lineage differentiation in the breast. We know that there is an increasing 
requirement for stem/progenitor cell population at various stages of mammary gland development 
(e.g. during puberty, pregnancy and lactation) that undergoes rapid cell proliferation and 
differentiation. SOX10 may play an important part in this developmental program and that further 
investigations are required to test this hypothesis. This could be explored further by performing 
mammary transplant assays, which can be achieved by isolating normal mammary epithelial cell 
populations from reduction mammoplasty cases (based on their cell surface markers) using FACS 
analysis [24]. Isolated cells can be separated as mature luminal, luminal progenitor and MaSc and 
maintained as individual cultures. shRNA-mediated SOX10 knockdown can be performed on these 
different cell populations, transduced cells can then be injected into the mice to examine ductal 
elongation and morphogenesis. The effect of SOX10 knockdown on mammary gland development 
could then be assessed by whole mount analysis. A similar analysis has been done to study the role 
of ID4 in breast cancer development [280].  
 
How SOX10 exerts its possible effects on differentiation is presumably through its role as a 
transcription factor, although this is still poorly characterised. Only a handful of target genes for 
SOX10 are known so far and these include MITF, P0, c-Ret, EGR2 and EDNRB [161, 166, 168-
170]. These gene targets are known to play an important role in melanocyte development and 
differentiation of Schwann cells. However, we are currently limited by our understanding of 
biological networks that SOX10 could be involved in regulating in normal breast and in breast 
cancer. Recent advances in the techniques of chromatin immunoprecipitation (ChIP) combined with 
DNA sequencing (ChIP-Seq) would enable one to create a global map of specific DNA-protein 
interactions in a given cell type and can facilitate identification of gene –gene/gene –protein 
interactions [281]. ChiP involves crosslinking DNA-binding proteins to DNA by treatment of the 
cells with formaldehyde and preparation of chromatin by enzyme digestion or sonication. 
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Immunoprecipitation of the cross-linked chromatin could then be performed using SOX10 antibody 
(as we know the SOX10 antibody used in this study is of good quality based on IHC and western 
blot results); followed by next generation sequencing of the captured DNA sequences. This analysis 
would allow for the identification of potential SOX10 biding sites throughout the genome. Thus, 
identification of downstream target genes for SOX10 will further help understand the functional 
role of SOX10 in normal breast and in breast cancer.  
 
There is evidence from the literature that breast cancer subtypes arise from different cell 
populations of the mammary cell hierarchy. Molecular profiling of basal-like cancers suggests that 
luminal progenitors are the cell of origin for BLBCs [24]. Mammary development studies have led 
to greater understandings into breast cancer biology, and it is now clear that transcription factors 
such as GATA3 and BRCA1 controlling luminal epithelial cell lineage are powerful breast tumour 
suppressors that are frequently mutated in malignancy [282-284]. Through cancer genomics, in 
vitro assays and experimental xenograft models, we have demonstrated that the transcription factor 
SOX10 is a luminal progenitor marker and that its expression is maintained in a subset of basal-like 
cancers and contribute to poor outcomes. This suggests that SOX10 could be one of the breast 
cancer genes that could be important in both normal mammary development and in breast cancer.  
 
As mentioned earlier, the main focus of this study was to identify prognostic biomarkers in 
TN/BLBs. In line with work on SOX10, we extended our investigations on two X-chromosome 
cancer testis (CT-X) antigens, MAGE-A and NY-ESO-1:  
i) MAGE-A expression identified a group of high grade, highly proliferative TN/BL tumours 
with poor outcome within the whole cohort. MAGE-A expression was not prognostic, however, 
within TN/BL tumours subgroup.  
ii) NY-ESO-1 identified a very small group of high-grade patients, which are also MAGE-A 
positive and showed a trend towards poor outcome.  
 
Overall, MAGE-A and NY-ESO-1 do not offer much value as prognostic markers in this cohort, but 
it is possible that with a larger sample size of TN/BLBCs one might see an effect for these makers. 
Further investigations of NY-ESO-1 are required to fully understand the role of MAGE-A and NY-
ESO-1 in breast cancer.  
 
In conclusion, this study is the first to assess the prognostic significance of SOX10, MAGE-A and 
NY-ESO-1 in breast cancer. All three proteins are associated with tumours with TN/BL phenotype, 
and SOX10 shows promise as a biomarker of prognostic significance. We have shown that SOX10 
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is a luminal progenitor marker whose expression is maintained in a subset of basal-like cancers with 
poor outcome. This is an observational study and there is a requirement for a more mechanistic 
approach in the future in order to fully understand the role of SOX10 in normal breast and in breast 
cancer. Some of the future experiments discussed in this section may further increase our 
knowledge on the functional role of SOX10.  
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Appendices  
Appendix 2.1: Proforma used for pathology review.  
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Appendix 2.2: Example of a TMA map. 
 
 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
1         L                     L 
2   L         L                 L 
3   L     L       L       L       
4                 L       L       
5   L L L L       L           L L 
6         L L L       L   L   L L 
7   L                           L 
8   L   L             L     L   L 
9 L         L L             L     
10       L               L L L L   
11 L L L L L P P                   
 
 
 
Controls used in this TMA: L= Liver, P= Placenta.  
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Appendix 3.1: Histopathologic features of 449 breast cancer cases used in this study. 
 
 
 
Histopathologic variables  n %  
        
Tumour grade  
    
1 
 
63 14 
2 
 
220 49 
3 
 
161 35.9 
Unknown 
 
5 1.1 
Total   449   
Lymph node status 
    
Positive 
 
116 25.8 
Negative 
 
135 30.1 
Unknown 
 
198 44.1 
Total   449   
Tumour size 
    
<2 
 
222 49.4 
2 to 5 
 
131 29.2 
>5 
 
18 4 
Unknown 
 
78 17.4 
Total    449   
Histological type 
    
Ductal NOS 
 
256 57 
Lobular 
 
34 7.6 
Lobular variant 
 
30 6.7 
Mixed 
 
77 17.1 
Tubular/Crib 
 
10 2.2 
Mucinous 
 
3 0.7 
Mataplastic 
 
18 4 
Medullary 
 
2 0.4 
Papillary 
 
2 2.4 
Others 
 
11 2.4 
Unknown 
 
6 1.3 
Total   449   
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Appendix 3.1 continued: Histopathologic features of 449 breast cancer cases used in this study. 
 
 
 
 
Histo pathological variables n % 
Immuno-marker positivity  
  
ER 
 
334 77.1 
Unknown    16   
PR   267 62.5 
Unknown    22   
HER2 (IHC 3+ only) 72 17 
HER2 (IHC 3+ & ISH >6) 38 9.2 
Unknown    37   
CK5/6   43 10.6 
Unknown    44   
CK14   29 7.4 
Unknown    55   
EGFR   84 21.4 
Unknown    57   
Ki67 > 10%   145 36.6 
Ki67 > 20% 
 
55 13.9 
Unknown    53   
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Appendix 3.2: Flow chart representing stratification of breast cancer cases into different prognostic 
subgroups based on expression of immunohistochemistry markers ER, PR, HER2, Ki67, EGFR and 
CK 5/6 and 14. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HER2-positive?                           
(CISH score >6, or 
where CISH data not 
available, IHC-3+) 
HER2 CISH/IHC 
data not available unassigned 
Yes HER2+ 
No 
Hormone receptor 
expression                 
(ER or PR) 
Ki67-high HR+   (proliferative) 
Ki67-low HR+               (Ki67-low) 
No Ki67 data 
available HR+ 
No hormone 
receptor 
expression 
Any basal marker 
expression      
(EGFR, CK14 or CK5/6) 
TN                
(basal-like) 
No basal marker 
expression 
TN                  
(non-basal) 
No basal marker 
data available TN 
HR data not 
available unassigned 
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Appendix 3.3: Kalpan-Meier survival analysis of QFU cohort according to breast cancer subgroups 
defined by IHC surrogate marker panel. 
 
 
 
 
 
 
 
 
Appendix 3.4: Kalpan-Meier survival analysis of QFU cohort based on expression of Ki67. Ten per 
cent threshold showed no difference in survival whereas 20% threshold showed a significant 
difference in survival outcome. 
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Appendix 3.5: Comparison of clinicopathologic variables within different breast cancer subtypes. 
 
 
	  	  
Total	   HR
+/HER2-­‐	  (low	  
Ki67)	  	  
HR+/HER2-­‐/+	  
(high	  Ki67)	  	   HR
-­‐/HER2+	   Triple	  negative	  (TN)	   TN-­‐basal	  like	  Parameters	  
	  	  
  	  	   n	   %	   n	   %	   n	   %	   n	   %	   n	   %	  
Number	  	   386	   248	   64.2	   49	   12.7	   18	   4.7	   71.0	   18.4	   54.0	   14.0	  
Tumour	  grade	  	  
1	   52	   51	   98.1	   0	   0.0	   0	   0.0	   1.0	   1.9	   0.0	   0.0	  
2	   177	   142	   80.2	   20	   11.3	   2	   1.1	   13.0	   7.3	   9.0	   5.1	  
3	   154	   53	   34.4	   29	   18.8	   15	   9.7	   57.0	   37.0	   46.0	   29.9	  
Lymph	  node	  status	  
Positive	   103	   61	   59.2	   15	   14.6	   11	   10.7	   16.0	   15.5	   11.0	   10.7	  
Negative	   114	   71	   62.3	   16	   14.0	   2	   1.8	   25.0	   21.9	   21.0	   18.4	  
unknown	   169	   116	   68.6	   18	   10.7	   5	   3.0	   30.0	   17.8	   23.0	   13.6	  
Tumour	  size	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	     
<2	   199	   144	   72.4	   21	   10.6	   7	   3.5	   27.0	   13.6	   21.0	   10.6	  
2	  to	  5	   114	   62	   54.4	   14	   12.3	   8	   7.0	   30.0	   26.3	   22.0	   19.3	  
>5	   17	   7	   41.2	   2	   11.8	   1	   5.9	   7.0	   41.2	   6.0	   35.3	  
unknown	   48	   35	   72.9	   10	   20.8	   2	   4.2	   1.0	   2.1	   6.0	   12.5	  
Histological	  type	  
Ductal	  NOS	   230	   147	   63.9	   31	   13.5	   10	   4.3	   42.0	   18.3	   34.0	   14.8	  
Lobular	   41	   32	   78.0	   5	   12.2	   2	   4.9	   2.0	   4.9	   0.0	   0.0	  
Mixed	   77	   39	   50.6	   8	   10.4	   3	   3.9	   17.0	   22.1	   13.0	   16.9	  
Tubular/Crib	   9	   9	   100.0	   0	   0.0	   0	   0.0	   0.0	   0.0	   0.0	   0.0	  
Mucinous	   3	   2	   66.7	   1	   33.3	   0	   0.0	   0.0	   0.0	   0.0	   0.0	  
Mataplastic	   17	   5	   29.4	   2	   11.8	   2	   11.8	   8.0	   47.1	   7.0	   41.2	  
Medullary	   2	   2	   100.0	   0	   0.0	   0	   0.0	   0.0	   0.0	   0.0	   0.0	  
Papillary	   2	   2	   100.0	   0	   0.0	   0	   0.0	   0.0	   0.0	   0.0	   0.0	  
others	   10	   8	   80.0	   2	   20.0	   0	   0.0	   0.0	   0.0	   1.0	   10.0	  
Immuno	  marker	  positivity	  	  
ER	  (>1%)	   297	   248	   83.5	   49	   16.5	   0	   0.0	   0.0	   0.0	   0.0	   0.0	  
PR	  (>1%)	   243	   209	   86.0	   34	   14.0	   0	   0.0	   0.0	   0.0	   0.0	   0.0	  
HER2	  (3+,	  >6	  by	  
ISH)	   41	   0	   0.0	   23	   56.1	   18	   43.9	   0.0	   0.0	   0.0	   0.0	  
CK5/6	   42	   5	   11.9	   5	   11.9	   2	   4.8	   30.0	   71.4	   30.0	   71.4	  
CK14	   26	   6	   23.1	   2	   7.7	   1	   3.8	   17.0	   65.4	   17.0	   65.4	  
EGFR	   81	   21	   25.9	   9	   11.1	   10	   12.3	   41.0	   50.6	   41.0	   50.6	  
Ki67	  >	  20%	   52	   0	   0.0	   26	   50.0	   3	   5.8	   23.0	   44.2	   19.0	   36.5	  
SOX10	   37	   2	   5.4	   4	   10.8	   0	   0.0	   31.0	   83.8	   27.0	   73.0	  
p53	  (3+)	   57	   14	   24.6	   10	   17.5	   7	   12.3	   26.0	   45.6	   20.0	   35.1	  
AR	   331	   241	   72.8	   41	   12.4	   17	   5.1	   32.0	   9.7	   19.0	   5.7	  
c-­‐kit	   154	   90	   58.4	   27	   17.5	   5	   3.2	   32.0	   20.8	   29.0	   18.8	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Appendix 3.6: Comparison of clinicopathologic variables based on SOX10 status in QFU cohort.  
 
 
 
Invasive breast carcinomas 
Variables Total 
n % 
P-value# SOX10 
positive 
SOX10 
negative 
SOX10 
positive 
SOX10 
negative 
Clinical 
parameters               
Age 
<40 41 6 35 14.6 85.4 
ns 
40-50 90 11 79 12.2 87.8 
51-60 86 7 79 8.1 91.9 
>60 205 11 194 5.4 94.6 
Tumour size 
<2 cm 171 14 157 8.2 91.8 
ns 
2-5 cm 163 15 148 9.2 90.8 
>5 cm 33 4 29 12.1 87.9 
n 367         
Lymph node status 
Positive 130 8 122 6.2 93.8 
ns Negative 119 12 107 10.1 89.9 
n 249         
LVI 
Positive 103 9 94 8.7 91.3 
ns Negative 338 28 310 8.3 91.7 
n 441         
Histopathologic parameters             
Histological type 
Ductal 
NOS 252 23 229 9.1 90.9 
ns 
Lobular 64 0 64 0.0 100.0 
Mixed type 76 11 65 14.5 85.5 
Metaplastic 18 2 16 11.1 88.9 
others 29 1 28 3.4 96.6 
n 439         
Grade 
I 61 0 61 0.0 100.0 
<0.0001 
II 218 7 211 3.2 96.8 
III 160 30 130 18.8 81.3 
n 439         
Mitotic score 
1 256 4 252 1.6 98.4 
<0.0001 
2 58 2 56 3.4 96.6 
3 124 31 93 25.0 75.0 
n 438         
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Appendix 3.6 continued: Comparison of clinicopathologic variables based on SOX10 status in QFU 
cohort.  
 
 
 
 
Invasive breast carcinomas 
Variables Total 
n % P-
value# SOX10 
positive 
SOX10 
negative 
SOX10 
positive 
SOX10 
negative 
Biomarkers 
Ki67 expression 
(20% threshold) 
High 55 15 40 27.3 72.7 
<0.0001 Low 338 22 316 6.5 93.5 
n 393         
HR Status (ER 
and/or PR) 
Yes 340 6 334 1.8 98.2 
<0.0001 No 91 31 60 34.1 65.9 
n 431         
HER2 status 
Yes 40 0 40 0.0 100.0 
0.0338 No 352 36 316 10.2 89.8 
n 392         
Triple negative 
(TN) status 
Yes 71 31 40 43.7 56.3 
<0.0001 No 357 6 351 1.7 98.3 
n 403        
Basal markers 
(CK5/6, CK14, 
EGFR) 
Yes 110 32 78 29.1 70.9 
<0.0001 No 280 3 277 1.1 98.9 
n           
TN-Basal status 
Yes 49 22 27 44.9 55.1 
<0.0001 No 375 10 365 2.7 97.3 
n 424         
p53 expression 
Positive  57 14 43 24.6 75.4 
<0.0001 Negative 267 15 252 5.6 94.4 
n 324         
AR expression 
Positive 362 12 350 3.3 96.7 
<0.0001 Negative 42 24 18 57.1 42.9 
n 404         
Vimentin 
expression 
Positive  46 24 22 52.2 47.8 
<0.0001 Negative 357 12 345 3.4 96.6 
n 403         
c-kit expression 
Positive 162 26 136 16.0 84.0 
<0.0001 Negative 249 10 239 4.0 96.0 
n 411         
#Chi-square test        
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Appendix 3.7: Comparison of clinicopathologic variables based on SOX10 status within triple 
negative and basal-like breast cancers 
 
 
Variables 
Triple negative (TN) TN basal-like 
total SOX10 positive 
SOX10 
negative P-value
# total SOX10 positive 
SOX10 
negative P-value
# 
Clinical parameters                 
Age 
<40 2 1 1 
ns 
6 4 2 
ns 
40-50 2 0 2 13 8 5 
51-60 5 2 3 8 2 6 
>60 5 0 5 25 11 14 
Tumour size 
<2 cm 26 10 16 
ns 
16 7 9 
ns 
2-5 cm 30 14 16 27 13 14 
>5 cm 7 4 3 6 4 2 
n 63     49     
Lymph node status 
Positive 16 8 8 
ns 
11 6 5 
ns Negative 25 11 14 21 10 11 
n 41   32   
LVI 
Positive 15 6 9 
ns 
15 6 9 
ns Negative 55 25 30 42 21 21 
n 70     57     
Histopathologic parameters                 
Histological type 
Ductal NOS 41 19 22 
ns 
33 16 17 
ns 
Lobular 2 0 2 0 0 0 
Mixed type 18 10 8 14 10 4 
Metaplastic 8 1 7 7 1 6 
others 1 1 0 1 1 0 
n 70     55     
Grade 
I 1 0 1 
ns 
0 0 0 
ns 
II 13 5 8 9 5 4 
III 56 26 30 46 23 23 
n 70     55     
Mitotic score 
1 12 4 8 
0.0467 
7 4 3 
ns 
2 9 1 8 8 1 7 
3 49 26 23 39 22 17 
n 70   54   
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Appendix 3.7 continued: Comparison of clinicopathologic variables based on SOX10 status within 
triple negative and basal-like breast cancers 
 
 
 
Variables 
Triple negative (TN) TN basal-like 
total SOX10 positive 
SOX10 
negative P-value
# total SOX10 positive 
SOX10 
negative P-value
# 
Biomarkers                 
Ki67 expression  
(20% threshold) 
High 23 11 12 
ns 
19 9 10 
ns Low 43 20 23 32 18 14 
n 66     51     
p53 expression 
Positive (3+) 25 11 14 
ns 
19 10 9 
ns Negative 31 14 17 23 12 11 
n 56     42     
AR expression 
Positive 32 8 24 
0.001 
19 6 13 
0.0177 Negative 32 22 10 29 20 9 
n 64     48     
Vimentin  
expression 
Positive  31 20 11 
0.007 
27 16 11 
ns Negative 35 10 24 23 10 13 
n 66     50     
c-kit expression 
Positive 32 20 12 
0.0068 
29 18 11 
ns Negative 36 10 26 23 8 15 
n 68     52     
#Chi-square test          
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Appendix 5.1: Comparison of clinicopathologic variables based on MAGE-A status in QFU cohort. 
 
 
Invasive Breast Carcinoma 
Variables Total 
n % 
P-
value# MAGE-A 
positive 
MAGE-A 
negative 
MAGE-A 
positive 
MAGE-A 
negative 
Clinical parameters             
Age 
<50 108 10 98 9.3 90.7 
ns 
>50 269 18 251 6.7 93.3 
Tumour size 
<2 cm 160 9 151 5.6 94.4 
ns 
2-5 cm 157 16 141 10.2 89.8 
>5 cm 17 3 14 17.6 82.4 
n 334         
Lymph node status 
Positive 101 7 94 6.9 93.1 
ns Negative 116 8 108 6.9 93.1 
n 217         
LVI 
Positive 98 6 92 6.1 93.9 
ns Negative 296 25 271 8.4 91.6 
n 394         
Histopathologic parameters             
Histological type 
Ductal NOS 232 16 216 6.9 93.1 
0.0244 
Lobular 43 1 42 2.3 97.7 
Mixed type 73 8 65 11.0 89.0 
Metaplastic 14 4 10 28.6 71.4 
others 26 2 24 7.7 92.3 
n 388         
Grade 
I 54 0 54 0.0 100.0 
< 
0.0001 
II 187 8 179 4.3 95.7 
III 150 23 127 15.3 84.7 
n 391        
Mitotic score 
1 218 7 211 3.2 96.8 
< 
0.0001 
2 54 4 50 7.4 92.6 
3 118 20 98 16.9 83.1 
n 390         
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Appendix 5.1 continued: Comparison of clinicopathologic variables based on MAGE-A status in 
QFU cohort. 
 
 
Invasive Breast Carcinoma 
Variables Total 
n % 
P-
value# MAGE-A 
positive 
MAGE-A 
negative 
MAGE-A 
positive 
MAGE-A 
negative 
Biomarkers             
Ki67 expression 
(20% threshold) 
High 55 12 43 21.8 78.2 
0.0003 Low 324 18 306 5.6 94.4 
n 379         
HR Status (ER 
and/or PR) 
Yes 305 8 297 2.6 97.4 
< 
0.0001 No 87 23 64 26.4 73.6 
n 392         
HER2 status 
Yes 68 3 65 4.4 95.6 
ns No 309 27 282 8.7 91.3 
n 377         
Triple negative (TN) 
status 
Yes 68 22 46 32.4 67.6 
< 
0.0001 No 323 9 314 2.8 97.2 
n 391       
TN-Basal status 
Yes 53 18 35 34.0 66.0 
< 
0.0001 No 320 11 309 3.4 96.6 
n 373         
Basal markers 
(CK5/6, CK14, 
EGFR) 
Yes 105 22 83 21.0 79.0 
< 
0.0001 No 259 7 252 2.7 97.3 
n 364         
p53 expression 
Positive 
(3+) 180 32 148 17.8 82.2 
0.0195 Negative 133 11 122 8.3 91.7 
n 313         
AR expression 
Positive 193 4 189 AR 97.9 
< 
0.0001 Negative 183 24 159 13.1 86.9 
n 376         
Vimentin expression 
Positive  46 12 34 26.1 73.9 
< 
0.0001 Negative 344 18 326 5.2 94.8 
n 390         
c-kit expression 
Positive 144 21 123 14.6 85.4 
0.0008 Negative 230 10 220 4.3 95.7 
n 374         
NY-ESO-1 
expression 
Positive  12 9 3 75.0 25.0 
< 
0.0001 Negative 381 23 358 6.0 94.0 
n 393         
#Chi-square test  
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Appendix 5.2: Comparison of clinicopathologic variables based on MAGE-A status within triple 
negative and basal-like breast cancers 
 
 
Variables 
Triple negative (TN) TN basal-like 
total MAGEA positive 
MAGEA 
negative 
P-
value# total 
MAGEA 
positive 
MAGEA 
negative 
P-
value# 
Clinical parameters               
Age <50 22 8 14 
ns 
18 6 12 
ns  >50 46 14 32 35 12 23 
  n 68   53     
Tumour 
size 
<2 cm 18 7 11 
ns 
14 4 10 
ns 
2-5 cm 35 11 24 26 10 16 
>5 cm 9 3 6 8 3 5 
n 62     48     
Lymph 
node status 
Positive 15 5 10 
ns 
10 3 7 
ns Negative 25 6 19 21 6 15 
n 40     31     
LVI 
Positive 5 10 15 
ns 
12 4 8 
ns Negative 17 36 53 41 14 27 
n 22     53     
Histopathologic 
parameters 
  
           
Histological 
type 
Ductal 
NOS 35 12 23 
ns 
32 9 23 
ns 
Lobular 2 0 2 0 0 0 
Mixed type 15 7 8 14 6 8 
Metaplastic 7 3 4 7 3 4 
others 0 0 0 0 0 0 
n 59   53     
Grade 
I 1 0 1 
ns 
0 0 0 
ns II 13 3 10 9 2 7 
III 54 19 35 44 16 28 
n 68   53     
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Appendix 5.2 continued: Comparison of clinicopathologic variables based on MAGE-A status 
within triple negative and basal-like breast cancers 
 
 
 
Variables 
Triple negative (TN) TN basal-like 
total MAGEA positive 
MAGEA 
negative 
P-
value# total 
MAGEA 
positive 
MAGEA 
negative 
P-
value# 
Biomarkers                 
Ki67 
expression 
(20% 
threshold) 
High 23 10 13 
ns 
19 8 11 
ns Low 42 11 31 31 9 22 
n 65   50   
p53 
expression 
Positive (3+) 25 10 15 
ns 
19 8 11 
ns Negative 31 9 22 23 7 16 
n 56     42     
AR 
expression 
Positive 31 8 23 
ns 
19 5 14 
ns Negative 32 13 19 29 12 17 
n 63     48     
Vimentin 
expression 
Positive  31 9 22 
ns 
27 7 20 
ns Negative 34 12 22 23 10 13 
n 65   50   
c-kit 
expression 
Positive 31 16 15 
0.0041 
28 14 14 
0.0201 Negative 35 6 29 23 4 19 
n 66   51   
NY-ESO-1 
expression 
Positive 9 7 2 
0.0048 
9 7 2 
0.006 Negative 57 15 42 42 11 31 
n 66     51     
#Chi-square test        
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Appendix 5.3: Characteristics of NY-ESO-1 positive tumours in QFU cohort. 
 
 
# Age Size (mm) Grade Invasive type  LFP Subtype 
Tumour  
border 
NY-ESO -1 
(%) 
NY-ESO-1 
Intensity 
NY-ESO- 1 
Location 
1 48 15 3 IC NST alive TNBC infiltrative 3 weak Cy 
2 53 15 3 IC NST dead TNBC infiltrative 2 weak Cy 
3 49 35 3 Mixed dead TNBC infiltrative 2 weak Nu 
4 46 15 3 IC NST dead TNBC infiltrative 2 weak Nu/Cy 
5 50 12 3 IC NST alive ER/PR+HER2- infiltrative 1 weak Nu/Cy 
6 54 25 3 IC NST alive TNBC Pushing <50% 3 weak Nu/Cy 
7 75 25 2 IC NST dead TNBC infiltrative 3 srong Nu/Cy 
8 72 25 2 Mixed alive TNBC infiltrative 3 strong Nu/Cy 
9 uk uk 2 Special type  dead uk Pushing >50% 3 strong Nu/Cy 
10 55 70 3 Mixed alive TNBC infiltrative 3 strong Nu/Cy 
11 73 180 3 IC NST alive TNBC Pushing <50% 2 strong Nu/Cy 
12 72 40 3 Mixed alive TNBC infiltrative 3 strong Nu/Cy 
13 58 11 3 IC NST alive TNBC infiltrative 2 strong Nu/Cy 
14 uk uk 2 IC NST uk ER/PR+HER2- infiltrative 1 weak Nu/Cy 
 
 
LFU- Last follow up, Cy- cytoplasm and Nu- nucleus
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